U.S. patent application number 15/630741 was filed with the patent office on 2017-10-05 for compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use.
The applicant listed for this patent is ADURO BIOTECH, INC.. Invention is credited to Thomas W. Dubensky, JR., Laura Hix Glickman, David B. Kanne, Edward Emile Lemmens, Meredith Lai Ling Leong.
Application Number | 20170283454 15/630741 |
Document ID | / |
Family ID | 50935019 |
Filed Date | 2017-10-05 |
United States Patent
Application |
20170283454 |
Kind Code |
A1 |
Dubensky, JR.; Thomas W. ;
et al. |
October 5, 2017 |
COMPOSITIONS COMPRISING CYCLIC PURINE DINUCLEOTIDES HAVING DEFINED
STEREOCHEMISTRIES AND METHODS FOR THEIR PREPARATION AND USE
Abstract
It is an object of the present invention to provide novel and
highly active cyclic-di-nucleotide (CDN) immune stimulators that
activates DCs via a recently discovered cytoplasmic receptor known
as STING (Stimulator of Interferon Genes). In particular, the CDNs
of the present invention are provided in the form of a composition
comprising one or more cyclic purine dinucleotides that induce
STING-dependent TBK1 activation, wherein the cyclic purine
dinuclotides present in the composition are substantially pure
Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure
Rp,Rp, or RpSp CDN thiophosphate diastereomers.
Inventors: |
Dubensky, JR.; Thomas W.;
(San Diego, CA) ; Kanne; David B.; (Corte Madera,
CA) ; Leong; Meredith Lai Ling; (Oakland, CA)
; Lemmens; Edward Emile; (Walnut Creek, CA) ;
Glickman; Laura Hix; (Oakland, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ADURO BIOTECH, INC. |
Berkeley |
CA |
US |
|
|
Family ID: |
50935019 |
Appl. No.: |
15/630741 |
Filed: |
June 22, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14106687 |
Dec 13, 2013 |
9695212 |
|
|
15630741 |
|
|
|
|
61737006 |
Dec 13, 2012 |
|
|
|
61790514 |
Mar 15, 2013 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 37/04 20180101;
A61P 35/00 20180101; A61P 43/00 20180101; A61K 39/39 20130101; C07H
21/00 20130101; C07H 21/04 20130101; A61K 39/0005 20130101; A61K
39/385 20130101; C07H 19/213 20130101; A61P 37/00 20180101; A61P
37/02 20180101; A61K 31/7084 20130101; A61K 39/12 20130101; A61P
31/00 20180101; A61P 35/02 20180101; A61K 39/02 20130101; C07H
21/02 20130101 |
International
Class: |
C07H 21/02 20060101
C07H021/02; A61K 39/385 20060101 A61K039/385 |
Claims
1. A composition comprising: one or more cyclic purine
dinucleotides or prodrugs or pharmaceutically acceptable salts
thereof which induce STING-dependent TBK1 activation, wherein the
cyclic purine dinuclotides present in the composition are
substantially pure Rp,Rp or Rp,Sp diastereomers, or prodrugs or
pharmaceutically acceptable salts thereof, wherein said cyclic
purine dinucleotides are preferably thiophposphate cyclic purine
dinucleotides.
Description
[0001] The present application is a continuation of U.S. patent
application Ser. No. 14/106,687, filed Dec. 13, 2013, now U.S. Pat.
No. 9,695,212, which claims priority to U.S. Provisional
Application 61/737,006, filed Dec. 13, 2012, and to U.S.
Provisional Application 61/790,514, filed Mar. 15, 2013, each of
which is hereby incorporated in its entirety including all tables,
figures, and claims.
BACKGROUND OF THE INVENTION
[0002] The following discussion of the background of the invention
is merely provided to aid the reader in understanding the invention
and is not admitted to describe or constitute prior art to the
present invention.
[0003] The human immune system may generally be divided into two
arms, referred to as "innate immunity" and "adaptive immunity." The
innate arm of the immune system is predominantly responsible for an
initial inflammatory response via a number of soluble factors,
including the complement system and the chemokine/cytokine system;
and a number of specialized cell types including mast cells,
macrophages, dendritic cells (DCs), and natural killer cells. In
contrast, the adaptive immune arm involves a delayed and a longer
lasting antibody response together with CD8+ and CD4+ T cell
responses that play a critical role in immunological memory against
an antigen. A third arm of the immune system may be identified as
involving .gamma..delta. T cells and T cells with limited T cell
receptor repertoires such as NKT cells and MAIT cells.
[0004] For an effective immune response to an antigen, antigen
presenting cells (APCs) must process and display the antigen in a
proper MHC context to a T cell, which then will result in either T
cell stimulation of cytotoxic and helper T cells. Following antigen
presentation successful interaction of co-stimulatory molecules on
both APCs and T cells must occur or activation will be aborted.
GM-CSF and IL-12 serve as effective pro-inflammatory molecules in
many tumor models. For example, GM-CSF induces myeloid precursor
cells to proliferate and differentiate into dendritic cells (DCs)
although additional signals are necessary to activate their
maturation to effective antigen-presenting cells necessary for
activation of T cells. Barriers to effective immune therapies
include tolerance to the targeted antigen that can limit induction
of cytotoxic CD8 T cells of appropriate magnitude and function,
poor trafficking of the generated T cells to sites of malignant
cells, and poor persistence of the induced T cell response.
[0005] DCs that phagocytose tumor-cell debris process the material
for major histocompatibility complex (MHC) presentation, upregulate
expression of costimulatory molecules, and migrate to regional
lymph nodes to stimulate tumor-specific lymphocytes. This pathway
results in the proliferation and activation of CD4+ and CD8+ T
cells that react to tumor-associated antigens. Indeed, such cells
can be detected frequently in the blood, lymphoid tissues, and
malignant lesions of patients.
[0006] New insights into the mechanisms underlying immune-evasion,
together with combination treatment regimens that potentiate the
potency of therapeutic vaccination--either directly or
indirectly--through combination with immune checkpoint inhibitors
or other therapies, have served as a basis for the development of
vaccines that induce effective antitumor immunity. The CDNs
cyclic-di-AMP (produced by Listeria monocytogenes) and its analog
cyclic-di-GMP (produced by Legionella pneumophila) are recognized
by the host cell as a PAMP (Pathogen Associated Molecular Pattern),
which bind to the PRR (Pathogen Recognition Receptor) known as
STING. STING is an adaptor protein in the cytoplasm of host
mammalian cells which activates the TANK binding kinase (TBK1)-IRF3
signaling axis, resulting in the induction of IFN-.beta. and other
IRF-3 dependent gene products that strongly activate innate
immunity. It is now recognized that STING is a component of the
host cytosolic surveillance pathway, that senses infection with
intracellular pathogens and in response induces the production of
IFN-.beta., leading to the development of an adaptive protective
pathogen-specific immune response consisting of both
antigen-specific CD4 and CD8 T cells as well as pathogen-specific
antibodies. Examples of cyclic purine dinucleotides are described
in some detail in, e.g., U.S. Pat. Nos. 7,709,458 and 7,592,326;
WO2007/054279; and Yan et al., Bioorg. Med. Chem Lett. 18: 5631
(2008), each of which is hereby incorporated by reference.
[0007] There remains a need for improved compositions and methods
for immunologic strategies to treating diseases such as cancer that
can be refractory to traditional therapeutic approaches.
SUMMARY OF THE INVENTION
[0008] It is an object of the present invention to provide novel
and highly active cyclic-di-nucleotide (CDN) immune stimulators
that activates DCs via a recently discovered cytoplasmic receptor
known as STING (Stimulator of Interferon Genes). In particular, the
CDNs of the present invention are provided in the form of a
composition comprising one or more cyclic purine dinucleotides that
induce STING-dependent TBK1 activation, wherein the cyclic purine
dinuclotides present in the composition are substantially pure
Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure
Rp,Rp, or RpSp CDN thiophosphate diastereomers.
[0009] In a first aspect, the present invention provides a
composition comprising one or more cyclic purine dinucleotide,
wherein the cyclic purine dinuclotides present in the composition
are substantially pure Rp,Rp or Rp,Sp diastereomers, or prodrugs or
pharmaceutically acceptable salts thereof. These compositions,
which induce STING-dependent TBK1 activation, may comprise one or
more pharmaceutically acceptable excipients and may find use as
adjuvants as described herein. Particularly preferred are
thiophosphate derivatives of cyclic purine dinucleotides as
described hereinafter
[0010] In their role as adjuvants, in certain embodiments the
present compositions may be used as adjuvants in a therapeutic or
prophylactic strategy employing vaccine(s). Thus, substantially
pure Rp,Rp or Rp,Sp diastereomers, or prodrugs or pharmaceutically
acceptable salts thereof, may be used together with one or more
vaccines selected to stimulate an immune response to one or more
predetermined antigens. The substantially pure Rp,Rp or Rp,Sp
diastereomers, or prodrugs or pharmaceutically acceptable salts
thereof of the present invention may be provided together with, or
in addition to, such vaccines.
[0011] Such vaccine(s) can comprise inactivated or attenuated
bacteria or viruses comprising the antigens of interest, purified
antigens, live viral or bacterial delivery vectors recombinantly
engineered to express and/or secrete the antigens, antigen
presenting cell (APC) vectors comprising cells that are loaded with
the antigens or transfected with a composition comprising a nucleic
acid encoding the antigens, liposomal antigen delivery vehicles, or
naked nucleic acid vectors encoding the antigens. This list is not
meant to be limiting. By way of example, such vaccine(s) may also
comprise an inactivated tumor cell that expresses and secretes one
or more of GM-CSF, CCL20, CCL3, IL-12p70, FLT-3 ligand.
[0012] The compositions of the present invention may be
administered to individuals in need thereof by a variety of
parenteral and nonparenteral routes in formulations containing
pharmaceutically acceptable carriers, adjuvants and vehicles.
Preferred routes are parenteral, and include but, are not limited
to, one or more of subcutaneous, intravenous, intramuscular,
intraarterial, intradermal, intrathecal and epidural
administrations. Particularly preferred is administration by
subcutaneous administration. Preferred pharmaceutical composition
are formulated as aqueous or oil-in-water emulsions.
[0013] The compositions of the present invention may comprise, or
be administered together with, one or more additional
pharmaceutically active compone
[0014] nts such as adjuvants, lipids such as digitonin, liposomes,
CTLA-4 and PD-1 pathway Antagonists, PD-1 pathway blocking agents,
inactivated bacteria which induce innate immunity (e.g.,
inactivated or attenuated Listeria monocytogenes), compositions
which mediate innate immune activation via Toll-like Receptors
(TLRs), (NOD)-like receptors (NLRs), Retinoic acid inducible
gene-based (RIG)-I-like receptors (RLRs), C-type lectin receptors
(CLRs), pathogen-associated molecular patterns ("PAMPs"),
chemotherapeutic agents, etc.
[0015] As described hereinafter, cyclic purine dinuclotides
formulated with one or more lipids can exhibit improved properties,
including improved dendritic cell activation activity. Thus, the
present invention also relates to a composition comprising one or
more CDNs and one or more lipids. In certain preferred embodiments,
one or more CDNs are formulated with digitonin, a liposomal
formulation, and/or an oil-in-water emulsion. A composition
according to one of claims 1-5, further comprising one or more of a
CTLA-4 antagonist and a TLR-4 agonist.
[0016] In preferred embodiments, the one or more thiophposphate
cyclic purine dinucleotides comprise a substantially pure Rp,Rp or
Rp,Sp thiophposphate diastereomer selected from the group
consisting of c-di-AMP thiophposphate, c-di-GMP thiophposphate,
c-di-IMP thiophposphate, c-AMP-GMP thiophposphate, c-AMP-IMP
thiophposphate, and c-GMP-IMP thiophposphate, or combinations
thereof, including prodrugs and pharmaceutically acceptable salts
thereof.
[0017] In a related aspect, the present invention relates to
methods of inducing, stimulating, or adjuvanting an immune response
in an individual. These methods comprise administering to the
individual a composition comprising one or more cyclic purine
dinucleotide, wherein the thiophposphate cyclic purine dinuclotides
present in the composition are substantially pure Rp,Rp or Rp,Sp
diastereomers, or prodrugs or pharmaceutically acceptable salts
thereof to the individual. Preferred routes of administration are
parenteral. As noted above, particularly preferred are
thiophosphate derivatives of such cyclic purine dinucleotides.
[0018] In certain embodiments, the method is a method of cancer
treatment. By way of example, the substantially pure Rp,Rp or Rp,Sp
diastereomers, or prodrugs or pharmaceutically acceptable salts
thereof of the present invention may be provided together with, or
in addition to, one or more cancer vaccine compositions that are
known in the art. The patient receiving such treatment may be
suffering from a cancer selected from the group consisting of a
colorectal cancer cell, an aero-digestive squamous cancer, a lung
cancer, a brain cancer, a liver cancer, a stomach cancer, a
sarcoma, a leukemia, a lymphoma, a multiple myeloma, an ovarian
cancer, a uterine cancer, a breast cancer, a melanoma, a prostate
cancer, a pancreatic carcinoma, and a renal carcinoma. In other
embodiments, the method is a method of inducing, stimulating, or
adjuvanting an immune response a pathogen.
[0019] In still other related aspects, the present invention
relates to methods of inducing STING-dependent TBK1 activation in
an individual, comprising administering one or more cyclic purine
dinucleotides which bind to STING to the individual, wherein the
cyclic purine dinuclotides present in the composition are
substantially pure Rp,Rp or Rp,Sp diastereomers, or prodrugs or
pharmaceutically acceptable salts thereof to the individual.
Preferred routes of administration are parenteral. As noted above,
particularly preferred are thiophosphate derivatives of such cyclic
purine dinucleotides.
[0020] The methods described herein can comprise administering to
the mammal an effective amount of the substantially pure CDNs of
the present invention, or prodrugs or pharmaceutically acceptable
salts thereof, prior to or following a primary therapy administered
to the mammal to remove or kill cancer cells expressing the cancer
antigen. The compositions of the present invention may be provided
as a neoadjuvant therapy; however in preferred embodiments, the
compositions of the present invention are administered following
the primary therapy. In various embodiments, the primary therapy
comprises surgery to remove the cancer cells from the mammal,
radiation therapy to kill the cancer cells in the mammal, or both
surgery and radiation therapy.
[0021] In other embodiments, the methods described herein can
comprise administering to the mammal an effective amount of the
substantially pure CDNs of the present invention for the treatment
of disorders in which shifting of Th1 to Th2 immunity confers
clinical benefit. Cell-mediated immunity (CMI) is associated with
TH1 CD4+T lymphocytes producing cytokines IL-2, interferon
(IFN)-.gamma. and tumor necrosis factor (TNF)-.alpha.. In contrast,
humoral immunity is associated with TH2 CD4+T lymphocytes producing
IL-4, IL-6 and IL-10. Immune deviation towards TH1 responses
typically produces activation of cytotoxic T-cell lymphocytes
(CTL), natural killer (NK) cells, macrophages and monocytes.
Generally, Th1 responses are more effective against intracellular
pathogens (viruses and bacteria that are inside host cells) and
tumors, while Th2 responses are more effective against
extracellular bacteria, parasites including helminths and toxins.
In addition, the activation of innate immunity is expected to
normalize the T-helper type 1 and 2 (Th1/Th2) immune system balance
and to suppress the excessive reaction of Th2 type responses that
cause immunoglobulin (Ig) E-dependent allergies and allergic
asthma.
BRIEF DESCRIPTION OF THE FIGURES
[0022] FIG. 1 depicts a general structure of CDNs.
[0023] FIG. 2 depicts a structure of c-di-GMP (compound 11A) and
c-di-AMP (compound 10A).
[0024] FIG. 3 depicts a structure of Rp,Rp-c-di-GMP-thiophosphate
(compound 11B) and Rp,Rp-c-di-AMP-thiophosphate (compound 10B).
[0025] FIG. 4 depicts a structure of Rp,Sp-c-di-GMP-thiophosphate
(compound 11C) and Rp,Sp-c-di-AMP-thiophosphate (compound 10C).
[0026] FIG. 5 depicts a structure of Sp,Sp-c-di-GMP-thiophosphate
and Sp,Sp-c-di-AMP-thiophosphate.
[0027] FIG. 6 depicts a synthesis scheme for c-di-AMP and
c-di-AMP-thiophosphate.
[0028] FIG. 7 depicts IFN-.beta. induction in antigen presenting
cells by parent CDNs and diatereomers of the corresponding dithio
derivative molecules.
[0029] FIG. 8 depicts IFN-.beta. induction in antigen presenting
cells by CDN diatereomers following treatment with snake venom
phosphodiesterase
[0030] FIG. 9 depicts OVA-specific CD4 and CD8 T cell responses
measured in PBMC at 10 days post vaccination in conjunction with
CDN treatment.
[0031] FIG. 10 depicts SIVgag-specific CD4 and CD8 T cell responses
measured in PBMC post vaccination in conjunction with CDN
treatment.
[0032] FIGS. 11A-C depict protection induced by CDN in a
Listeria-OVA challenge murine model. FIG. 11A shows mice immunized
with vaccines adjuvanted with Rp, Rp dithio-diphosphate c-di-GMP
generated a higher magnitude of OVA-specific CD8 T cell memory, as
compared to mice immunized with vaccines adjuvanted with unmodified
c-di-GMP.
[0033] FIG. 11B depicts the FACS plot which demonstrates that the
magnitude of OVA-specific CD8 T cell memory approached 30% of the
total CD8 T cell population in PBMC from mice immunized with Rp, Rp
dithio-diphosphate c-di-GMP adjuvanted vaccines.
[0034] FIG. 11C shows that immunization of mice with Rp, Rp
dithio-diphosphate c-di-GMP adjuvanted vaccines afforded complete
protection (below the limit of detection, LOD) against virulent
pathogen challenge.
[0035] FIG. 12 depicts anti-tumor efficacy induced by CDNs
formulated with GVAX in a murine prostate cancer model.
[0036] FIG. 13 depicts 2'-O-substituent prodrug analogs of CDNs of
the present invention.
[0037] FIG. 14 depicts synthesis of 0- or S-substituent prodrug
analog of CDNs of the present invention.
[0038] FIG. 15 depicts IFN-.beta. induction in a human monocytic
cell line following administration of a mono-2'-O-myristoyl
c-di-GMP prodrug form of c-di-GMP.
[0039] FIG. 16 depicts OVA-specific CD8 T cell responses following
vaccination with a mono-2'-O-myristoyl c-di-GMP prodrug form of
c-di-GMP.
DETAILED DESCRIPTION OF THE INVENTION
[0040] The present invention relates to the use of novel and highly
active cyclic-di-nucleotide (CDN) immune stimulators that activates
DCs via a recently discovered cytoplasmic receptor known as STING
(Stimulator of Interferon Genes). In particular, the CDNs of the
present invention are provided in the form of a composition
comprising one or more cyclic purine dinucleotides induce
STING-dependent TBK1 activation, wherein the cyclic purine
dinuclotides present in the composition are substantially pure
Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure
Rp,Rp, or RpSp CDN thiophosphate diastereomers.
[0041] Recent insights into the design and development of adjuvants
are informed by a fundamental understanding that conserved
microbial structures known as Pathogen-Associated Molecular
Patterns (PAMPs) are sensed by host cell Pattern Recognition
Receptors (PRRs), triggering a downstream signaling cascade
resulting in the induction of cytokines and chemokines, and
initiation of a specific adaptive immune response. How the innate
immune system is engaged by the PAMP complement of a microbe shapes
the development of an adaptive response that is appropriate to
combat the invading pathogen from causing disease. An objective of
adjuvant design is to select defined PAMPs or synthetic molecules
specific for designated PRRs to initiate a desired response.
Adjuvants such as monophosphoryl lipid A (MPL) and CpG are PAMPs
recognized by Toll-like receptors (TLRs), a class of transmembrane
PRRs that signal through MyD88 and Trif adaptor molecules and
mediate induction of NF-kB dependent proinflammatory cytokines. MPL
(TLR-4 agonist) and CpG (TLR-9 agonist) are clinically advanced
adjuvants, and are components of vaccines that are approved or
pending approval by the FDA. While TLRs present on the cell surface
(e.g., TLR-4) and endosomes (e.g., CpG) sense extracellular and
vacuolar pathogens, the productive growth cycle of multiple
pathogens including viruses and intracellular bacteria occurs in
the cytosol. The compartmentalization of extracellular, vacuolar,
and cytosolic PRRs has led to the hypothesis that the innate immune
system distinguishes between pathogenic and non-pathogenic microbes
by monitoring the cytosol. It should be apparent to one skilled in
the art that agonists specific for PRRs comprising the cytosolic
surveillance pathway that initiate development of protective
immunity against intracellular pathogens, and is relevant to
vaccine design. These same targeting ligands will also be essential
in the development of effective vaccines targeting malignancies,
know to require tumor-specific CD4+ and CD8+ T cells.
[0042] Activation of the Cytosolic Surveillance Pathway (CSP) is
Integral to Development of Protective Immunity to Intracellular
Pathogens. The CSP detects bacterial, viral, and protozoan
pathogens, leading to activation of the TANK binding kinase
(TBK-1)/IRF-3 signaling axis and induction of IFN-.beta. and other
co-regulated genes. Both viral and bacterial nucleic acids activate
this pathway, and induction of IFN-.beta. is MyD88 and Trif
independent. While Type I interferon is often thought of primarily
as a host anti-viral response, induction of IFN-.beta. is a
signature of cytosolic growth in macrophages infected with the
intracellular bacterium, Listeria monocytogenes (Lm). A well-known
dichotomy in the mouse listeriosis model is that, whereas wild-type
Lm primes potent CD4 and CD8 T-cell immunity that protects mice
against bacterial challenge, vaccination with listeriolysin O
(LLO)-deleted Lm does not elicit functional T cells or induce
protective immunity. This difference is evidence of the requirement
for expression of host cell genes and cytosolic access by Lm to
elicit functional T-cell mediated protective immunity. The level of
IFN-.beta. in infected host cells is regulated by Lm multidrug
efflux pumps (MDRs), which that secrete structurally unrelated
small molecules, including antibiotics. IFN-.beta. is not induced
in host cells infected with Lm LLO mutants that are confined to the
phagolysosome. Normal levels of IFN-.beta. are induced in infected
MyD88.sup.-/- Trif.sup.-/- macrophages deficient in all
TLR-mediated signaling. These data demonstrate that although Lm
engages TLRs, in response to infection with wild-type Lm, the host
cell CSP is required for development of protective immunity,
correlated with induction of IFN-.beta..
[0043] The term "cyclic-di-nucleotides" ("CDNs") as used herein
refers to a class of molecules comprising 2'-5' and/or 3'-5'
phosphodiester linkages between two purine nucleotides. This
includes 2'-5'-2',5', 2'-5'-3'5', and 3',5'-3',5' linkages. CDNs
activate the cytosolic surveillance pathway through direct binding
of two cytosolic PRRs, DDX41 and STING. The Type I interferon
response to infection by Lm and other intracellular bacteria
results from the secretion of c-di-AMP or its related cyclic
dinucleotide (CDN), c-di-GMP, and its direct binding to DDX41 and
DEAD (aspartate-glutamate-alanine-aspartate) box helicase and STING
(Stimulator of Interferon Genes), a recently defined receptor of
the cytosolic surveillance pathway. CDNs are second messengers
expressed by most bacteria and regulate diverse processes,
including motility and formation of biofilms. CDNs bind with high
affinity to DDX41, and complex with the STING adaptor protein,
resulting in the activation of the TBK1/IRF3 signaling pathway, and
induction of IFN-.beta. and other IRF-3 dependent gene products
that strongly activate innate immunity.
[0044] Native CDN molecules are sensitive to degradation by
phosphodiesterases that are present in host cells, for example in
antigen presenting cells, that take up vaccine formulations that
contain said native CDN molecules. The potency of a defined
adjuvant may be diminished by such degradation, as the adjuvant
would be unable to bind and activate its defined PRR target. Lower
adjuvant potency could be measured, for example by a lower amount
of induced expression of a signature molecule of innate immunity
(e.g., IFN-.beta.), correlated with weaker vaccine potency, as
defined by the magnitude of a measured antigen-specific immune
response.
[0045] In the present invention, dithio-diphosphate derivatives of
c-di-AMP and c-di-GMP are provided. The synthesis process for said
dithio-diphosphate derivatives of c-di-AMP and c-di-GMP molecules
results in a mixture of diastereomers, including Rp,Rp, Sp,Sp and
Rp,Sp dithio-diphosphate derivatives of c-di-AMP and c-di-GMP
molecules. It has been shown previously that said mixtures of
diastereomers containing Rp, Rp and Rp, Sp dithio-diphosphate
derivatives of c-di-GMP recruited and activated inflammatory cells
into the bronchoalveolar spaces when administered to mice by an
intranasal route. However, there was no evidence that this such
dithio-diphosphate derivatives of c-di-GMP provided any advantages
with regard to stimulating an immune response, as compared to the
parent c-di-GMP molecules, and, in fact, such dithio-diphosphate
c-di-GMP preparations had only similar or weaker potency as
compared to the parent c-di-GMP molecules.
Definitions
[0046] "Administration" as it is used herein with regard to a
human, mammal, mammalian subject, animal, veterinary subject,
placebo subject, research subject, experimental subject, cell,
tissue, organ, or biological fluid, refers without limitation to
contact of an exogenous ligand, reagent, placebo, small molecule,
pharmaceutical agent, therapeutic agent, diagnostic agent, or
composition to the subject, cell, tissue, organ, or biological
fluid, and the like. "Administration" can refer, e.g., to
therapeutic, pharmacokinetic, diagnostic, research, placebo, and
experimental methods. Treatment of a cell encompasses contact of a
reagent to the cell, as well as contact of a reagent to a fluid,
where the fluid is in contact with the cell. "Administration" also
encompasses in vitro and ex vivo treatments, e.g., of a cell, by a
reagent, diagnostic, binding composition, or by another cell. By
"administered together" it is not meant to be implied that two or
more agents be administered as a single composition. Although
administration as a single composition is contemplated by the
present invention, such agents may be delivered to a single subject
as separate administrations, which may be at the same or different
time, and which may be by the same route or different routes of
administration.
[0047] An "agonist," as it relates to a ligand and receptor,
comprises a molecule, combination of molecules, a complex, or a
combination of reagents, that stimulates the receptor. For example,
an agonist of granulocyte-macrophage colony stimulating factor
(GM-CSF) can encompass GM-CSF, a mutein or derivative of GM-CSF, a
peptide mimetic of GM-CSF, a small molecule that mimics the
biological function of GM-CSF, or an antibody that stimulates
GM-CSF receptor.
[0048] An "antagonist," as it relates to a ligand and receptor,
comprises a molecule, combination of molecules, or a complex, that
inhibits, counteracts, downregulates, and/or desensitizes the
receptor. "Antagonist" encompasses any reagent that inhibits a
constitutive activity of the receptor. A constitutive activity is
one that is manifest in the absence of a ligand/receptor
interaction. "Antagonist" also encompasses any reagent that
inhibits or prevents a stimulated (or regulated) activity of a
receptor. By way of example, an antagonist of GM-CSF receptor
includes, without implying any limitation, an antibody that binds
to the ligand (GM-CSF) and prevents it from binding to the
receptor, or an antibody that binds to the receptor and prevents
the ligand from binding to the receptor, or where the antibody
locks the receptor in an inactive conformation.
[0049] As used herein, an "analog" or "derivative" with reference
to a peptide, polypeptide or protein refers to another peptide,
polypeptide or protein that possesses a similar or identical
function as the original peptide, polypeptide or protein, but does
not necessarily comprise a similar or identical amino acid sequence
or structure of the original peptide, polypeptide or protein. An
analog preferably satisfies at least one of the following: (a) a
proteinaceous agent having an amino acid sequence that is at least
30%, at least 35%, at least 40%, at least 45%, at least 50%, at
least 55%, at least 60%, at least 65%, at least 70%, at least 75%,
at least 80%, at least 85%, at least 90%, at least 95% or at least
99% identical to the original amino acid sequence (b) a
proteinaceous agent encoded by a nucleotide sequence that
hybridizes under stringent conditions to a nucleotide sequence
encoding the original amino acid sequence; and (c) a proteinaceous
agent encoded by a nucleotide sequence that is at least 30%, at
least 35%, at least 40%, at least 45%, at least 50%, at least 55%,
at least 60%, at least 65%, at least 70%, at least 75%, at least
80%, at least 85%, at least 90%, at least 95% or at least 99%
identical to the nucleotide sequence encoding the original amino
acid sequence.
[0050] "Antigen presenting cells" (APCs) are cells of the immune
system used for presenting antigen to T cells. APCs include
dendritic cells, monocytes, macrophages, marginal zone Kupffer
cells, microglia, Langerhans cells, T cells, and B cells. Dendritic
cells occur in at least two lineages. The first lineage encompasses
pre-DC1, myeloid DC1, and mature DC1. The second lineage
encompasses CD34.sup.+CD45RA.sup.- early progenitor multipotent
cells, CD34.sup.+CD45RA.sup.+ cells,
CD34.sup.+CD45RA.sup.+CD4+IL-3R.alpha..sup.+ pro-DC2 cells,
CD4.sup.+CD11c.sup.- plasmacytoid pre-DC2 cells, lymphoid human DC2
plasmacytoid-derived DC2s, and mature DC2s.
[0051] "Attenuation" and "attenuated" encompasses a bacterium,
virus, parasite, infectious organism, prion, tumor cell, gene in
the infectious organism, and the like, that is modified to reduce
toxicity to a host. The host can be a human or animal host, or an
organ, tissue, or cell. The bacterium, to give a non-limiting
example, can be attenuated to reduce binding to a host cell, to
reduce spread from one host cell to another host cell, to reduce
extracellular growth, or to reduce intracellular growth in a host
cell. Attenuation can be assessed by measuring, e.g., an indicum or
indicia of toxicity, the LD.sub.50, the rate of clearance from an
organ, or the competitive index (see, e.g., Auerbuch, et al. (2001)
Infect. Immunity 69:5953-5957). Generally, an attenuation results
an increase in the LD.sub.50 and/or an increase in the rate of
clearance by at least 25%; more generally by at least 50%; most
generally by at least 100% (2-fold); normally by at least 5-fold;
more normally by at least 10-fold; most normally by at least
50-fold; often by at least 100-fold; more often by at least
500-fold; and most often by at least 1000-fold; usually by at least
5000-fold; more usually by at least 10,000-fold; and most usually
by at least 50,000-fold; and most often by at least
100,000-fold.
[0052] By "purified" and "isolated" is meant that a specified
species accounts for at least 50%, more often accounts for at least
60%, typically accounts for at least 70%, more typically accounts
for at least 75%, most typically accounts for at least 80%, usually
accounts for at least 85%, more usually accounts for at least 90%,
most usually accounts for at least 95%, and conventionally accounts
for at least 98% by weight, or greater, of the species present in a
composition. The weights of water, buffers, salts, detergents,
reductants, protease inhibitors, stabilizers (including an added
protein such as albumin), and excipients are generally not used in
the determination of purity.
[0053] "Specifically" or "selectively" binds, when referring to a
ligand/receptor, nucleic acid/complementary nucleic acid,
antibody/antigen, or other binding pair (e.g., a cytokine to a
cytokine receptor) (each generally referred to herein as a "target
biomolecule" or a "target") indicates a binding reaction which is
related to the presence of the target in a heterogeneous population
of proteins and other biologics. Specific binding can mean, e.g.,
that the binding compound, nucleic acid ligand, antibody, or
binding composition derived from the antigen-binding site of an
antibody, of the contemplated method binds to its target with an
affinity that is often at least 25% greater, more often at least
50% greater, most often at least 100% (2-fold) greater, normally at
least ten times greater, more normally at least 20-times greater,
and most normally at least 100-times greater than the affinity with
a non-target molecule.
[0054] "Ligand" refers to a small molecule, nucleic acid, peptide,
polypeptide, saccharide, polysaccharide, glycan, glycoprotein,
glycolipid, or combinations thereof that binds to a target
biomolecule. While such ligands may be agonists or antagonists of a
receptor, a ligand also encompasses a binding agent that is not an
agonist or antagonist, and has no agonist or antagonist properties.
Specific binding of a ligand for its cognate target is often
expressed in terms of an "Affinity." In preferred embodiments, the
ligands of the present invention bind with affinities of between
about 10.sup.4 M.sup.-1 and about 10.sup.8 M.sup.-1. Affinity is
calculated as K.sub.d=k.sub.off/k.sub.on (k.sub.off is the
dissociation rate constant, K.sub.on is the association rate
constant and K.sub.d is the equilibrium constant).
[0055] Affinity can be determined at equilibrium by measuring the
fraction bound (r) of labeled ligand at various concentrations (c).
The data are graphed using the Scatchard equation: r/c=K(n-r):
where r=moles of bound ligand/mole of receptor at equilibrium;
c=free ligand concentration at equilibrium; K=equilibrium
association constant; and n=number of ligand binding sites per
receptor molecule. By graphical analysis, r/c is plotted on the
Y-axis versus r on the X-axis, thus producing a Scatchard plot.
Affinity measurement by Scatchard analysis is well known in the
art. See, e.g., van Erp et al., J. Immunoassay 12: 425-43, 1991;
Nelson and Griswold, Comput. Methods Programs Biomed. 27: 65-8,
1988. In an alternative, affinity can be measured by isothermal
titration calorimetry (ITC). In a typical ITC experiment, a
solution of ligand is titrated into a solution of its cognate
target. The heat released upon their interaction (.DELTA.H) is
monitored over time. As successive amounts of the ligand are
titrated into the ITC cell, the quantity of heat absorbed or
released is in direct proportion to the amount of binding. As the
system reaches saturation, the heat signal diminishes until only
heats of dilution are observed. A binding curve is then obtained
from a plot of the heats from each injection against the ratio of
ligand and binding partner in the cell. The binding curve is
analyzed with the appropriate binding model to determine K.sub.B, n
and .DELTA.H. Note that K.sub.B=1/K.sub.d.
[0056] The term "subject" as used herein refers to a human or
non-human organism. Thus, the methods and compositions described
herein are applicable to both human and veterinary disease. In
certain embodiments, subjects are "patients," i.e., living humans
that are receiving medical care for a disease or condition. This
includes persons with no defined illness who are being investigated
for signs of pathology. Preferred are subjects who have an existing
diagnosis of a particular cancer which is being targeted by the
compositions and methods of the present invention. Preferred
cancers for treatment with the compositions described herein
include, but are not limited to prostate cancer, renal carcinoma,
melanoma, pancreatic cancer, cervical cancer, ovarian cancer, colon
cancer, head & neck cancer, lung cancer and breast cancer.
[0057] "Therapeutically effective amount" is defined as an amount
of a reagent or pharmaceutical composition that is sufficient to
show a patient benefit, i.e., to cause a decrease, prevention, or
amelioration of the symptoms of the condition being treated. When
the agent or pharmaceutical composition comprises a diagnostic
agent, a "diagnostically effective amount" is defined as an amount
that is sufficient to produce a signal, image, or other diagnostic
parameter. Effective amounts of the pharmaceutical formulation will
vary according to factors such as the degree of susceptibility of
the individual, the age, gender, and weight of the individual, and
idiosyncratic responses of the individual. "Effective amount"
encompasses, without limitation, an amount that can ameliorate,
reverse, mitigate, prevent, or diagnose a symptom or sign of a
medical condition or disorder or a causative process thereof.
Unless dictated otherwise, explicitly or by context, an "effective
amount" is not limited to a minimal amount sufficient to ameliorate
a condition.
[0058] "Treatment" or "treating" (with respect to a condition or a
disease) is an approach for obtaining beneficial or desired results
including and preferably clinical results. For purposes of this
invention, beneficial or desired results with respect to a disease
include, but are not limited to, one or more of the following:
preventing a disease, improving a condition associated with a
disease, curing a disease, lessening severity of a disease,
delaying progression of a disease, alleviating one or more symptoms
associated with a disease, increasing the quality of life of one
suffering from a disease, and/or prolonging survival. Likewise, for
purposes of this invention, beneficial or desired results with
respect to a condition include, but are not limited to, one or more
of the following: preventing a condition, improving a condition,
curing a condition, lessening severity of a condition, delaying
progression of a condition, alleviating one or more symptoms
associated with a condition, increasing the quality of life of one
suffering from a condition, and/or prolonging survival. For
instance, in embodiments where the compositions described herein
are used for treatment of cancer, the beneficial or desired results
include, but are not limited to, one or more of the following:
reducing the proliferation of (or destroying) neoplastic or
cancerous cells, reducing metastasis of neoplastic cells found in
cancers, shrinking the size of a tumor, decreasing symptoms
resulting from the cancer, increasing the quality of life of those
suffering from the cancer, decreasing the dose of other medications
required to treat the disease, delaying the progression of the
cancer, and/or prolonging survival of patients having cancer.
Depending on the context, "treatment" of a subject can imply that
the subject is in need of treatment, e.g., in the situation where
the subject comprises a disorder expected to be ameliorated by
administration of a reagent.
[0059] By "purified" and "isolated" is meant, when referring to a
polypeptide, that the polypeptide is present in the substantial
absence of the other biological macromolecules with which it is
associated in nature. The term "purified" as used herein means that
an identified polypeptide often accounts for at least 50%, more
often accounts for at least 60%, typically accounts for at least
70%, more typically accounts for at least 75%, most typically
accounts for at least 80%, usually accounts for at least 85%, more
usually accounts for at least 90%, most usually accounts for at
least 95%, and conventionally accounts for at least 98% by weight,
or greater, of the polypeptides present. The weights of water,
buffers, salts, detergents, reductants, protease inhibitors,
stabilizers (including an added protein such as albumin), and
excipients, and molecules having a molecular weight of less than
1000, are generally not used in the determination of polypeptide
purity. See, e.g., discussion of purity in U.S. Pat. No. 6,090,611
issued to Covacci, et al.
[0060] "Peptide" refers to a short sequence of amino acids, where
the amino acids are connected to each other by peptide bonds. A
peptide may occur free or bound to another moiety, such as a
macromolecule, lipid, oligo- or polysaccharide, and/or a
polypeptide. Where a peptide is incorporated into a polypeptide
chain, the term "peptide" may still be used to refer specifically
to the short sequence of amino acids. A "peptide" may be connected
to another moiety by way of a peptide bond or some other type of
linkage. A peptide is at least two amino acids in length and
generally less than about 25 amino acids in length, where the
maximal length is a function of custom or context. The terms
"peptide" and "oligopeptide" may be used interchangeably.
[0061] "Protein" generally refers to the sequence of amino acids
comprising a polypeptide chain. Protein may also refer to a three
dimensional structure of the polypeptide. "Denatured protein"
refers to a partially denatured polypeptide, having some residual
three dimensional structure or, alternatively, to an essentially
random three dimensional structure, i.e., totally denatured. The
invention encompasses reagents of, and methods using, polypeptide
variants, e.g., involving glycosylation, phosphorylation,
sulfation, disulfide bond formation, deamidation, isomerization,
cleavage points in signal or leader sequence processing, covalent
and non-covalently bound cofactors, oxidized variants, and the
like. The formation of disulfide linked proteins is described (see,
e.g., Woycechowsky and Raines (2000) Curr. Opin. Chem. Biol.
4:533-539; Creighton, et al. (1995) Trends Biotechnol.
13:18-23).
[0062] "Recombinant" when used with reference, e.g., to a nucleic
acid, cell, animal, virus, plasmid, vector, or the like, indicates
modification by the introduction of an exogenous, non-native
nucleic acid, alteration of a native nucleic acid, or by derivation
in whole or in part from a recombinant nucleic acid, cell, virus,
plasmid, or vector. Recombinant protein refers to a protein
derived, e.g., from a recombinant nucleic acid, virus, plasmid,
vector, or the like. "Recombinant bacterium" encompasses a
bacterium where the genome is engineered by recombinant methods,
e.g., by way of a mutation, deletion, insertion, and/or a
rearrangement. "Recombinant bacterium" also encompasses a bacterium
modified to include a recombinant extra-genomic nucleic acid, e.g.,
a plasmid or a second chromosome, or a bacterium where an existing
extra-genomic nucleic acid is altered.
[0063] "Sample" refers to a sample from a human, animal, placebo,
or research sample, e.g., a cell, tissue, organ, fluid, gas,
aerosol, slurry, colloid, or coagulated material. The "sample" may
be tested in vivo, e.g., without removal from the human or animal,
or it may be tested in vitro. The sample may be tested after
processing, e.g., by histological methods. "Sample" also refers,
e.g., to a cell comprising a fluid or tissue sample or a cell
separated from a fluid or tissue sample. "Sample" may also refer to
a cell, tissue, organ, or fluid that is freshly taken from a human
or animal, or to a cell, tissue, organ, or fluid that is processed
or stored.
[0064] "Vaccine" encompasses preventative vaccines. Vaccine also
encompasses therapeutic vaccines, e.g., a vaccine administered to a
mammal that comprises a condition or disorder associated with the
antigen or epitope provided by the vaccine.
[0065] The term "antibody" as used herein refers to a peptide or
polypeptide derived from, modeled after or substantially encoded by
an immunoglobulin gene or immunoglobulin genes, or fragments
thereof, capable of specifically binding an antigen or epitope.
See, e.g. Fundamental Immunology, 3rd Edition, W. E. Paul, ed.,
Raven Press, N.Y. (1993); Wilson (1994; J. Immunol. Methods
175:267-273; Yarmush (1992) J. Biochem. Biophys. Methods 25:85-97.
The term antibody includes antigen-binding portions, i.e., "antigen
binding sites," (e.g., fragments, subsequences, complementarity
determining regions (CDRs)) that retain capacity to bind antigen,
including (i) a Fab fragment, a monovalent fragment consisting of
the VL, VH, CL and CH1 domains; (ii) a F(ab')2 fragment, a bivalent
fragment comprising two Fab fragments linked by a disulfide bridge
at the hinge region; (iii) a Fd fragment consisting of the VH and
CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains
of a single arm of an antibody, (v) a dAb fragment (Ward et al.,
(1989) Nature 341:544-546), which consists of a VH domain; and (vi)
an isolated complementarity determining region (CDR). Single chain
antibodies are also included by reference in the term
"antibody."
[0066] Cyclic Purine Dinucleotides
[0067] As described herein, the present invention relates to
stereochemically purified cyclic purine dinucleotides which induce
STING-dependent TBK1 activation and their methods of preparation
and use.
[0068] Prokaryotic as well as eukaryotic cells use various small
molecules for cell signaling and intra- and intercellular
communication. Cyclic nucleotides like cGMP, cAMP, etc. are known
to have regulatory and initiating activity in pro- and eukaryotic
cells. Unlike eukaryotic cells, prokaryotic cells also use cyclic
purine dinucleotides as regulatory molecules. In prokaryotes, the
condensation of two GTP molecules is catalyst by the enzyme
diguanylate cyclase (DGC) to give c-diGMP, which represents an
important regulator in bacteria.
[0069] Recent work suggests that CDNs suvch as cyclic diGMP or
analogs thereof can also stimulate or enhance immune or
inflammatory response in a patient or can enhance the immune
response to a vaccine by serving as an adjuvant in mammals.
Cytosolic detection of pathogen-derived DNA requires signaling
through TANK binding kinase 1 (TBK1) and its downstream
transcription factor, IFN-regulatory factor 3 (IRF3). A
transmembrane protein called STING (stimulator of IFN genes; also
known as MITA, ERIS, MPYS and TMEM173) functions as the signaling
receptor for these cyclic purine dinucleotides, causing stimulation
of the TBK1-IRF3 signalling axis and a STING-dependent type I
interferon response. See, e.g., FIG. 1. Burdette et al., Nature
478: 515-18, 2011 demonstrated that STING binds directly to cyclic
diguanylate monophosphate, but not to other unrelated nucleotides
or nucleic acids.
[0070] The goal of vaccine formulation is typically to provide a
combination of antigens and adjuvants capable of generating a
sufficient population of memory T cells and/or B cells to react
quickly to a pathogen, tumor cell, etc., bearing an antigen of
interest. The present invention relates to methods for providing
adjuvant compositions comprising one or more cyclic purine
dinucleotides, wherein the cyclic purine dinuclotides present in
the composition are substantially pure Rp,Rp or Rp,Sp
diastereomers, methods for the manufacture thereof, and methods for
the use thereof to stimulate an immune response in an animal.
[0071] Preferred cyclic purine dinuclotides include, but are not
limited to, c-di-AMP, c-di-GMP, c-di-IMP, c-AMP-GMP, c-AMP-IMP, and
c-GMP-IMP, and analogs thereof including, but not limited to,
phosphorothioate analogues, referred to herein as "thiophosphates".
A general structure of CDN thiophsphate is provided in FIG. 1. In
this figure, B1 and B2 represent the base moiety. Phosphorothioates
are a variant of normal nucleotides in which one of the nonbridging
oxygens is replaced by a sulfur. The sulfurization of the
internucleotide bond dramatically reduces the action of endo- and
exonucleases, including 5' to 3' and 3' to 5' DNA POL 1
exonuclease, nucleases S1 and P1, RNases, serum nucleases and snake
venom phosphodiesterase. In addition, the potential for crossing
the lipid bilayer increases.
[0072] A phosphorothioate linkage in inherently chiral. The skilled
artisan will recognize that the phosphates in this structure may
each exist in R or S forms. Thus, Rp,Rp, Sp,Sp, and Rp,Sp forms are
possible. In each case, preferred are substantially pure Rp,Rp and
Rp,Sp diastereomers of these molecules. Examples of such CDN
thiophosphate molecules are depicted in FIGS. 2-6 herein, which
show thiophosphate forms of Rp,Rp-c-di-adenosine monophosphate;
Rp,Sp-c-di-adenosine monophosphate; Rp,Rp-c-di-guanosine
monophosphate and Rp,Sp-c-di-guanosine monophosphate. In these
figures, the stereochemistry of the phosphate center is shown as R
or S, as appropriate.
[0073] Preferred cyclic purine dinuclotides also include
2'-O-substituent forms of CDNs, and in particular CDN
thiophosphates. Additional stability and bioavailability can be
provided by the substitution of the 2'-OH of the ribose moiety. An
example of such 2'-O-substituent analogs are shown in FIG. 11.
Substituent groups amenable herein include without limitation,
halogen, hydroxyl, alkyl, alkenyl, alkynyl, acyl (--C(0)R.sub.aa),
carboxyl (--C(0)0-R.sub.aa), aliphatic groups, alicyclic groups,
alkoxy, substituted oxy (-0-R.sub.aa), aryl, aralkyl, heterocyclic
radical, heteroaryl, heteroarylalkyl, amino
(--N(R.sub.bb)(R.sub.cc)), imino(=NR.sub.bb), amido
(--C(0)N(R.sub.bb)(Rc.sub.C) or --N(R.sub.bb)C(0)R.sub.aa), azido
(--N.sub.3), nitro (--N0.sub.2), cyano (--CN), carbamido
(--OC(0)N(R.sub.bb)(R.sub.cc) or --N(R.sub.bb)C(0)OR.sub.aa),
ureido (--N(R.sub.bb)C(0)-N(R.sub.bb)(R.sub.cc)), thioureido
(--N(R.sub.bb)C(S)N(R.sub.bb)(R.sub.cc)), guanidinyl
(--N(R.sub.bb)C(.dbd.NR.sub.bb)N(R.sub.bb)(R.sub.cc)), amidinyl
(--C(.dbd.NR.sub.bb)N(R.sub.bb)(R.sub.cc) or
--N(R.sub.bb)C(.dbd.NR.sub.bb)(R.sub.aa)), thiol (--SR.sub.bb),
sulfinyl (--S(0)R.sub.bb), sulfonyl (--S(0).sub.2R.sub.b) and
sulfonamidyl (--S(0).sub.2N(R.sub.bb)(Rc.sub.C) or
--N(R.sub.bb)S(0).sub.2R.sub.bb). Wherein each R.sub.aa, R.sub.bb
and R.sub.cC is, independently, H, an optionally linked chemical
functional group or a further substituent group with a preferred
list including without limitation, H, alkyl, alkenyl, alkynyl,
aliphatic, alkoxy, acyl, aryl, aralkyl, heteroaryl, alicyclic,
heterocyclic and heteroarylalkyl. Selected substituents within the
compounds described herein are present to a recursive degree.
[0074] Still other preferred cyclic purine dinuclotides also
include S-substituent forms of CDNs, and in particular CDN
thiophosphates, which can advantageously provide prodrugs with
improved bioavailability. The term "prodrug" as used herein refers
to a modification of contemplated compounds, wherein the modified
compound is converted within the body (e.g., in a target cell or
target organ) back into the unmodified form through enzymatic or
non-enzymatic reactions. In certain embodiments, the hydroxyl on
one ribose comprises a prodrug leaving group. Prodrugs can modify
the physicochemical, biopharmaceutic, and pharmacokinetic
properties of drugs. Traditional prodrugs are classified as drugs
that are activated by undergoing transformation in vivo to form the
active drug. Reasons for prodrug development are typically poor
aqueous solubility, chemical instability, low oral bioavailability,
lack of blood brain barrier penetration, and high first pass
metabolism associated with the parent drug. Suitable prodrug
moieties are described in, for example, "Prodrugs and Targeted
Delivery," J. Rautico, Ed., John Wiley & Sons, 2011.
[0075] An example of such prodrug analogs are shown in FIG. 12.
This produrg form with improved lipophilicity may be cleaved into
active forms through the action of esterases present in target
organisms. Substituent groups amenable herein include without
limitation, halogen, hydroxyl, alkyl, alkenyl, alkynyl, acyl
(--C(0)R.sub.aa), carboxyl (--C(0)0-R.sub.aa), aliphatic groups,
alicyclic groups, alkoxy, substituted oxy (-0-R.sub.aa), aryl,
aralkyl, heterocyclic radical, heteroaryl, heteroarylalkyl, amino
(--N(R.sub.bb)(R.sub.cc)), imino(=NR.sub.bb), amido
(--C(0)N(R.sub.bb)(R.sub.cc) or --N(R.sub.bb)C(0)R.sub.aa), azido
(--N.sub.3), nitro (--N0.sub.2), cyano (--CN), carbamido
(--OC(0)N(R.sub.bb)(R.sub.cc) or --N(R.sub.bb)C(0)OR.sub.aa),
ureido (--N(R.sub.bb)C(0)-N(Rbb)(Rcc)), thioureido
(--N(R.sub.bb)C(S)N(R.sub.bb)(R.sub.cc)), guanidinyl
(--N(R.sub.bb)C(.dbd.NR.sub.bb)N(R.sub.bb)(R.sub.cc)), amidinyl
(--C(.dbd.NR.sub.bb)N(R.sub.bb)(Rc.sub.C) or
--N(R.sub.bb)C(.dbd.NR.sub.bb)(R.sub.aa)), thiol (--SR.sub.bb),
sulfinyl (--S(0)R.sub.bb), sulfonyl (--S(0).sub.2R.sub.b) and
sulfonamidyl (--S(0).sub.2N(R.sub.bb)(Rc.sub.C) or
--N(R.sub.bb)S(0).sub.2R.sub.bb). Wherein each R.sub.aa, R.sub.bb
and R.sub.cC is, independently, H, an optionally linked chemical
functional group or a further substituent group with a preferred
list including without limitation, H, alkyl, alkenyl, alkynyl,
aliphatic, alkoxy, acyl, aryl, aralkyl, heteroaryl, alicyclic,
heterocyclic and heteroarylalkyl. Selected substituents within the
compounds described herein are present to a recursive degree.
Preferred substituents include methyl, isopropyl and t-butyl.
Prodrug forms of nucleotides are known in the art. See, e.g.,
Nucleotide Prodrugs for HCV Therapy, Sofia, M. J., Antiviral Chem
and Chemother., 2011, 22: 23-49; Nucleoside, Nucleotide, and
Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent
RNA-Polymerase, Sofia, M. J., et al., J. Med. Chem., 2012, 55:
2481-2531.
[0076] The term "alkyl," as used herein, refers to a saturated
straight or branched hydrocarbon radical containing up to twenty
four carbon atoms. Examples of alkyl groups include without
limitation, methyl, ethyl, propyl, butyl, isopropyl, n-hexyl,
octyl, decyl, dodecyl and the like. Alkyl groups typically include
from 1 to about 24 carbon atoms, more typically from 1 to about 12
carbon atoms with from 1 to about 6 carbon atoms being more
preferred. The term "lower alkyl" as used herein includes from 1 to
about 6 carbon atoms. Alkyl groups as used herein may optionally
include one or more further substituent groups.
[0077] The term "alkenyl," as used herein, refers to a straight or
branched hydrocarbon chain radical containing up to twenty four
carbon atoms and having at least one carbon-carbon double bond.
Examples of alkenyl groups include without limitation, ethenyl,
propenyl, butenyl, 1-methyl-2-buten-1-yl, dienes such as
1,3-butadiene and the like. Alkenyl groups typically include from 2
to about 24 carbon atoms, more typically from 2 to about 12 carbon
atoms with from 2 to about 6 carbon atoms being more preferred.
Alkenyl groups as used herein may optionally include one or more
further substituent groups.
[0078] The term "alkynyl," as used herein, refers to a straight or
branched hydrocarbon radical containing up to twenty four carbon
atoms and having at least one carbon-carbon triple bond. Examples
of alkynyl groups include, without limitation, ethynyl, 1-propynyl,
1-butynyl, and the like. Alkynyl groups typically include from 2 to
about 24 carbon atoms, more typically from 2 to about 12 carbon
atoms with from 2 to about 6 carbon atoms being more preferred.
Alkynyl groups as used herein may optionally include one or more
further substituent groups.
[0079] The term "acyl," as used herein, refers to a radical formed
by removal of a hydroxyl group from an organic acid and has the
general Formula --C(O)--X where X is typically aliphatic, alicyclic
or aromatic. Examples include aliphatic carbonyls, aromatic
carbonyls, aliphatic sulfonyls, aromatic sulfinyls, aliphatic
sulfinyls, aromatic phosphates, aliphatic phosphates and the like.
Acyl groups as used herein may optionally include further
substituent groups.
[0080] The term "alicyclic" refers to a cyclic ring system wherein
the ring is aliphatic. The ring system can comprise one or more
rings wherein at least one ring is aliphatic. Preferred alicyclics
include rings having from about 5 to about 9 carbon atoms in the
ring. Alicyclic as used herein may optionally include further
substituent groups.
[0081] The term "aliphatic," as used herein, refers to a straight
or branched hydrocarbon radical containing up to twenty four carbon
atoms wherein the saturation between any two carbon atoms is a
single, double or triple bond. An aliphatic group preferably
contains from 1 to about 24 carbon atoms, more typically from 1 to
about 12 carbon atoms with from 1 to about 6 carbon atoms being
more preferred. The straight or branched chain of an aliphatic
group may be interrupted with one or more heteroatoms that include
nitrogen, oxygen, sulfur and phosphorus. Such aliphatic groups
interrupted by heteroatoms include without limitation, polyalkoxys,
such as polyalkylene glycols, polyamines, and polyimines. Aliphatic
groups as used herein may optionally include further substituent
groups.
[0082] The term "alkoxy," as used herein, refers to a radical
formed between an alkyl group and an oxygen atom wherein the oxygen
atom is used to attach the alkoxy group to a parent molecule.
Examples of alkoxy groups include without limitation, methoxy,
ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy,
n-pentoxy, neopentoxy, n-hexoxy and the like. Alkoxy groups as used
herein may optionally include further substituent groups.
[0083] The term "aminoalkyl" as used herein, refers to an amino
substituted C\-Cn alkyl radical. The alkyl portion of the radical
forms a covalent bond with a parent molecule. The amino group can
be located at any position and the aminoalkyl group can be
substituted with a further substituent group at the alkyl and/or
amino portions.
[0084] The terms "aralkyl" and "arylalkyl," as used herein, refer
to an aromatic group that is covalently linked to a C\-Cn alkyl
radical. The alkyl radical portion of the resulting aralkyl (or
arylalkyl) group forms a covalent bond with a parent molecule.
Examples include without limitation, benzyl, phenethyl and the
like. Aralkyl groups as used herein may optionally include further
substituent groups attached to the alkyl, the aryl or both groups
that form the radical group.
[0085] The terms "aryl" and "aromatic," as used herein, refer to a
mono- or polycyclic carbocyclic ring system radicals having one or
more aromatic rings. Examples of aryl groups include without
limitation, phenyl, naphthyl, tetrahydronaphthyl, indanyl, idenyl
and the like. Preferred aryl ring systems have from about 5 to
about 20 carbon atoms in one or more rings. Aryl groups as used
herein may optionally include further substituent groups.
[0086] The terms "halo" and "halogen," as used herein, refer to an
atom selected from fluorine, chlorine, bromine and iodine.
[0087] The terms "heteroaryl," and "heteroaromatic," as used
herein, refer to a radical comprising a mono- or poly-cyclic
aromatic ring, ring system or fused ring system wherein at least
one of the rings is aromatic and includes one or more heteroatoms.
Heteroaryl is also meant to include fused ring systems including
systems where one or more of the fused rings contain no
heteroatoms. Heteroaryl groups typically include one ring atom
selected from sulfur, nitrogen or oxygen. Examples of heteroaryl
groups include without limitation, pyridinyl, pyrazinyl,
pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl,
isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl,
quinolinyl, isoquinolinyl, benzimidazolyl, benzooxazolyl,
quinoxalinyl and the like. Heteroaryl radicals can be attached to a
parent molecule directly or through a linking moiety such as an
aliphatic group or hetero atom. Heteroaryl groups as used herein
may optionally include further substituent groups.
[0088] The term "heteroarylalkyl," as used herein, refers to a
heteroaryl group as previously defined that further includes a
covalently attached C.sub.1-C.sub.12 alkyl radical. The alkyl
radical portion of the resulting heteroarylalkyl group is capable
of forming a covalent bond with a parent molecule. Examples include
without limitation, pyridinylmethyl, pyrimidinylethyl,
napthyridinylpropyl and the like. Heteroarylalkyl groups as used
herein may optionally include further substituent groups on one or
both of the heteroaryl or alkyl portions.
[0089] As noted above, preferred cyclic purine dinuclotides also
include prodrug forms of CDNs, and in particular CDN
thiophosphates. Produrgs can modify the physicochemical,
biopharmaceutic, and pharmacokinetic properties of drugs.
Traditional prodrugs are classified as drugs that are activated by
undergoing transformation in vivo to form the active drug. Reasons
for prodrug development are typically poor aqueous solubility,
chemical instability, low oral bioavailability, lack of blood brain
barrier penetration, and high first pass metabolism associated with
the parent drug. Suitable prodrug moieties are described in, for
example, "Prodrugs and Targeted Delivery," J. Rautico, Ed., John
Wiley & Sons, 2011.
[0090] The term "substantially pure" as used herein with regard to
cyclic purine dinuclotides refers to an Rp,Rp or Rp,Sp form which
is at least 75% pure relative to other possible stereochemistries
at the chiral centers indicated in the figure above. By way of
example, a "substantially pure Rp,Rp c-di-GMP thiophosphate" would
be at least 75% pure with regard to the Rp,Sp and Sp,Sp forms of
c-di-GMP thiophosphate. In preferred embodiments, a substantially
pure cyclic purine dinuclotide is at least 85% pure, at least 90%
pure, at least 95% pure, at least 97% pure, and at least 99% pure.
While a substantially pure cyclic purine dinuclotide preparation of
the invention is "stereochemically pure," this is not meant to
indicate that all CDNs within the preparation having a particular
stereochemistry at these chiral centers are otherwise identical.
For example, a substantially pure cyclic purine dinuclotide
preparation may contain a combination of Rp,Rp c-di-GMP
thiophosphate and Rp,Rp c-di-AMP thiophosphate and still be a
substantially pure cyclic purine dinuclotide preparation. Such a
preparation may also include other components as described
hereinafter that are advantageous for patient treatment, provided
that all CDNs within the preparation having a particular
stereochemistry at these chiral centers.
[0091] The CDN compositions described herein can be administered to
a host, either alone or in combination with a pharmaceutically
acceptable excipient, in an amount sufficient to induce, modify, or
stimulate an appropriate immune response. The immune response can
comprise, without limitation, specific immune response,
non-specific immune response, both specific and non-specific
response, innate response, primary immune response, adaptive
immunity, secondary immune response, memory immune response, immune
cell activation, immune cell proliferation, immune cell
differentiation, and cytokine expression. In certain embodiments,
the CDN compositions are administered in conjunction with one or
more additional compositions including vaccines intended to
stimulate an immune response to one or more predetermined antigens;
adjuvants; CTLA-4 and PD-1 pathway antagonists, lipids, liposomes,
chemotherapeutic agents, immunomodulatory cell lines, etc.
[0092] The CDN compositions may be administered before, after,
and/or together with an additional therapeutic or prophylactic
composition. These include, without limitation, B7 costimulatory
molecule, interleukin-2, interferon-.gamma., GM-CSF, CTLA-4
antagonists, OX-40/OX-40 ligand, CD40/CD40 ligand, sargramostim,
levamisol, vaccinia virus, Bacille Calmette-Guerin (BCG),
liposomes, alum, Freund's complete or incomplete adjuvant,
detoxified endotoxins, mineral oils, surface active substances such
as lipolecithin, pluronic polyols, polyanions, peptides, and oil or
hydrocarbon emulsions. Carriers for inducing a T cell immune
response which preferentially stimulate a cytolytic T cell response
versus an antibody response are preferred, although those that
stimulate both types of response can be used as well. In cases
where the agent is a polypeptide, the polypeptide itself or a
polynucleotide encoding the polypeptide can be administered. The
carrier can be a cell, such as an antigen presenting cell (APC) or
a dendritic cell. Antigen presenting cells include such cell types
as macrophages, dendritic cells and B cells. Other professional
antigen-presenting cells include monocytes, marginal zone Kupffer
cells, microglia, Langerhans' cells, interdigitating dendritic
cells, follicular dendritic cells, and T cells. Facultative
antigen-presenting cells can also be used. Examples of facultative
antigen-presenting cells include astrocytes, follicular cells,
endothelium and fibroblasts. The carrier can be a bacterial cell
that is transformed to express the polypeptide or to deliver a
polynucleoteide which is subsequently expressed in cells of the
vaccinated individual. Adjuvants, such as aluminum hydroxide or
aluminum phosphate, can be added to increase the ability of the
vaccine to trigger, enhance, or prolong an immune response.
Additional materials, such as cytokines, chemokines, and bacterial
nucleic acid sequences, like CpG, a toll-like receptor (TLR) 9
agonist as well as additional agonists for TLR 2, TLR 4, TLR 5, TLR
7, TLR 8, TLR9, including lipoprotein, LPS, monophosphoryl lipid A,
lipoteichoic acid, imiquimod, resiquimod, used separately or in
combination with the described compositions are also potential
adjuvants. Other representative examples of adjuvants include the
synthetic adjuvant QS-21 comprising a homogeneous saponin purified
from the bark of Quillaja saponaria and Corynebacterium parvum
(McCune et al., Cancer, 1979; 43:1619). It will be understood that
the adjuvant is subject to optimization. In other words, the
skilled artisan can engage in routine experimentation to determine
the best adjuvant to use.
[0093] Methods for co-administration with an additional therapeutic
agent are well known in the art (Hardman, et al. (eds.) (2001)
Goodman and Gilman's The Pharmacological Basis of Therapeutics,
10th ed., McGraw-Hill, New York, N.Y.; Poole and Peterson (eds.)
(2001) Pharmacotherapeutics for Advanced Practice: A Practical
Approach, Lippincott, Williams & Wilkins, Phila., PA; Chabner
and Longo (eds.) (2001) Cancer Chemotherapy and Biotherapy,
Lippincott, Williams & Wilkins, Phila., PA).
[0094] Adjuvants
[0095] In addition to the cyclic purine dinuclotide(s) described
above, the compositions of the present invention may further
comprise one or more additional substances which, because of their
adjuvant nature, can act to stimulate the immune system to respond
to the cancer antigens present on the inactivated tumor cell(s).
Such adjuvants include, but are not limited to, lipids, liposomes,
inactivated bacteria which induce innate immunity (e.g.,
inactivated or attenuated Listeria monocytogenes), compositions
which mediate innate immune activation via Toll-like Receptors
(TLRs), (NOD)-like receptors (NLRs), Retinoic acid inducible
gene-based (RIG)-I-like receptors (RLRs), and/or C-type lectin
receptors (CLRs). Examples of PAMPs include lipoproteins,
lipopolypeptides, peptidoglycans, zymosan, lipopolysaccharide, neis
serial porins, flagellin, profillin, galactoceramide, muramyl
dipeptide. Peptidoglycans, lipoproteins, and lipoteichoic acids are
cell wall components of Gram-positive. Lipopolysaccharides are
expressed by most bacteria, with MPL being one example. Flagellin
refers to the structural component of bacterial flagella that is
secreted by pathogenic and commensal bacterial.
.alpha.-Galactosylceramide (.alpha.-GalCer) is an activator of
natural killer T (NKT) cells. Muramyl dipeptide is a bioactive
peptidoglycan motif common to all bacteria. This list is not meant
to be limiting. Preferred adjuvant compositions are described
below.
[0096] CTLA-4 and PD-1 Pathway Antagonists
[0097] CTLA-4 is thought to be an important negative regulator of
the adaptive immune response. Activated T cells upregulate CTLA-4,
which binds CD80 and CD86 on antigen-presenting cells with higher
affinity than CD28, thus inhibiting T-cell stimulation, IL-2 gene
expression and T-cell proliferation. Anti-tumor effects of CTLA4
blockade have been observed in murine models of colon carcinoma,
metastatic prostate cancer, and metastatic melanoma.
[0098] Ipilimumab (Yervoy.TM.) and tremelimumab are humanized
monoclonal antibodies that bind to human CTLA4 and prevent its
interaction with CD80 and CD86. Phase I and II studies using
ipilimumab and tremelimumab have demonstrated clinical activity in
cancer patients. Other negative immune regulators which may be
targeted by a similar strategy include programmed cell death 1, B
and T lymphocyte attenuator, transforming growth factor beta (3,
interleukin-10, and vascular endothelial growth factor.
[0099] PD-1 is another negative regulator of adaptive immune
response that is expressed on activated T-cells. PD-1 binds to
B7-H1 and B7-DC, and the engagement of PD-1 suppresses T-cell
activation. Anti-tumor effects have been demonstrated with PD-1
pathway blockade. BMS-936558, MK3475, CT-011, AMP-224 and MDX-1106
have been reported in the literature to be examples of PD-1 pathway
blockers which may find use in the present invention.
[0100] TLR Agonists
[0101] The term "Toll like receptor" (or "TLR") as used herein
refers to a member of the Toll-like receptor family of proteins or
a fragment thereof that senses a microbial product and/or initiates
an adaptive immune response. In one embodiment, a TLR activates a
dendritic cell (DC). Toll like receptors (TLRs) are a family of
pattern recognition receptors that were initially identified as
sensors of the innate immune system that recognize microbial
pathogens. TLRs comprise a family of conserved membrane spanning
molecules containing an ectodomain of leucine-rich repeats, a
transmembrane domain and an intracellular TIR (Toll/IL-1R) domain.
TLRs recognize distinct structures in microbes, often referred to
as "PAMPs" (pathogen associated molecular patterns). Ligand binding
to TLRs invokes a cascade of intra-cellular signaling pathways that
induce the production of factors involved in inflammation and
immunity.
[0102] In humans, ten TLR have been identified. TLRs that are
expressed on the surface of cells include TLR-1, -2, -4, -5, and
-6, while TLR-3, -7/8, and -9 are expressed with the ER
compartment. Human dendritic cell subsets can be identified on the
basis of distinct TLR expression patterns. By way of example, the
myeloid or "conventional" subset of DC (mDC) expresses TLRs 1-8
when stimulated, and a cascade of activation markers (e.g. CD80,
CD86, MHC class I and II, CCR7), pro-inflammatory cytokines, and
chemokines are produced. A result of this stimulation and resulting
expression is antigen-specific CD4+ and CD8+ T cell priming. These
DCs acquire an enhanced capacity to take up antigens and present
them in an appropriate form to T cells. In contrast, the
plasmacytoid subset of DC (pDC) expresses only TLR7 and TLR9 upon
activation, with a resulting activation of NK cells as well as
T-cells. As dying tumor cells may adversely affect DC function, it
has been suggested that activating DC with TLR agonists may be
beneficial for priming anti-tumor immunity in an immunotherapy
approach to the treatment of cancer. It has also been suggested
that successful treatment of breast cancer using radiation and
chemotherapy requires TLR4 activation.
[0103] TLR agonists known in the art and finding use in the present
invention include, but are not limited to, the following:
Pam3Cys, a TLR-1/2 agonist; CFA, a TLR-2 agonist; MALP2, a TLR-2
agonist; Pam2Cys, a TLR-2 agonist; FSL-1, a TLR-2 agonist;
Hib-OMPC, a TLR-2 agonist; polyribosinic:polyribocytidic acid (Poly
I:C), a TLR-3 agonist; polyadenosine-polyuridylic acid (poly AU), a
TLR-3 agonist; Polyinosinic-Polycytidylic acid stabilized with
poly-L-lysine and carboxymethylcellulose (Hiltonol.RTM.), a TLR-3
agonist; monophosphoryl lipid A (MPL), a TLR-4 agonist; LPS, a
TLR-4 agonist; bacterial flagellin, a TLR-5 agonist; sialyl-Tn
(STn), a carbohydrate associated with the MUC1 mucin on a number of
human cancer cells and a TLR-4 agonist; imiquimod, a TLR-7 agonist;
resiquimod, a TLR-7/8 agonist; loxoribine, a TLR-7/8 agonist; and
unmethylated CpG dinucleotide (CpG-ODN), a TLR-9 agonist.
[0104] Because of their adjuvant qualities, TLR agonists are
preferably used in combinations with other vaccines, adjuvants
and/or immune modulators, and may be combined in various
combinations. Thus, in certain embodiments, the cyclic purine
dinucleotides that bind to STING and induces STING-dependent TBK1
activation and an inactivated tumor cell which expresses and
secretes one or more cytokines which stimulate dendritic cell
induction, recruitment and/or maturation, as described herein can
be administered together with one or more TLR agonists for
therapeutic purposes.
[0105] Lipids and Liposomes
[0106] Liposomes are vesicles formed from one ("unilamellar") or
more ("multilamellar") layers of phospholipid. Because of the
amphipathic character of the phospholipid building blocks,
liposomes typically comprise a hydrophilic layer presenting a
hydrophilic external face and enclosing a hydrophilic core. The
versatility of liposomes in the incorporation of
hydrophilic/hydrophobic components, their non-toxic nature,
biodegradability, biocompatibility, adjuvanticity, induction of
cellular immunity, property of sustained release and prompt uptake
by macrophages, makes them attractive candidates for the delivery
of antigens.
[0107] WO2010/104833, which is incorporated by reference herein in
its entirety, describes liposomal preparations which comprise:
[0108] a) an aqueous vehicle;
[0109] b) liposomes comprising [0110] (i)
dimyristoylphosphatidylcholine ("DMPC"), [0111] (ii)
dimyristoylphosphatidylglycerol ("DMPG"),
dimyristoyltrimethylammonium propane ("DMTAP"), or both DMPG and
DMTAP,
[0112] and [0113] (iii) at least one sterol derivative; and
[0114] c) one or more immunogenic polypeptide(s) or carbohydrate(s)
covalently linked to between 1% and 100% of said at least one
sterol derivative.
[0115] Such liposomal formulations, referred to herein as
VesiVax.RTM. (Molecular Express, Inc.), with our without the
"immunogenic polypeptide(s) or carbohydrate(s)" referred to above,
can contain one or more additional components such as
peptidoglycan, lipopeptide, lipopolysaccharide, monophosphoryl
lipid A, lipoteichoic acid, resiquimod, imiquimod, flagellin,
oligonucleotides containing unmethylated CpG motifs,
beta-galactosylceramide, muramyl dipeptide, all-trans retinoic
acid, double-stranded viral RNA, heat shock proteins,
dioctadecyldimethylammonium bromide, cationic surfactants,
toll-like receptor agonists, dimyristoyltrimethylammoniumpropane,
and nod-like receptor agonists. Advantageously, these liposomal
formulations can be used to deliver one or more cyclic purine
dinucleotides in accordance with the present invention.
[0116] Moreover, while the liposomal formulations discussed above
employ a "steroid derivative" as an anchor for attaching an
immunogenic polypeptide or carbohydrate to a liposome, the steroid
may simply be provided as an unconjugated steroid such as
cholesterol.
[0117] Suitable methods for preparing liposomes from lipid mixtures
are well known in the art. See, e.g., Basu & Basu, Liposome
Methods and Protocols (Methods in Molecular Biology), Humana Press,
2002; Gregoriadis, Liposome Technology, 3.sup.rd Edition, Informa
HealthCare, 2006. Preferred methods include extrusion,
homogenization, and sonication methods described therein. An
exemplary method for preparing liposomes for use in the present
invention, which comprises drying a lipid mixture, followed by
hydration in an aqueous vehicle and sonication to form liposomes,
is described in WO2010/104833.
[0118] In certain embodiments, the liposomes are provided within a
particular average size range. Liposome size can be selected, for
example, by extrusion of an aqueous vehicle comprising liposomes
through membranes having a preselected pore size and collecting the
material flowing through the membrane. In preferred embodiments,
the liposomes are selected to be substantially between 50 and 500
nm in diameter, more preferably substantially between 50 and 200 nm
in diameter, and most preferably substantially between 50 and 150
nm in diameter. The term "substantially" as used herein in this
context means that at least 75%, more preferably 80%, and most
preferably at least 90% of the liposomes are within the designated
range.
[0119] Other lipid and lipid-like adjuvants which may find use in
the present invention include oil-in-water (o/w) emulsions (see,
e.g., Muderhwa et al., J. Pharmaceut. Sci. 88: 1332-9, 1999)),
VesiVax.RTM. TLR (Molecular Express, Inc.), digitonin (see, e.g.,
U.S. Pat. No. 5,698,432), and glucopyranosyl lipids (see, e.g.,
United States Patent Application 20100310602).
[0120] Chemotherapeutic Agents
[0121] In additional embodiments the methods further involve
administering to the subject an effective amount of one or more
chemotherapeutics as an additional treatment. In certain
embodiments the one or more chemotherapeutics is selected from
abiraterone acetate, altretamine, anhydrovinblastine, auristatin,
bexarotene, bicalutamide, BMS 184476,
2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzene
sulfonamide, bleomycin,
N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-proly-1-Lproline-t-butyla-
mide, cachectin, cemadotin, chlorambucil, cyclophosphamide,
3',4'-didehydro-4'-deoxy-8'-norvin-caleukoblastine, docetaxol,
doxetaxel, cyclophosphamide, carboplatin, carmustine, cisplatin,
cryptophycin, cyclophosphamide, cytarabine, dacarbazine (DTIC),
dactinomycin, daunorubicin, decitabine dolastatin, doxorubicin
(adriamycin), etoposide, 5-fluorouracil, finasteride, flutamide,
hydroxyurea and hydroxyureataxanes, ifosfamide, liarozole,
lonidamine, lomustine (CCNU), MDV3100, mechlorethamine (nitrogen
mustard), melphalan, mivobulin isethionate, rhizoxin, sertenef,
streptozocin, mitomycin, methotrexate, taxanes, nilutamide,
onapristone, paclitaxel, prednimustine, procarbazine, RPR109881,
stramustine phosphate, tamoxifen, tasonermin, taxol, tretinoin,
vinblastine, vincristine, vindesine sulfate, and vinflunine.
[0122] Immunomodulatory Cell Lines
[0123] By "inactivated tumor cell" is meant a tumor cell (either
"autologous" or "allogeneic" to the patient) which has which been
treated to prevent division of the cells. For purposes of the
present invention, such cells preserve their immunogenicity and
their metabolic activity. Such tumor cells are genetically modified
to express a transgene which is expressed within a patient as part
of cancer therapy. Thus, a composition or vaccine of the invention
comprises neoplastic (e.g., tumor) cells that are autologous or
allogeneic to the patient undergoing treatment and is most
preferably the same general type of tumor cell as is afflicting the
patient. For example, a patient suffering from melanoma will
typically be administered a genetically modified cell derived from
a melanoma. Methods for inactivating tumor cells for use in the
present invention, such as the use of irradiation, are well known
in the art.
[0124] The inactivated tumor cells of the present invention are
administered to the patient together with one or more costimulatory
molecules or agents. A preferred costimulatory agent comprises one
or more cytokines which stimulate dendritic cell induction,
recruitment, and/or maturation. Methods for assessing such
costimulatory agents are well known in the literature. Induction
and maturation of DCs is typically assessed by increased expression
of certain membrane molecules such as CD80 and CD86, and/or
secretion of pro-inflammatory cytokines, such as IL-12 and type I
interferons following stimulation.
[0125] In preferred embodiments, the inactivated tumor cells
themselves are modified to express and secrete one or more
cytokines which stimulate dendritic cell induction, recruitment,
and/or maturation. The present invention is described in exemplary
terms with regard to the use of GM-CSF. Thus, by way of example,
the tumor cell may express a transgene encoding GM-CSF as described
in U.S. Pat. Nos. 5,637,483, 5,904,920, 6,277,368 and 6,350,445, as
well as in US Patent Publication No. 20100150946, each of which is
expressly incorporated by reference herein. A form of
GM-CSF-expressing genetically modified cancer cells or a
"cytokine-expressing cellular vaccine" for the treatment of
pancreatic cancer is described in U.S. Pat. Nos. 6,033,674 and
5,985,290, both of which are expressly incorporated by reference
herein.
[0126] Other suitable cytokines which may be expressed by such
inactivated tumor cells and/or bystander cells instead of, or
together with, GM-CSF include, but are not limited to, one or more
of CD40 ligand, IL-12, CCL3, CCL20, and CCL21. This list is not
meant to be limiting.
[0127] While it is preferred that the inactivated tumor cells
administered to the subject express one or more cytokines of
interest, the tumor cell line may be accompanied by an inactivated
bystander cell line which expresses and secretes one or more
cytokines which stimulate dendritic cell induction, recruitment,
and/or maturation. The bystander cell line may provide all of the
cytokines which stimulate dendritic cell induction, recruitment,
and/or maturation, or may supplement cytokines which stimulate
dendritic cell induction, recruitment, and/or maturation expressed
and secreted by the inactivated tumor cells. By way of example,
immunomodulatory cytokine-expressing bystander cell lines are
disclosed in U.S. Pat. Nos. 6,464,973, and 8,012,469, Dessureault
et al., Ann. Surg. Oncol. 14: 869-84, 2007, and Eager and
Nemunaitis, Mol. Ther. 12: 18-27, 2005, each of which is expressly
incorporated by reference herein.
[0128] By "Granulocyte-macrophage colony stimulating factor
(GM-CSF) polypeptide" is meant a cytokine or fragment thereof
having immunomodulatory activity and having at least about 85%
amino acid sequence identity to GenBank Accession No.
AAA52122.1.
[0129] Vaccines
[0130] In certain embodiments, the CDN compositions are
administered in conjunction with one or more vaccines intended to
stimulate an immune response to one or more predetermined antigens.
Examples of target antigens that may find use in the invention are
listed in the following table. The target antigen may also be a
fragment or fusion polypeptide comprising an immunologically active
portion of the antigens listed in the table. This list is not meant
to be limiting.
TABLE-US-00001 TABLE 1 Antigens. Antigen Reference Tumor antigens
Mesothelin GenBank Acc. No. NM_005823; U40434; NM_013404; BC003512
(see also, e.g., Hassan, et al. (2004) Clin. Cancer Res. 10:
3937-3942; Muminova, et al. (2004) BMC Cancer 4: 19;
Iacobuzio-Donahue, et al. (2003) Cancer Res. 63: 8614-8622). Wilms'
tumor-1 WT-1 isoform A (GenBank Acc. Nos. NM_000378; NP_000369).
associated protein WT-1 isoform B (GenBank Acc. Nos. NM_024424;
NP_077742). (Wt-1), including WT-1 isoform C (GenBank Acc. Nos.
NM_024425; NP_077743). isoform A; isoform B; WT-1 isoform D
(GenBank Acc. Nos. NM_024426; NP_077744). isoform C; isoform D.
Stratum corneum GenBank Acc. No. NM_005046; NM_139277; AF332583.
See also, chymotryptic enzyme e.g., Bondurant, et al. (2005) Clin.
Cancer Res. 11: 3446-3454; Santin, (SCCE), and variants et al.
(2004) Gynecol. Oncol. 94: 283-288; Shigemasa, et al. (2001)
thereof. Int. J. Gynecol. Cancer 11: 454-461; Sepehr, et al. (2001)
Oncogene 20: 7368-7374. MHC class I See, e.g., Groh, et al. (2005)
Proc. Natl. Acad. Sci. USA 102: 6461-6466; chain-related protein A
GenBank Acc. Nos. NM_000247; BC_016929; AY750850; (MICA); MHC class
I NM_005931. chain-related protein A (MICB). Gastrin and peptides
Harris, et al. (2004) Cancer Res. 64: 5624-5631; Gilliam, et al.
(2004) derived from gastrin; Eur. J. Surg. Oncol. 30: 536-543;
Laheru and Jaffee (2005) Nature gastrin/CCK-2 receptor Reviews
Cancer 5: 459-467. (also known as CCK-B). Glypican-3 (an antigen
GenBank Acc. No. NM_004484. Nakatsura, et al. (2003) Biochem. of,
e.g., hepatocellular Biophys. Res. Commun. 306: 16-25; Capurro, et
al. (2003) carcinoma and Gasteroenterol. 125: 89-97; Nakatsura, et
al. (2004) Clin. Cancer Res. melanoma). 10: 6612-6621).
Coactosin-like protein. Nakatsura, et al. (2002) Eur. J. Immunol.
32: 826-836; Laheru and Jaffee (2005) Nature Reviews Cancer 5:
459-467. Prostate stem cell GenBank Acc. No. AF043498; AR026974;
AR302232 (see also, e.g., antigen (PSCA). Argani, et al. (2001)
Cancer Res. 61: 4320-4324; Christiansen, et al. (2003) Prostate 55:
9-19; Fuessel, et al. (2003) 23: 221-228). Prostate acid Small, et
al. (2000) J. Clin. Oncol. 18: 3894-3903; Altwein and phosphatase
(PAP); Luboldt (1999) Urol. Int. 63: 62-71; Chan, et al. (1999)
Prostate 41: 99-109; prostate-specific Ito, et al. (2005) Cancer
103: 242-250; Schmittgen, et al. (2003) antigen (PSA); PSM; Int. J.
Cancer 107: 323-329; Millon, et al. (1999) Eur. Urol. 36: 278-285.
PSMA. Six-transmembrane See, e.g., Machlenkin, et al. (2005) Cancer
Res. 65: 6435-6442; epithelial antigen of GenBank Acc. No.
NM_018234; NM_001008410; NM_182915; prostate (STEAP). NM_024636;
NM_012449; BC011802. Prostate carcinoma See, e.g., Machlenkin, et
al. (2005) Cancer Res. 65: 6435-6442; tumor antigen-1 GenBank Acc.
No. L78132. (PCTA-1). Prostate See, e.g., Machlenkin, et al. (2005)
Cancer Res. 65: 6435-6442). tumor-inducing gene-1 (PTI-1).
Prostate-specific gene See, e.g., Machlenkin, et al. (2005) Cancer
Res. 65: 6435-6442). with homology to G protein-coupled receptor.
Prostase (an antrogen See, e.g., Machlenkin, et al. (2005) Cancer
Res. 65: 6435-6442; regulated serine GenBank Acc. No. BC096178;
BC096176; BC096175. protease). Proteinase 3. GenBank Acc. No.
X55668. Cancer-testis antigens, GenBank Acc. No. NM_001327
(NY-ESO-1) (see also, e.g., Li, et al. e.g., NY-ESO-1; SCP- (2005)
Clin. Cancer Res. 11: 1809-1814; Chen, et al. (2004) Proc. 1;
SSX-1; SSX-2; SSX- Natl. Acad. Sci. USA. 101(25): 9363-9368;
Kubuschok, et al. (2004) 4; GAGE, CT7; CT8; Int. J. Cancer. 109:
568-575; Scanlan, et al. (2004) Cancer Immun. CT10; MAGE-1; 4: 1;
Scanlan, et al. (2002) Cancer Res. 62: 4041-4047; Scanlan, et al.
MAGE-2; MAGE-3; (2000) Cancer Lett. 150: 155-164; Dalerba, et al.
(2001) Int. J. Cancer MAGE-4; MAGE-6; 93: 85-90; Ries, et al.
(2005) Int. J. Oncol. 26: 817-824. LAGE-1. MAGE-A1, Otte, et al.
(2001) Cancer Res. 61: 6682-6687; Lee, et al. (2003) Proc. MAGE-A2;
Natl. Acad. Sci. USA 100: 2651-2656; Sarcevic, et al. (2003)
MAGE-A3; Oncology 64: 443-449; Lin, et al. (2004) Clin. Cancer Res.
10: 5708-5716. MAGE-A4; MAGE-A6; MAGE-A9; MAGE-A10; MAGE-A12;
GAGE-3/6; NT-SAR-35; BAGE; CA125. GAGE-1; GAGE-2; De Backer, et al.
(1999) Cancer Res. 59: 3157-3165; Scarcella, et al. GAGE-3; GAGE-4;
(1999) Clin. Cancer Res. 5: 335-341. GAGE-5; GAGE-6; GAGE-7;
GAGE-8; GAGE-65; GAGE-11; GAGE-13; GAGE-7B. HIP1R; LMNA; Scanlan,
et al. (2002) Cancer Res. 62: 4041-4047. KIAA1416; Seb4D; KNSL6;
TRIP4; MBD2; HCAC5; MAGEA3. DAM family of genes, Fleishhauer, et
al. (1998) Cancer Res. 58: 2969-2972. e.g., DAM-1; DAM-6. RCAS1.
Enjoji, et al. (2004) Dig. Dis. Sci. 49: 1654-1656. RU2. Van Den
Eynde, et al. (1999) J. Exp. Med. 190: 1793-1800. CAMEL. Slager, et
al. (2004) J. Immunol. 172: 5095-5102; Slager, et al. (2004) Cancer
Gene Ther. 11: 227-236. Colon cancer associated Scanlan, et al.
(2002) Cancer Res. 62: 4041-4047. antigens, e.g., NY-CO-8; NY-CO-9;
NY-CO-13; NY-CO-16; NY-CO-20; NY-CO-38; NY-CO-45; NY-CO-9/HDAC5;
NY-CO-41/MBD2; NY-CO-42/TRIP4; NY-CO-95/KIAA1416; KNSL6; seb4D.
N-Acetylglucosaminyl- Dosaka-Akita, et al. (2004) Clin. Cancer Res.
10: 1773-1779. tranferase V (GnT-V). Elongation factor 2 Renkvist,
et al. (2001) Cancer Immunol Immunother. 50: 3-15. mutated (ELF2M).
HOM-MEL-40/SSX2 Neumann, et al. (2004) Int. J. Cancer 112: 661-668;
Scanlan, et al. (2000) Cancer Lett. 150: 155-164. BRDT. Scanlan, et
al. (2000) Cancer Lett. 150: 155-164. SAGE; HAGE. Sasaki, et al.
(2003) Eur. J. Surg. Oncol. 29: 900-903. RAGE. See, e.g., Li, et
al. (2004) Am. J. Pathol. 164: 1389-1397; Shirasawa, et al. (2004)
Genes to Cells 9: 165-174. MUM-1 (melanoma Gueguen, et al. (1998)
J. Immunol. 160: 6188-6194; Hirose, et al. ubiquitous mutated);
(2005) Int. J. Hematol. 81: 48-57; Baurain, et al. (2000) J.
Immunol. MUM-2; MUM-2 Arg- 164: 6057-6066; Chiari, et al. (1999)
Cancer Res. 59: 5785-5792. Gly mutation; MUM-3. LDLR/FUT fusion
Wang, et al. (1999) J. Exp. Med. 189: 1659-1667. protein antigen of
melanoma. NY-REN series of renal Scanlan, et al. (2002) Cancer Res.
62: 4041-4047; Scanlan, et al. cancer antigens. (1999) Cancer Res.
83: 456-464. NY-BR series of breast Scanlan, et al. (2002) Cancer
Res. 62: 4041-4047; Scanlan, et al. cancer antigens, e.g., (2001)
Cancer Immunity 1: 4. NY-BR-62; NY- BR-75; NY-BR-85; NY-BR-62;
NY-BR-85. BRCA-1; BRCA-2. Stolier, et al. (2004) Breast J. 10:
475-480; Nicoletto, et al. (2001) Cancer Treat Rev. 27: 295-304.
DEK/CAN fusion Von Lindern, et al. (1992) Mol. Cell. Biol. 12:
1687-1697. protein. Ras, e.g., wild type ras, GenBank Acc. Nos.
P01112; P01116; M54969; M54968; P01111; ras with mutations at
P01112; K00654. See also, e.g., GenBank Acc. Nos. M26261; codon 12,
13, 59, or 61, M34904; K01519; K01520; BC006499; NM_006270;
NM_002890; e.g., mutations G12C; NM_004985; NM_033360; NM_176795;
NM_005343. G12D; G12R; G12S; G12V; G13D; A59T; Q61H. K-RAS; H-RAS;
N-RAS. BRAF (an isoform of Tannapfel, et al. (2005) Am. J. Clin.
Pathol. 123: 256-2601; Tsao and RAF). Sober (2005) Dermatol. Clin.
23: 323-333. Melanoma antigens, GenBank Acc. No. NM_206956;
NM_206955; NM_206954; including HST-2 NM_206953; NM_006115;
NM_005367; NM_004988; AY148486; melanoma cell U10340; U10339;
M77481. See, e g., Suzuki, et al. (1999) J. antigens. Immunol. 163:
2783-2791. Survivin GenBank Acc. No. AB028869; U75285 (see also,
e.g., Tsuruma, et al. (2004) J. Translational Med. 2: 19 (11
pages); Pisarev, et al. (2003) Clin. Cancer Res. 9: 6523-6533;
Siegel, et al. (2003) Br. J. Haematol. 122: 911-914; Andersen, et
al. (2002) Histol. Histopathol. 17: 669-675). MDM-2 NM_002392;
NM_006878 (see also, e.g., Mayo, et al. (1997) Cancer Res. 57:
5013-5016; Demidenko and Blagosklonny (2004) Cancer Res. 64:
3653-3660). Methyl-CpG-binding Muller, et al. (2003) Br. J. Cancer
89: 1934-1939; Fang, et al. (2004) proteins (MeCP2; World J.
Gastreenterol. 10: 3394-3398. MBD2). NA88-A. Moreau-Aubry, et al.
(2000) J. Exp. Med. 191: 1617-1624. Histone deacetylases Waltregny,
et al. (2004) Eur. J. Histochem. 48: 273-290; Scanlan, et (HDAC),
e.g., HDAC5. al. (2002) Cancer Res. 62: 4041-4047. Cyclophilin B
(Cyp-B). Tamura, et al. (2001) Jpn. J. Cancer Res. 92: 762-767. CA
15-3; CA 27.29. Clinton, et al. (2003) Biomed. Sci. Instrum. 39:
408-414. Heat shock protein Faure, et al. (2004) Int. J. Cancer
108: 863-870. Hsp70. GAGE/PAGE family, Brinkmann, et al. (1999)
Cancer Res. 59: 1445-1448. e.g., PAGE-1; PAGE-2; PAGE-3; PAGE-4;
XAGE-1; XAGE-2; XAGE-3. MAGE-A, B, C, and D Lucas, et al. (2000)
Int. J. Cancer 87: 55-60; Scanlan, et al. (2001) families. MAGE-B5;
Cancer Immun. 1: 4. MAGE-B6; MAGE-C2; MAGE-C3; MAGE-3; MAGE-6.
Kinesin 2; TATA Scanlan, et al. (2001) Cancer Immun. 30: 1-4.
element modulatory factor 1; tumor protein D53; NY
Alpha-fetoprotein Grimm, et al. (2000) Gastroenterol. 119:
1104-1112. (AFP) SART1; SART2; Kumamuru, et al. (2004) Int. J.
Cancer 108: 686-695; Sasatomi, et al. SART3; ART4. (2002) Cancer
94: 1636-1641; Matsumoto, et al. (1998) Jpn. J. Cancer Res. 89:
1292-1295; Tanaka, et al. (2000) Jpn. J. Cancer Res. 91: 1177-1184.
Preferentially expressed Matsushita, et al. (2003) Leuk. Lymphoma
44:
439-444; Oberthuer, et antigen of melanoma al. (2004) Clin. Cancer
Res. 10: 4307-4313. (PRAME). Carcinoembryonic GenBank Acc. No.
M29540; E03352; X98311; M17303 (see also, antigen (CEA), e.g.,
Zaremba (1997) Cancer Res. 57: 4570-4577; Sarobe, et al. (2004)
CAP1-6D enhancer Curr. Cancer Drug Targets 4: 443-454; Tsang, et
al. (1997) Clin. agonist peptide. Cancer Res. 3: 2439-2449; Fong,
et al. (2001) Proc. Natl. Acad. Sci. USA 98: 8809-8814). HER-2/neu.
Disis, et al. (2004) J. Clin. Immunol. 24: 571-578; Disis and
Cheever (1997) Adv. Cancer Res. 71: 343-371. Cdk4; cdk6; p16
Ghazizadeh, et al. (2005) Respiration 72: 68-73; Ericson, et al.
(2003) (INK4); Rb protein. Mol. Cancer Res. 1: 654-664. TEL; AML1;
Stams, et al. (2005) Clin. Cancer Res. 11: 2974-2980. TEL/AML1.
Telomerase (TERT). Nair, et al. (2000) Nat. Med. 6: 1011-1017.
707-AP. Takahashi, et al. (1997) Clin. Cancer Res. 3: 1363-1370.
Annexin, e.g., Zimmerman, et al. (2004) Virchows Arch. 445:
368-374. Annexin II. BCR/ABL; BCR/ABL Cobaldda, et al. (2000) Blood
95: 1007-1013; Hakansson, et al. (2004) p210; BCR/ABL p190;
Leukemia 18: 538-547; Schwartz, et al. (2003) Semin. Hematol.
CML-66; CML-28. 40: 87-96; Lim, et al. (1999) Int. J. Mol. Med. 4:
665-667. BCL2; BLC6; Iqbal, et al. (2004) Am. J. Pathol. 165:
159-166. CD10 protein. CDC27 (this is a Wang, et al. (1999) Science
284: 1351-1354. melanoma antigen). Sperm protein 17 Arora, et al.
(2005) Mol. Carcinog. 42: 97-108. (SP17); 14-3-3-zeta; MEMD;
KIAA0471; TC21. Tyrosinase-related GenBank Acc. No. NM_001922. (see
also, e.g., Bronte, et al. (2000) proteins 1 and 2 (TRP-1 Cancer
Res. 60: 253-258). and TRP-2). Gp100/pmel-17. GenBank Acc. Nos.
AH003567; U31798; U31799; U31807; U31799 (see also, e.g., Bronte,
et al. (2000) Cancer Res. 60: 253-258). TARP. See, e.g., Clifton,
et al. (2004) Proc. Natl. Acad. Sci. USA 101: 10166-10171; Virok,
et al. (2005) Infection Immunity 73: 1939-1946. Tyrosinase-related
GenBank Acc. No. NM_001922. (see also, e.g., Bronte, et al. (2000)
proteins 1 and 2 (TRP-1 Cancer Res. 60: 253-258). and TRP-2).
Melanocortin 1 receptor Salazar-Onfray, et al. (1997) Cancer Res.
57: 4348-4355; Reynolds, et (MC1R); MAGE-3; al. (1998) J. Immunol.
161: 6970-6976; Chang, et al. (2002) Clin. gp100; tyrosinase;
Cancer Res. 8: 1021-1032. dopachrome tautomerase (TRP-2); MART-1.
MUC-1; MUC-2. See, e.g., Davies, et al. (1994) Cancer Lett. 82:
179-184; Gambus, et al. (1995) Int. J. Cancer 60: 146-148; McCool,
et al. (1999) Biochem. J. 341: 593-600. Spas-1. U.S. Published Pat.
Appl. No. 20020150588 of Allison, et al. CASP-8; FLICE;
Mandruzzato, et al. (1997) J. Exp. Med. 186: 785-793. MACH.
CEACAM6; CAP-1. Duxbury, et al. (2004) Biochem. Biophys. Res.
Commun. 317: 837-843; Morse, et al. (1999) Clin. Cancer Res. 5:
1331-1338. HMGB1 (a DNA Brezniceanu, et al. (2003) FASEB J. 17:
1295-1297. binding protein and cytokine). ETV6/AML1. Codrington, et
al. (2000) Br. J. Haematol. 111: 1071-1079. Mutant and wild type
Clements, et al. (2003) Clin. Colorectal Cancer 3: 113-120;
Gulmann, forms of adenomatous et al. (2003) Appl. Immunohistochem.
Mol. Morphol. 11: 230-237; polyposis coli (APC); Jungck, et al.
(2004) Int. J. Colorectal. Dis. 19: 438-445; Wang, et al.
beta-catenin; c-met; (2004) J. Surg. Res. 120: 242-248; Abutaily,
et al. (2003) J. Pathol. p53; E-cadherin; 201: 355-362; Liang, et
al. (2004) Br. J. Surg. 91: 355-361; Shirakawa, cyclooxygenase-2 et
al. (2004) Clin. Cancer Res. 10: 4342-4348. (COX-2). Renal cell
carcinoma Mulders, et al. (2003) Urol. Clin. North Am. 30: 455-465;
Steffens, et antigen bound by mAB al. (1999) Anticancer Res. 19:
1197-1200. G250. EphA2 See, e.g., U.S. Patent Publication No.
2005/0281783 A1; Genbank Accession No. NM_004431 (human); Genbank
Accession No. NM_010139 (Mouse); Genbank Accession No. AB038986
(Chicken, partial sequence); GenBank Accession Nos. NP_004422,
AAH37166, and AAA53375 (human); GenBank Accession Nos. NP_034269
(mouse), AAH06954 (mouse), XP_345597 (rat), and BAB63910 (chicken).
EGFRvIII See, e.g., WO/2012/068360 Francisella tularensis antigens
Francisella tularensis Complete genome of subspecies Schu S4
(GenBank Acc. No. A and B. AJ749949); of subspecies Schu 4 (GenBank
Acc. No. NC_006570). Outer membrane protein (43 kDa) Bevanger, et
al. (1988) J. Clin. Microbiol. 27: 922-926; Porsch-Ozcurumez, et
al. (2004) Clin. Diagnostic. Lab. Immunol. 11: 1008-1015).
Antigenic components of F. tularensis include, e.g., 80 antigens,
including 10 kDa and 60 kDa chaperonins (Havlasova, et al. (2002)
Proteomics 2: 857-86), nucleoside diphosphate kinase, isocitrate
dehydrogenase, RNA-binding protein Hfq, the chaperone ClpB
(Havlasova, et al. (2005) Proteomics 5: 2090-2103). See also, e.g.,
Oyston and Quarry (2005) Antonie Van Leeuwenhoek 87: 277-281;
Isherwood, et al. (2005) Adv. Drug Deliv. Rev. 57: 1403-1414;
Biagini, et al. (2005) Anal. Bioanal. Chem. 382: 1027-1034.
Malarial antigens Circumsporozoite See, e.g., Haddad, et al. (2004)
Infection Immunity 72: 1594-1602; protein (CSP); SSP2; Hoffman, et
al. (1997) Vaccine 15: 842-845; Oliveira-Ferreira and HEP17; Exp-1
Daniel-Ribeiro (2001) Mem. Inst. Oswaldo Cruz, Rio de Janeiro
orthologs found in 96: 221-227. CSP (see, e.g., GenBank Acc. No.
AB121024). SSP2 P. falciparum; and (see, e.g., GenBank Acc. No.
AF249739). LSA-1 (see, e.g., GenBank LSA-1. Acc. No. Z30319).
Ring-infected See, e.g., Stirnadel, et al. (2000) Int. J.
Epidemiol. 29: 579-586; erythrocyte survace Krzych, et al. (1995)
J. Immunol. 155: 4072-4077. See also, Good, et protein (RESA); al.
(2004) Immunol. Rev. 201: 254-267; Good, et al. (2004) Ann. Rev.
merozoite surface Immunol. 23: 69-99. MSP2 (see, e.g., GenBank Acc.
No. X96399; protein 2 (MSP2); X96397). MSP1 (see, e.g., GenBank
Acc. No. X03371). RESA (see, Spf66; merozoite e.g., GenBank Acc.
No. X05181; X05182). surface protein 1(MSP1); 195A; BVp42. Apical
membrane See, e.g., Gupta, et al. (2005) Protein Expr. Purif. 41:
186-198. AMA1 antigen 1 (AMA1). (see, e.g., GenBank Acc. No. A`13;
AJ494905; AJ490565). Viruses and viral antigens Hepatitis A GenBank
Acc. Nos., e.g., NC_001489; AY644670; X83302; K02990; M14707.
Hepatitis B Complete genome (see, e.g., GenBank Acc. Nos. AB214516;
NC_003977; AB205192; AB205191; AB205190; AJ748098; AB198079;
AB198078; AB198076; AB074756). Hepatitis C Complete genome (see,
e.g., GenBank Acc. Nos. NC_004102; AJ238800; AJ238799; AJ132997;
AJ132996; AJ000009; D84263). Hepatitis D GenBank Acc. Nos, e.g.
NC_001653; AB118847; AY261457. Human papillomavirus, See, e.g.,
Trimble, et al. (2003) Vaccine 21: 4036-4042; Kim, et al. including
all 200+ (2004) Gene Ther. 11: 1011-1018; Simon, et al. (2003) Eur.
J. Obstet. subtypes (classed in Gynecol. Reprod. Biol. 109:
219-223; Jung, et al. (2004) J. Microbiol. 16 groups), such as the
42: 255-266; Damasus-Awatai and Freeman-Wang (2003) Curr. Opin.
high risk subtypes 16, Obstet. Gynecol. 15: 473-477; Jansen and
Shaw (2004) Annu. Rev. 18, 30, 31, 33, 45. Med. 55: 319-331; Roden
and Wu (2003) Expert Rev. Vaccines 2: 495-516; de Villiers, et al.
(2004) Virology 324: 17-24; Hussain and Paterson (2005) Cancer
Immunol. Immunother. 54: 577-586; Molijn, et al. (2005) J. Clin.
Virol. 32 (Suppl. 1) S43-S51. GenBank Acc. Nos. AY686584; AY686583;
AY686582; NC_006169; NC_006168; NC_006164; NC_001355; NC_001349;
NC_005351; NC_001596). Human T-cell See, e.g., Capdepont, et al.
(2005) AIDS Res. Hum. Retrovirus 21: 28-42; lymphotropic virus
Bhigjee, et al. (1999) AIDS Res. Hum. Restrovirus 15: 1229-1233;
(HTLV) types I and II, Vandamme, et al. (1998) J. Virol. 72:
4327-4340; Vallejo, et al. (1996) including the J. Acquir. Immune
Defic. Syndr. Hum. Retrovirol. 13: 384-391. HTLV type I subtypes
HTLV type I (see, e.g., GenBank Acc. Nos. AY563954; AY563953.
Cosmopolitan, Central HTLV type II (see, e.g., GenBank Acc. Nos.
L03561; Y13051; African, and AF139382). Austro-Melanesian, and the
HTLV type II subtypes Iia, Iib, Iic, and Iid. Coronaviridae, See,
e.g., Brian and Baric (2005) Curr. Top. Microbiol. Immunol.
including 287: 1-30; Gonzalez, et al. (2003) Arch. Virol. 148:
2207-2235; Smits, Coronaviruses, such as et al. (2003) J. Virol.
77: 9567-9577; Jamieson, et al. (1998) J. Infect. SARS-coronavirus
Dis. 178: 1263-1269 (GenBank Acc. Nos. AY348314; NC_004718;
(SARS-CoV), and AY394850). Toroviruses. Rubella virus. GenBank Acc.
Nos. NC_001545; AF435866. Mumps virus, including See, e.g., Orvell,
eta 1. (2002) J. Gen. Virol. 83: 2489-2496. See, e.g., the
genotypes A, C, D, GenBank Acc. Nos. AY681495; NC_002200; AY685921;
AF201473. G, H, and I. Coxsackie virus A See, e.g., Brown, et al.
(2003) J. Virol. 77: 8973-8984. GenBank Acc. including the
serotypes Nos. AY421768; AY790926: X67706. 1, 11, 13, 15, 17, 18,
19, 20, 21, 22, and 24 (also known as Human enterovirus C; HEV-C).
Coxsackie virus B, See, e.g., Ahn, et al. (2005) J. Med. Virol. 75:
290-294; Patel, et al. including subtypes 1-6. (2004) J. Virol.
Methods 120: 167-172; Rezig, et al. (2004) J. Med. Virol. 72:
268-274. GenBank Acc. No. X05690. Human enteroviruses See, e.g.,
Oberste, et al. (2004) J. Virol. 78: 855-867. Human including,
e.g., human enterovirus A (GenBank Acc. Nos. NC_001612); human
enterovirus A (HEV-A, enterovirus B (NC_001472); human enterovirus
C (NC_001428); CAV2 to CAV8, human enterovirus D (NC_001430).
Simian enterovirus A (GenBank CAV10, CAV12, Acc. No. NC_003988).
CAV14, CAV16, and EV71) and also including HEV-B (CAV9, CBV1 to
CBV6, E1 to E7, E9, E11 to E21, E24 to E27, E29 to E33, and EV69
and E73), as well as HEV. Polioviruses including See, e.g., He, et
al. (2003) J. Virol. 77: 4827-4835; Hahsido, et al. PV1, PV2, and
PV3. (1999) Microbiol. Immunol. 43: 73-77. GenBank Acc. No.
AJ132961 (type 1); AY278550 (type 2); X04468 (type 3). Viral
encephalitides See, e.g., Hoke (2005) Mil. Med. 170: 92-105;
Estrada-Franco, et al. viruses, including (2004) Emerg. Infect.
Dis. 10: 2113-2121; Das, et al. (2004) Antiviral equine
encephalitis, Res. 64: 85-92; Aguilar, et al. (2004) Emerg. Infect.
Dis. 10: 880-888; Venezuelan equine Weaver, et al. (2004) Arch.
Virol. Suppl. 18: 43-64; Weaver, et al. encephalitis (VEE) (2004)
Annu. Rev. Entomol. 49: 141-174. Eastern equine encephalitis
(including subtypes IA, (GenBank Acc. No. NC_003899; AY722102);
Western equine IB, IC, ID, IIIC, IIID), encephalitis (NC_003908).
Eastern equine encephalitis (EEE), Western equine encephalitis
(WEE),
St. Louis encephalitis, Murray Valley (Australian) encephalitis,
Japanese encephalitis, and tick-born encephalitis. Human
herpesviruses, See, e.g., Studahl, et al. (2000) Scand. J. Infect.
Dis. 32: 237-248; including Padilla, et al. (2003) J. Med. Virol.
70 (Suppl. 1) S103-S110; cytomegalovirus Jainkittivong and Langlais
(1998) Oral Surg. Oral Med. 85: 399-403. (CMV), Epstein-Barr
GenBank Nos. NC_001806 (herpesvirus 1); NC_001798 virus (EBV),
human (herpesvirus 2); X04370 and NC_001348 (herpesvirus 3);
herpesvirus-1 (HHV-1), NC_001345 (herpesvirus 4); NC_001347
(herpesvirus 5); X83413 HHV-2, HHV-3, and NC_000898 (herpesvirus
6); NC_001716 (herpesvirus 7). HHV-4, HHV-5, Human herpesviruses
types 6 and 7 (HHV-6; HHV-7) are disclosed HHV-6, HHV-7, by, e.g.,
Padilla, et al. (2003) J. Med. Virol. 70 (Suppl. 1)S103-S110.
HHV-8, herpes B virus, Human herpesvirus 8 (HHV-8), including
subtypes A-E, are disclosed herpes simplex virus in, e.g.,
Treurnicht, et al. (2002) J. Med. Virul. 66: 235-240. types 1 and 2
(HSV-1, HSV-2), and varicella zoster virus (VZV). HIV-1 including
group See, e.g., Smith, et al. (1998) J. Med. Virol. 56: 264-268.
See also, M (including subtypes e.g., GenBank Acc. Nos. DQ054367;
NC_001802; AY968312; A to J) and group O DQ011180; DQ011179;
DQ011178; DQ011177; AY588971; (including any AY588970; AY781127;
AY781126; AY970950; AY970949; distinguishable AY970948; X61240;
AJ006287; AJ508597; and AJ508596. subtypes) (HIV-2, including
subtypes A-E. Epstein-Barr virus See, e.g., Peh, et al. (2002)
Pathology 34: 446-450. Epstein-Barr virus (EBV), including strain
B95-8 (GenBank Acc. No. V01555). subtypes A and B. Reovirus,
including See, e.g., Barthold, et al. (1993) Lab. Anim. Sci. 43:
425-430; Roner, serotypes and strains 1, et al. (1995) Proc. Natl.
Acad. Sci. USA 92: 12362-12366; Kedl, et al. 2, and 3, type 1 Lang,
(1995) J. Virol. 69: 552-559. GenBank Acc. No. K02739 (sigma-3 type
2 Jones, and type 3 gene surface protein). Dearing. Cytomegalovirus
See, e.g., Chern, et al. (1998) J. Infect. Dis. 178: 1149-1153;
Vilas (CMV) subtypes Boas, et al. (2003) J. Med. Virol. 71:
404-407; Trincado, et al. (2000) include CMV subtypes J. Med.
Virol. 61: 481-487. GenBank Acc. No. X17403. I-VII. Rhinovirus,
including Human rhinovirus 2 (GenBank Acc. No. X02316); Human all
serotypes. rhinovirus B (GenBank Acc. No. NC_001490); Human
rhinovirus 89 (GenBank Acc. No. NC_001617); Human rhinovirus 39
(GenBank Acc. No. AY751783). Adenovirus, including AY803294;
NC_004001; AC_000019; AC_000018; AC_000017; all serotypes.
AC_000015; AC_000008; AC_000007; AC_000006; AC_000005; AY737798;
AY737797; NC_003266; NC_002067; AY594256; AY594254; AY875648;
AJ854486; AY163756; AY594255; AY594253; NC_001460; NC_001405;
AY598970; AY458656; AY487947; NC_001454; AF534906; AY45969;
AY128640; L19443; AY339865; AF532578. Filoviruses, including See,
e.g., Geisbert and Jahrling (1995) Virus Res. 39: 129-150; Marburg
virus and Hutchinson, et al. (2001) J. Med. Virol. 65: 561-566.
Marburg virus Ebola virus, and strains (see, e.g., GenBank Acc. No.
NC_001608). Ebola virus (see, e.g., such as Ebola-Sudan GenBank
Acc. Nos. NC_006432; AY769362; NC_002549; (EBO-S), Ebola-Zaire
AF272001; AF086833). (EBO-Z), and Ebola-Reston (EBO-R).
Arenaviruses, including Junin virus, segment S (GenBank Acc. No.
NC_005081); Junin virus, lymphocytic segment L (GenBank Acc. No.
NC_005080). choriomeningitis (LCM) virus, Lassa virus, Junin virus,
and Machupo virus. Rabies virus. See, e.g., GenBank Acc. Nos.
NC_001542; AY956319; AY705373; AF499686; AB128149; AB085828;
AB009663. Arboviruses, including Dengue virus type 1 (see, e.g.,
GenBank Acc. Nos. AB195673; West Nile virus, AY762084). Dengue
virus type 2 (see, e.g., GenBank Acc. Nos. Dengue viruses 1 to 4,
NC_001474; AY702040; AY702039; AY702037). Dengue virus type
Colorado tick fever 3 (see, e.g., GenBank Acc. Nos. AY923865;
AT858043). Dengue virus, Sindbis virus, virus type 4 (see, e.g.,
GenBank Acc. Nos. AY947539; AY947539; Togaviraidae, AF326573).
Sindbis virus (see, e.g., GenBank Acc. Nos. NC_001547;
Flaviviridae, AF429428; J02363; AF103728). West Nile virus (see,
e.g., GenBank Bunyaviridae, Acc. Nos. NC_001563; AY603654).
Reoviridae, Rhabdoviridae, Orthomyxoviridae, and the like. Poxvirus
including Viriola virus (see, e.g., GenBank Acc. Nos. NC_001611;
Y16780; orthopoxvirus (variola X72086; X69198). virus, monkeypox
virus, vaccinia virus, cowpox virus), yatapoxvirus (tanapox virus,
Yaba monkey tumor virus), parapoxvirus, and molluscipoxvirus.
Yellow fever. See, e.g., GenBank Acc. No. NC_002031; AY640589;
X03700. Hantaviruses, including See, e.g., Elgh, et al. (1997) J.
Clin. Microbiol. 35: 1122-1130; serotypes Hantaan Sjolander, et al.
(2002) Epidemiol. Infect. 128: 99-103; Zeier, et al. (HTN), Seoul
(SEO), (2005) Virus Genes 30: 157-180. GenBank Acc. No. NC_005222
and Dobrava (DOB), Sin NC_005219 (Hantavirus). See also, e.g.,
GenBank Acc. Nos. Nombre (SN), Puumala NC_005218; NC_005222;
NC_005219. (PUU), and Dobrava-like Saaremaa (SAAV). Flaviviruses,
including See, e.g., Mukhopadhyay, et al. (2005) Nature Rev.
Microbiol. 3: 13-22. Dengue virus, Japanese GenBank Acc. Nos
NC_001474 and AY702040 (Dengue). encephalitis virus, West GenBank
Acc. Nos. NC_001563 and AY603654. Nile virus, and yellow fever
virus. Measles virus. See, e.g., GenBank Acc. Nos. AB040874 and
AY486084. Human Human parainfluenza virus 2 (see, e.g., GenBank
Acc. Nos. parainfluenzaviruses AB176531; NC003443). Human
parainfluenza virus 3 (see, e.g., (HPV), including HPV GenBank Acc.
No. NC_001796). types 1-56. Influenza virus, Influenza nucleocapsid
(see, e.g., GenBank Acc. No. AY626145). including influenza
Influenza hemagglutinin (see, e.g., GenBank Acc. Nos. AY627885;
virus types A, B, and C. AY555153). Influenza neuraminidase (see,
e.g., GenBank Acc. Nos. AY555151; AY577316). Influenza matrix
protein 2 (see, e.g., GenBank Acc. Nos. AY626144(. Influenza basic
protein 1 (see, e.g., GenBank Acc. No. AY627897). Influenza
polymerase acid protein (see, e.g., GenBank Acc. No. AY627896).
Influenza nucleoprotein (see, e.g., GenBank Acc. Nno. AY627895).
Influenza A virus Hemagglutinin of H1N1 (GenBank Acc. No. S67220).
Influenza A subtypes, e.g., swine virus matrix protein (GenBank
Acc. No. AY700216). Influenza virus viruses (SIV): H1N1 A H5H1
nucleoprotein (GenBank Acc. No. AY646426). H1N1 influenzaA and
swine haemagglutinin (GenBank Acc. No. D00837). See also, GenBank
influenza virus. Acc. Nos. BD006058; BD006055; BD006052. See also,
e.g., Wentworth, et al. (1994) J. Virol. 68: 2051-2058; Wells, et
al. (1991) J.A.M.A. 265: 478-481. Respiratory syncytial Respiratory
syncytial virus (RSV) (see, e.g., GenBank Acc. Nos. virus (RSV),
including AY353550; NC_001803; NC001781). subgroup A and subgroup
B. Rotaviruses, including Human rotavirus C segment 8 (GenBank Acc.
No. AJ549087); human rotaviruses A to Human rotavirus G9 strain
outer capsid protein (see, e.g., GenBank E, bovine rotavirus, Acc.
No. DQ056300); Human rotavirus B strain non-structural protein
rhesus monkey 4 (see, e.g., GenBank Acc. No. AY548957); human
rotavirus A strain rotavirus, and major inner capsid protein (see,
e.g., GenBank Acc. No. AY601554). human-RVV reassortments.
Polyomavirus, See, e.g., Engels, et al. (2004) J. Infect. Dis. 190:
2065-2069; Vilchez including simian and Butel (2004) Clin.
Microbiol. Rev. 17: 495-508; Shivapurkar, et virus 40 (SV40), JC
al. (2004) Cancer Res. 64: 3757-3760; Carbone, et al. (2003) virus
(JCV) and BK Oncogene 2: 5173-5180; Barbanti-Brodano, et al. (2004)
Virology virus (BKV). 318: 1-9) (SV40 complete genome in, e.g.,
GenBank Acc. Nos. NC_001669; AF168994; AY271817; AY271816;
AY120890; AF345344; AF332562). Coltiviruses, including Attoui, et
al. (1998) J. Gen. Virol. 79: 2481-2489. Segments of Eyach Colorado
tick fever virus (see, e.g., GenBank Acc. Nos. AF282475; AF282472;
virus, Eyach virus. AF282473; AF282478; AF282476; NC_003707;
NC_003702; NC_003703; NC_003704; NC_003705; NC_003696; NC_003697;
NC_003698; NC_003699; NC_003701; NC_003706; NC_003700; AF282471;
AF282477). Calciviruses, including Snow Mountain virus (see, e.g.,
GenBank Acc. No. AY134748). the genogroups Norwalk, Snow Mountain
group (SMA), and Saaporo. Parvoviridae, including See, e.g., Brown
(2004) Dev. Biol. (Basel) 118: 71-77; Alvarez- dependovirus,
Lafuente, et al. (2005) Ann. Rheum. Dis. 64: 780-782; Ziyaeyan, et
al. parvovirus (including (2005) Jpn. J. Infect. Dis. 58: 95-97;
Kaufman, et al. (2005) Virology parvovirus B19), and 332: 189-198.
erythrovirus.
[0131] Other organisms for which suitable antigens are known in the
art include, but are not limited to, Chlamydia trachomatis,
Streptococcus pyogenes (Group A Strep), Streptococcus agalactia
(Group B Strep), Streptococcus pneumonia, Staphylococcus aureus,
Escherichia coli, Haemophilus influenzae, Neisseria meningitidis,
Neisseria gonorrheae, Vibrio cholerae, Salmonella species
(including typhi, typhimurium), enterica (including Helicobactor
pylori Shigella flexneri and other Group D shigella species),
Burkholderia mallei, Burkholderia pseudomallei, Klebsiella
pneumonia, Clostridium species (including C. difficile), Vibrio
parahaemolyticus and V. vulnificus. This list is not meant to be
limiting.
PHARMACEUTICAL COMPOSITIONS
[0132] The term "pharmaceutical" as used herein refers to a
chemical substance intended for use in the cure, treatment, or
prevention of disease and which is subject to an approval process
by the U.S. Food and Drug Administration (or a non-U.S. equivalent
thereof) as a prescription or over-the-counter drug product.
Details on techniques for formulation and administration of such
compositions may be found in Remington, The Science and Practice of
Pharmacy 21.sup.st Edition (Mack Publishing Co., Easton, Pa.) and
Nielloud and Marti-Mestres, Pharmaceutical Emulsions and
Suspensions: 2.sup.nd Edition (Marcel Dekker, Inc, New York).
[0133] For the purposes of this disclosure, the pharmaceutical
compositions may be administered by a variety of means including
orally, parenterally, by inhalation spray, topically, or rectally
in formulations containing pharmaceutically acceptable carriers,
adjuvants and vehicles. The term parenteral as used here includes
but is not limited to subcutaneous, intravenous, intramuscular,
intraarterial, intradermal, intrathecal and epidural injections
with a variety of infusion techniques. Intraarterial and
intravenous injection as used herein includes administration
through catheters. Administration via intracoronary stents and
intracoronary reservoirs is also contemplated. The term oral as
used herein includes, but is not limited to oral ingestion, or
delivery by a sublingual or buccal route. Oral administration
includes fluid drinks, energy bars, as well as pill
formulations.
[0134] Pharmaceutical compositions may be in any form suitable for
the intended method of administration. When used for oral use for
example, tablets, troches, lozenges, aqueous or oil suspensions,
dispersible powders or granules, emulsions, hard or soft capsules,
syrups or elixirs may be prepared. Compositions intended for oral
use may be prepared according to any method known to the art for
the manufacture of pharmaceutical compositions and such
compositions may contain one or more agents including sweetening
agents, flavoring agents, coloring agents and preserving agents, in
order to provide a palatable preparation. Tablets containing a drug
compound in admixture with non-toxic pharmaceutically acceptable
excipient which are suitable for manufacture of tablets are
acceptable. These excipients may be, for example, inert diluents,
such as calcium or sodium carbonate, lactose, calcium or sodium
phosphate; granulating and disintegrating agents, such as maize
starch, or alginic acid; binding agents, such as starch, gelatin or
acacia; and lubricating agents; such as magnesium stearate, stearic
acid or talc. Tablets may be uncoated, or may be coated by known
techniques including enteric coating, colonic coating, or
microencapsulation to delay disintegration and adsorption in the
gastrointestinal tract and/or provide a sustained action over a
longer period. For example, a time delay material such as glyceryl
monostearate or glyceryl distearate alone or with a wax may be
employed.
[0135] Formulations for oral use may be also presented as hard
gelatin capsules where the drug compound is mixed with an inert
solid diluent, for example calcium phosphate or kaolin, or as soft
gelatin capsules wherein the active ingredient is mixed with water
or an oil medium, such as peanut oil, liquid paraffin or olive
oil.
[0136] Pharmaceutical compositions may be formulated as aqueous
suspensions in admixture with excipients suitable for the
manufacture of aqueous-suspensions. Such excipients include a
suspending agent, such as sodium carboxymethylcellulose,
methylcellulose, hydroxypropyl methylcellulose, sodium alginate,
polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing
or wetting agents such as a naturally occurring phosphatide (e.g.,
lecithin), a condensation product of an alkylene oxide with a fatty
acid (e.g., polyoxyethylene stearate), a condensation product of
ethylene oxide with a long chain aliphatic alcohol (e.g.,
heptadecaethyleneoxycetanol), a condensation product of ethylene
oxide with a partial ester derived from a fatty acid and a hexitol
anhydride (e.g., polyoxyethylene sorbitan monooleate). The aqueous
suspension may also contain one or more preservatives such as ethyl
or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or
more flavoring agents and one or more sweetening agents, such as
sucrose or saccharin.
[0137] Oil suspensions may be formulated by suspending the active
ingredient in a vegetable oil, such as arachis oil, olive oil,
sesame oil or coconut oil, or a mineral oil such as liquid
paraffin. The oral suspensions may contain a thickening agent, such
as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such
as those set forth above, and flavoring agents may be added to
provide a palatable oral preparation. These compositions may be
preserved by the addition of an antioxidant such as ascorbic
acid.
[0138] Dispersible powders and granules of the disclosure suitable
for preparation of an aqueous suspension by the addition of water
provide the active ingredient in admixture with a dispersing or
wetting agent, a suspending agent, and one or more preservatives.
Suitable dispersing or wetting agents and suspending agents are
exemplified by those disclosed above. Additional excipients, for
example sweetening, flavoring and coloring agents, may also be
present.
[0139] The pharmaceutical compositions of the disclosure may also
be in the form of oil-in-water emulsions. The oily phase may be a
vegetable oil, such as olive oil or arachis oil, a mineral oil,
such as liquid paraffin, or a mixture of these. Suitable
emulsifying agents include naturally-occurring gums, such as gum
acacia and gum tragacanth, naturally occurring phosphatides, such
as soybean lecithin, esters or partial esters derived from fatty
acids and hexitol anhydrides, such as sorbitan monooleate, and
condensation products of these partial esters with ethylene oxide,
such as polyoxyethylene sorbitan monooleate. The emulsion may also
contain sweetening and flavoring agents.
[0140] Syrups and elixirs may be formulated with sweetening agents,
such as glycerol, sorbitol or sucrose. Such formulations may also
contain a demulcent, a preservative, a flavoring or a coloring
agent.
[0141] The pharmaceutical compositions of the disclosure may be in
the form of a sterile injectable preparation, such as a sterile
injectable aqueous or oleaginous suspension. This suspension may be
formulated according to the known art using those suitable
dispersing or wetting agents and suspending agents which have been
mentioned above. The sterile injectable preparation may also be a
sterile injectable solution or suspension in a non-toxic
parenterally acceptable diluent or solvent such as a solution in
1,3-butane-diol or prepared as a lyophilized powder. Among the
acceptable vehicles and solvents that may be employed are water,
Ringer's solution and isotonic sodium chloride solution. In
addition, sterile fixed oils may conventionally be employed as a
solvent or suspending medium. For this purpose any bland fixed oil
may be employed including synthetic mono- or diglycerides. In
addition, fatty acids such as oleic acid may likewise be used in
the preparation of injectables.
[0142] The amount of active ingredient that may be combined with
the carrier material to produce a single dosage form will vary
depending upon the host treated and the particular mode of
administration. For example, a time-release formulation intended
for oral administration to humans may contain approximately 20 to
500 mg of active material compounded with an appropriate and
convenient amount of carrier material which may vary from about 5
to about 95% of the total compositions. It is preferred that the
pharmaceutical composition be prepared which provides easily
measurable amounts for administration. Typically, an effective
amount to be administered systemically is about 0.1 mg/kg to about
100 mg/kg and depends upon a number of factors including, for
example, the age and weight of the subject (e.g., a mammal such as
a human), the precise condition requiring treatment and its
severity, the route of administration, and will ultimately be at
the discretion of the attendant physician or veterinarian. It will
be understood, however, that the specific dose level for any
particular patient will depend on a variety of factors including
the activity of the specific compound employed, the age, body
weight, general health, sex and diet of the individual being
treated; the time and route of administration; the rate of
excretion; other drugs which have previously been administered; and
the severity of the particular condition undergoing therapy, as is
well understood by those skilled in the art.
[0143] As noted above, formulations of the disclosure suitable for
oral administration may be presented as discrete units such as
capsules, cachets or tablets each containing a predetermined amount
of the active ingredient, as a powder or granules; as a solution or
a suspension in an aqueous or non-aqueous liquid, or as an
oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The
pharmaceutical compositions may also be administered as a bolus,
electuary or paste.
[0144] A tablet may be made by compression or molding, optionally
with one or more accessory ingredients. Compressed tablets may be
prepared by compressing in a suitable machine the active ingredient
in a free flowing form such as a powder or granules, optionally
mixed with a binder (e.g., povidone, gelatin, hydroxypropyl ethyl
cellulose), lubricant, inert diluent, preservative, disintegrant
(e.g., sodium starch glycolate, cross-linked povidone, cross-linked
sodium carboxymethyl cellulose) surface active or dispersing agent.
Molded tablets may be made in a suitable machine using a mixture of
the powdered compound moistened with an inert liquid diluent. The
tablets may optionally be coated or scored and may be formulated so
as to provide slow or controlled release of the active ingredient
therein using, for example, hydroxypropyl methylcellulose in
varying proportions to provide the desired release profile. Tablets
may optionally be provided with an enteric or colonic coating to
provide release in parts of the gut other than the stomach. This is
particularly advantageous with the compounds of formula 1 when such
compounds are susceptible to acid hydrolysis.
[0145] Formulations suitable for topical administration in the
mouth include lozenges comprising the active ingredient in a
flavored base, usually sucrose and acacia or tragacanth; pastilles
comprising the active ingredient in an inert base such as gelatin
and glycerin, or sucrose and acacia; and mouthwashes comprising the
active ingredient in a suitable liquid carrier.
[0146] Formulations for rectal administration may be presented as a
suppository with a suitable base comprising for example cocoa
butter or a salicylate.
[0147] Formulations suitable for vaginal administration may be
presented as pessaries, tampons, creams, gels, pastes, foams or
spray formulations containing in addition to the active ingredient
such carriers as are known in the art to be appropriate.
[0148] Formulations suitable for parenteral administration include
aqueous and non-aqueous isotonic sterile injection solutions which
may contain antioxidants, buffers, bacteriostats and solutes which
render the formulation isotonic with the blood of the intended
recipient; and aqueous and non-aqueous sterile suspensions which
may include suspending agents and thickening agents. The
formulations may be presented in unit-dose or multi-dose sealed
containers, for example, ampoules and vials, and may be stored in a
freeze-dried (lyophilized) condition requiring only the addition of
the sterile liquid carrier, for example water for injections,
immediately prior to use. Injection solutions and suspensions may
be prepared from sterile powders, granules and tablets of the kind
previously described.
[0149] As used herein, pharmaceutically acceptable salts include,
but are not limited to: acetate, pyridine, ammonium, piperazine,
diethylamine, nicotinamide, formic, urea, sodium, potassium,
calcium, magnesium, zinc, lithium, cinnamic, methylamino,
methanesulfonic, picric, tartaric, triethylamino, dimethylamino,
and tris(hydoxymethyl)aminomethane. Additional pharmaceutically
acceptable salts are known to those skilled in the art.
[0150] An effective amount for a particular patient may vary
depending on factors such as the condition being treated, the
overall health of the patient, the route and dose of administration
and the severity of side effects. Guidance for methods of treatment
and diagnosis is available (see, e.g., Maynard, et al. (1996) A
Handbook of SOPs for Good Clinical Practice, Interpharm Press, Boca
Raton, Fla.; Dent (2001) Good Laboratory and Good Clinical
Practice, Urch Publ., London, UK).
[0151] An effective amount may be given in one dose, but is not
restricted to one dose. Thus, the administration can be two, three,
four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen,
fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty,
or more, administrations of pharmaceutical composition. Where there
is more than one administration of a pharmaceutical composition in
the present methods, the administrations can be spaced by time
intervals of one minute, two minutes, three, four, five, six,
seven, eight, nine, ten, or more minutes, by intervals of about one
hour, two hours, three, four, five, six, seven, eight, nine, ten,
11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 hours, and
so on. In the context of hours, the term "about" means plus or
minus any time interval within 30 minutes. The administrations can
also be spaced by time intervals of one day, two days, three days,
four days, five days, six days, seven days, eight days, nine days,
ten days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17
days, 18 days, 19 days, 20 days, 21 days, and combinations thereof.
The invention is not limited to dosing intervals that are spaced
equally in time, but encompass doses at non-equal intervals.
[0152] A dosing schedule of, for example, once/week, twice/week,
three times/week, four times/week, five times/week, six times/week,
seven times/week, once every two weeks, once every three weeks,
once every four weeks, once every five weeks, and the like, is
available for the invention. The dosing schedules encompass dosing
for a total period of time of, for example, one week, two weeks,
three weeks, four weeks, five weeks, six weeks, two months, three
months, four months, five months, six months, seven months, eight
months, nine months, ten months, eleven months, and twelve
months.
[0153] Provided are cycles of the above dosing schedules. The cycle
can be repeated about, e.g., every seven days; every 14 days; every
21 days; every 28 days; every 35 days; 42 days; every 49 days;
every 56 days; every 63 days; every 70 days; and the like. An
interval of non dosing can occur between a cycle, where the
interval can be about, e.g., seven days; 14 days; 21 days; 28 days;
35 days; 42 days; 49 days; 56 days; 63 days; 70 days; and the like.
In this context, the term "about" means plus or minus one day, plus
or minus two days, plus or minus three days, plus or minus four
days, plus or minus five days, plus or minus six days, or plus or
minus seven days.
[0154] Methods for co-administration with an additional therapeutic
agent are well known in the art (Hardman, et al. (eds.) (2001)
Goodman and Gilman's The Pharmacological Basis of Therapeutics,
10th ed., McGraw-Hill, New York, N.Y.; Poole and Peterson (eds.)
(2001) Pharmacotherapeutics for Advanced Practice: A Practical
Approach, Lippincott, Williams & Wilkins, Phila., PA; Chabner
and Longo (eds.) (2001) Cancer Chemotherapy and Biotherapy,
Lippincott, Williams & Wilkins, Phila., PA).
[0155] As noted, the compositions of the present invention are
preferably formulated as pharmaceutical compositions for parenteral
or enteral delivery. A typical pharmaceutical composition for
administration to an animal comprises a pharmaceutically acceptable
vehicle such as aqueous solutions, non-toxic excipients, including
salts, preservatives, buffers and the like. See, e.g., Remington's
Pharmaceutical Sciences, 15th Ed., Easton ed., Mack Publishing Co.,
pp 1405-1412 and 1461-1487 (1975); The National Formulary XIV, 14th
Ed., American Pharmaceutical Association, Washington, D.C. (1975).
Examples of non-aqueous solvents are propylene glycol, polyethylene
glycol, vegetable oil and injectable organic esters such as
ethyloleate. Aqueous carriers include water, alcoholic/aqueous
solutions, saline solutions, parenteral vehicles such as sodium
chloride, Ringer's dextrose, etc. Intravenous vehicles include
fluid and nutrient replenishers. Preservatives include
antimicrobial agents, anti-oxidants, chelating agents and inert
gases. The pH and exact concentration of the various components the
pharmaceutical composition are adjusted according to routine skills
in the art.
[0156] Repeated administrations of a particular vaccine (homologous
boosting) have proven effective for boosting humoral responses.
Such an approach may not be effective at boosting cellular immunity
because prior immunity to the vector tends to impair robust antigen
presentation and the generation of appropriate inflammatory
signals. One approach to circumvent this problem has been the
sequential administration of vaccines that use different
antigen-delivery systems (heterologous boosting). In a heterologous
boosting regimen, at least one prime or boost delivery comprises
delivery of the inactivated tumor cell/cyclic purine dinucleotide
compositions described herein. The heterologous arm of the regimen
may comprise delivery of antigen using one or more of the following
strategies: [0157] inactivated or attenuated bacteria or viruses
comprising the antigen of interest, which are particles that have
been treated with some denaturing condition to render them
ineffective or inefficient in mounting a pathogenic invasion;
[0158] purified antigens, which are typically naturally-produced
antigens purified from a cell culture of the pathogen or a tissue
sample containing the pathogen, or a recombinant version thereof;
[0159] live viral or bacterial delivery vectors recombinantly
engineered to express and/or secrete antigens in the host cells of
the subject. These strategies rely on attenuating (e.g., via
genetic engineering) the viral or bacterial vectors to be
non-pathogenic and non-toxic; [0160] antigen presenting cell (APC)
vectors, such as a dendritic cell (DC) vector, which comprise cells
that are loaded with an antigen, or transfected with a composition
comprising a nucleic acid encoding the antigen (e.g., Provenge.RTM.
(Dendreon Corporation) for the treatment of castration-resistant
metastatic prostate cancer); [0161] liposomal antigen delivery
vehicles; and [0162] naked DNA vectors and naked RNA vectors which
may be administered by a gene gun, electroporation, bacterial
ghosts, microspheres, microparticles, liposomes, polycationic
nanoparticles, and the like.
[0163] A prime vaccine and a boost vaccine can be administered by
any one or combination of the following routes. In one aspect, the
prime vaccine and boost vaccine are administered by the same route.
In another aspect, the prime vaccine and boost vaccine are
administered by different routes. The term "different routes"
encompasses, but is not limited to, different sites on the body,
for example, a site that is oral, non-oral, enteral, parenteral,
rectal, intranode (lymph node), intravenous, arterial,
subcutaneous, intramuscular, intratumor, peritumor, intratumor,
infusion, mucosal, nasal, in the cerebrospinal space or
cerebrospinal fluid, and so on, as well as by different modes, for
example, oral, intravenous, and intramuscular.
[0164] An effective amount of a prime or boost vaccine may be given
in one dose, but is not restricted to one dose. Thus, the
administration can be two, three, four, five, six, seven, eight,
nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen,
seventeen, eighteen, nineteen, twenty, or more, administrations of
the vaccine. Where there is more than one administration of a
vaccine the administrations can be spaced by time intervals of one
minute, two minutes, three, four, five, six, seven, eight, nine,
ten, or more minutes, by intervals of about one hour, two hours,
three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14,
15, 16, 17, 18, 19, 20, 21, 22, 23, 24 hours, and so on. In the
context of hours, the term "about" means plus or minus any time
interval within 30 minutes. The administrations can also be spaced
by time intervals of one day, two days, three days, four days, five
days, six days, seven days, eight days, nine days, ten days, 11
days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18
days, 19 days, 20 days, 21 days, and combinations thereof. The
invention is not limited to dosing intervals that are spaced
equally in time, but encompass doses at non-equal intervals, such
as a priming schedule consisting of administration at 1 day, 4
days, 7 days, and 25 days, just to provide a non-limiting
example.
EXAMPLES
[0165] The following examples serve to illustrate the present
invention. These examples are in no way intended to limit the scope
of the invention.
Example 1. General Methods
[0166] Anhydrous solvents and reagents suitable for solution phase
oligonucleotide synthesis were purchased and handled under dry
argon or nitrogen using anhydrous technique. Amidite coupling
reactions and cyclizations were carried out in anhydrous
acetonitrile or pyridine under dry argon or nitrogen. The starting
materials for all reactions in dry pyridine were dried by
concentration (three times) from pyridine. Preparative silica gel
flash chromatography was carried out using Fluka 60 .ANG.
high-purity grade or Merck Grade 9385 silica using gradients of
methanol in dichloromethane. Analytical HPLC was carried out on a
Varian ProStar 210 HPLC system with a ProStar 330 photodiode array
detector monitoring at 254 nm on a Varian Microsorb 100-10 C.sub.18
250.times.4.6 mm column using gradients of 10 mM TEAA and
acetonitrile at 1.0 ml/min flow. Preparative HPLC was carried out
on a Shimadzu preparative LC20-AP HPLC system, equipped with a
SPD-20A UV/Vis detector monitoring at 254 nm on a Varian Microsorb
60-8 C-18 41.6.times.250 mm column using gradients of 10 mM TEAA
and acetonitrile at a flow rate 50 ml/min. Solid phase extractions
using C-18 Sep-Pak (Waters) were carried out at a loadings of
.about.3% (wt/wt). LC/MS (ESI/APCI) was obtained on a single
quadrapole Shimadzu 2010EV instrument with PDA, MS, and ELSD
detection using a Shimadzu LC20D analytical HPLC. High resolution
FT-ICR mass spec was obtained from WM Keck Foundation Biotechnology
Resource Laboratory at Yale University in New Haven, Conn. The
.sup.1H and .sup.31P NMR spectra were acquired on either a Bruker
400 MHz or a Varian Inova 500 MHz spectrometer. The .sup.31P NMR
were referenced indirectly to dioxane in D2O.
[0167] The assignment of the HPLC purified cyclic dinucleotides and
derivatives are summarized in Table 2 and described in detail in
the Examples.
TABLE-US-00002 TABLE 2 Retention times on Reverse Phase HPLC (min)
and .sup.31P Chemical Shifts (ppm) at 25.degree. C. of
triethylammonium salts (10a, 10b, 10c, 11a, 11b, 11c, 12, 13)
retention compound time .sup.31P .delta. c-di-AMP 10a 8.2* -1.74
dithio [Rp,Sp] c-di-AMP 10c 12.1* 54.54, 54.84, 55.92 (integration
ratio 1.0:0.9:0.1) dithio [Rp,Rp] c-di-AMP 10b 14.4* 54.41 c-di-GMP
11a 6.9* -1.24 dithio [Rp,Sp] c-di-GMP 11c 11.0* 54.77, 56.00
(integration ratio 1:1) dithio [Rp,Rp] c-di-GMP 11b 13.2* 54.87
C.sub.14-acyl-c-di-GMP 12 13.7.sup..sctn. -1.37, -2.06 (integration
ratio 1:1) C.sub.14-acyl-dithio 15.3.sup..sctn. 56.46, 56.66
[Rp,Rp] c-di-GMP 13 (integration ratio 1:1) *HPLC gradient: 2 to
20% CH.sub.3CN in 10 mM TEAA over 20 min at 1 ml/min flow.
.sup..sctn.HPLC gradient: 2 to 80% CH.sub.3CN in 10 mM TEAA over 20
min at 1 ml/min flow.
Example 2. Synthesis of 10a
[0168] The following synthesis of cyclic-di-AMP is described
schematically in FIG. 6 and is a modification of a synthesis of
cyclic-di-GMP reported by Gaffney et al. (One-flask synthesis of
c-di-GMP and the [Rp,Rp] and [Rp,Sp] thiophosphate analogues.
Organic Letters 12, 3269-3271 (2010)).
[0169] a) Phosphitylation of 1 with
2-Chloro-5,6-Benzo-1,3,2-Dioxaphosphorin-4-One (2) and Solid-Liquid
Extraction with CH2Cl2/Hexane (1:1) to Give the
5'-DMT-3'-H-Phosphonate 4.
[0170] To a solution of 1 (3.94 g, 5 mmol) in 15 ml anhydrous
dioxane and 5 ml of dry pyridine was added with stirring 5.6 ml
(7.0 mmol) of a 1.25 M stock solution in dioxane of
2-chloro-5,6-benzo-1,3,2-dioxaphosphorin-4-one (2). After 15 min
the reaction was quenched with 1 ml water and the mixture poured
into 10 ml 0.25 M NaHCO3 followed by extraction (3.times.15 ml)
with ethyl acetate. The organic phase was dried (Na2SO4) and
concentrated to yield 3.8 g. The solid was tritrated with 100 ml of
CH2Cl2/hexane (1:1), filtered, and the residual solid dried to give
a fine white powder (3.5 g) that ran as one spot on TLC (Rf=0.1)
eluting with 5% CH3OH in CH2Cl2 with 0.5% triethylamine.
[0171] b) Detritylation by Sodium Bisulfate Absorbed to Silica Gel
(NaHSO4-SiO2) and Precipitation of the 5'-OH-3'-H-Phosphonate
(5).
[0172] To a solution of 4 (1.74 g, 2 mmol) in 85 ml dichloromethane
and 0.072 ml of water (4 mmole) was added 0.55 g of NaHSO4-SiO2
(2.4 mmol H.sup.+/gr NaHSO4-SiO2). The reaction was complete after
stirring at room temperature for 35 minutes (TLC in 10% MeOH in
CH2Cl2 with 0.5% TEA). The NaHSO4-SiO2 was removed by filtration
and washed (3.times.5 ml) with CH2Cl2. 100 ml of hexane:toluene
(1:1) was added, vortexed for 5 minutes and the solvent was
decanted (repeated twice). Evaporation gave 0.92 g of 5 as a solid.
Analytical HPLC indicated purity of 96.4%. LC/MS in negative mode
confirmed m/z (M-1) 548.2 (calculated for
C.sub.23H.sub.31N.sub.5O.sub.7PSi.sup.-: 548.2).
[0173] c) Coupling, Oxidation and Detritylation.
[0174] DMT-rA(bz)-.beta.CE-TBDMS-phosphoramidite (3) (3.5 g, 3.6
mmole) was co-evaporated three times with 20 ml dry acetonitrile,
the last time leaving about 10 ml volume, to which was added ten 3
.ANG. molecular sieves. The solution was left under dry argon.
[0175] 1.6 g of H-phosphonate (5) was evaporated three times from
anhydrous CH3CN, the last time leaving 100 ml. This solution was
added to the dried phosphoramidite solution via syringe, followed
by 1.4 g of pyridinium trifluoroacetate (which had been dried by
evaporating 3.times.20 ml from anhydrous pyridine). After 20 min 3
ml of 5.5 M tert-butylhydroperoxide was added and stirred for 30
min. After cooling in ice bath, 0.3 g of NaHSO3 in 1 ml of water
was added and the mix stirred for 5 min. The solvent was then
evaporated and the residue taken up in 20 ml (CH2Cl2/MeOH, 98:2).
The sieves were filtered off and solvent switched to 81 ml CH2Cl2.
NaHSO4-SiO2 (513 mg) and water (65 microliters) were added and the
reaction stirred for 40 min. The mixture was filtered through
Celite, the pad washed with CH2Cl2, and the filtrate evaporated to
give crude 7a. LC/MS in negative mode confirmed m/z (M-1) 1148.5
(calcd for C.sub.49H.sub.64N.sub.11O.sub.14P.sub.2Si.sub.2.sup.-:
1148.37.
[0176] d) Cyclization of Linear Dimer (7a) and Oxidation to Give
8a.
[0177] To crude 7a (dried by evaporation from anhydrous pyridine
leaving 100 ml after final evaporation) was added DMOCP (1.9 g,
10.15 mmol). After 12 minutes, the reaction was quenched with water
(2.3 g) followed immediately by the addition of iodine (0.96 g,
3.78 mmol). The reaction mix was poured into 400 ml water
containing 0.6 g NaHSO3. After 5 min stirring, 11.2 g NaHCO3 was
added in portions and the solution stirred for 5 min. The mixture
was partitioned two times with 500 ml ethyl acetate/ether (3:2).
The organic layers were combined, dried (Na2SO4), and evaporated.
Toluene (3.times.10 ml) was added and evaporated to remove residual
pyridine to give 2.37 g of 8a as a yellow-brown solid. LC/MS in
negative mode confirmed m/z (M-1) 1146.6 (calcd for
C.sub.49H.sub.62N.sub.11O.sub.14P.sub.2Si.sub.2.sup.-: 1146.4
[0178] e) Deprotection Crude 8a with Concentrated Ammonium
Hydroxide to Give Crude 9a and Prep HPLC to Give 9a in Pure
Form.
[0179] To 600 mg of 8a in a 200 ml thick walled glass pressure tube
was added 40 ml methanol and 40 ml concentrated aqueous ammonia,
and the resulting mixture was stirred at 50.degree. C. for 16 hr.
The reaction mixture was concentrated under vacuum and the residue
washed with ethyl acetate (3.times.10 ml) to give 510 mg of crude
9a.
[0180] A 102 mg portion of crude 9a in 4 ml of 20% CH3CN in 10 mM
triethylammonium acetate was applied to the prep HPLC column and
eluted using a gradient of acetonitrile and 10 mM triethylammonium
acetate in water (20->50% CH3CN over 20 minutes at 50 ml/min
flow). HPLC fractions containing pure 9a were pooled, evaporated to
remove CH3CN and lyophilized to remove remaining water and volatile
buffer to give 32 mg of pure 9a as the bis-triethylammonium salt.
LC/MS in negative mode confirmed m/z (M-1) 885.5 (calcd for
C.sub.32H.sub.51N.sub.10O.sub.12P.sub.2Si.sub.2.sup.-: 885.3. (It
was also possible to defer the prep HPLC purification until after
the last step as described in the c-di-GMP and dithio-c-di-GMP
series below).
[0181] f) Deprotection of TBS Groups of 9a with Triethylamine
Trihydrofluoride, Neutralization with TEAB, and Solid Phase
Extraction with a C-18 Sep-Pak to Give Pure 10a as the
Bis-Triethylammonium Salt.
[0182] To 20 mg of 9a was added 0.25 ml of triethylamine
trihydrofluoride. The mixture was put on a shaker for 48 h at which
point an analytical HPLC of a 10 microliter sample neutralized with
100 microliter of 1 M triethylammonium bicarbonate indicated
consumption of starting material and appearance of a single new
product. The reaction mixture was then added dropwise with stirring
to a 10.times. volume of chilled 1 M triethylammonium bicarbonate.
The neutralized solution was then loaded on a Waters C-18 Sep-Pak,
and after washing the column with 6 volumes of 10 mM
triethylammmonium acetate, the product was eluted with CH3CN:
triethylammonium acetate (1:1). The CH3CN was removed via
rotoevaporation and the aqueous sample was lyophilized to dryness
to give 14 mg of 10a as the bis-triethylammonium salt. HRMS of 10a
in negative mode confirms m/z (M-H) 657.0985 (calculated for
C.sub.20H.sub.23N.sub.10O.sub.12P.sub.2.sup.-: 657.0978). .sup.1H
NMR (D.sub.2O) 45.degree. C. .delta.(ppm) 8.34 (s, 2H), 8.11 (s,
2H), 6.15 (s, 2H), 4.34 (m, 4H), 4.15 (m, 2H), 3.77 (m, 2H), 3.19
(q, J=7 Hz), 1.27 (t, J=7 Hz). .sup.31P NMR (D.sub.2O) 25.degree.
C. .delta.(ppm) -1.74.
Example 3. Synthesis of 10b and 10c
[0183] The following synthesis is described schematically in FIG.
6.
[0184] a) Hydrolysis of Commercially Available
DMT-rA(Bz)-.beta.CE-TBDMS-Phosphoramidite (3), .beta.-Elimination,
and Silica Chromatography of the Resulting 5'-DMT-3'-H-Phosphonate
(4):
[0185] To a solution of DMT-rA(bz)-.beta.CE-TBDMS-phosphoramidite
(3) (11 g, 11.1 mmole) in 50 ml acetonitrile was added water (0.36
ml, 20 mmole, 1.8 equiv) and pyridinium trifluroacetate (2.3 g,
11.9 mmole, 1.07 equiv) After stirring the mixture for 5 minutes at
room temperature tert-butylamine (50 ml) was added and stirring
continued for an additional 10 minutes. The mixture was then
concentrated to a foam which was taken up in dichloromethane and
applied to a silica gel column eluting with a gradient of 5% to 10%
MeOH in dichloromethane. Column fractions containing the desired
product were pooled and concentrated to yield the
5'-DMT-3'-H-phosphonate (4) as a foam (6.68 g, 7.8 mmole, 70%
yield)
[0186] b) Detritylation and Precipitation of the
5'-OH-3'-H-Phosphonate (5):
[0187] To a solution of 4 (6.68 g, 7.8 mmol) in 60 ml
dichloromethane and 1.4 ml of water (78 mmole, 10 equiv) was added
a 100 ml portion of 6% dichloroacetic acid in dichloromethane (73
mmole, 9.35 equiv). After stirring at room temperature for 10
minutes, pyridine (11.2 ml, 139 mmole, 1.9 equiv based on DCA) was
added to quench the acid and the mixture concentrated to give 5 as
a yellow/orange glass. The glass was taken up in about 20 ml of
dichloromethane and added dropwise with stirring to 500 ml of 7:3
hexane:diethylether to precipitate out the desired
5'-OH-3'-H-phosphonate (5). The supernatant was decanted away from
the precipitate (most of which formed a gum clinging to the walls
of the flask) and was dried down under reduced pressure to form a
granular slurry. This slurry was evaporated three times with 40 ml
of dry acetonitrile, the last time leaving about 12 ml.
[0188] c) Preparation of a Dry Solution of Phosphoramidite (3) in
Acetonitrile, Coupling with 5'-OH-3'-H-Phosphonate 5), and
Sulfurization to the Linear Dimer Thiophosphate (6b), and
Detritylation to 7b.
[0189] The DMT-rA(bz)-.beta.CE-TBDMS-phosphoramidite (3) (9.08 g,
9.36 mmole, 1.2 equiv based on H-phosphonate (5) was coevaporated
three times with 40 ml dry acetonitrile, the last time leaving
about 20 ml volume, to which was added ten 3 .ANG. molecular
sieves. The solution was left under dry argon.
[0190] To the solution of phosphoramidite (3) was added 5 (from b)
with stirring under dry argon. After stirring for 10 minutes at
room temperature, half of the reaction mixture (for conversion to
the dithio analogs) was transferred under argon to a second
reaction vessel, and
3-((N,N-dimethylaminomethylidene)amino-3H-1,2,4-dithiazole-5-thione
(0.88 g, 4.29 mmol, 1.1 equivalent) was added. After 30 min
stirring at room temp the reaction was stopped by placing in a
freezer at -20.degree. C. While stored in freezer for >48 h a
yellow precipitate separated from the solution. The mixture was
filtered and the filtrate concentrated to a foam (3.9 g), dissolved
in 50 ml CH2Cl2 and treated with 100 ul water followed immediately
by 800 mg of NaHSO4-silica. The mixture was stirred for 30 min at
room temperature and filtered to remove the silica. Sixty ml of
hexane was then added to the filtrate and a lower phase oiled out
of the solution. The oil was separated and evaporated to yield 3.1
g of crude 7b.
[0191] d) Cyclization of Linear Dimer (7b), Sulfurization, and
Silica Chromatography to Give a Mixture of 8b and 8c.
[0192] 7b (3.05 g, 2.6 mmol) was dried by evaporation from
anhydrous pyridine (200 ml pyridine was added and rotoevaporated to
leave 120 ml) followed by addition of DMOCP (1.68 g, 9.1 mmol, 3.5
equiv). After 12 minutes, the reaction was quenched with water
(1.63 g, 91 mmol) followed immediately by the addition of 0.675 g
(3.0 mmol, 1.2 equiv) of 3-H-1,2-benzodithiol-3-one. The reaction
mix was poured into 500 ml of 0.25 M sodium bicarbonate and then
extracted 2.times.500 ml with ethylaceate/diethylether (3:2). The
organic layers were combined, dried (Na2SO4), and evaporated under
vacuum. Toluene (3.times.10 ml) was added and evaporated to remove
residual pyridine. The residue was applied to a silica column and
eluted with a gradient of 0 to 10% of CH3OH in CH2Cl2 to give a
total of 1.47 g containing mostly diastereomers 8b and 8c.
[0193] e) Deprotection of the Mixture of 8b and 8c with
Concentrated Ammonium Hydroxide to Give 9b and 9c, and Separation
Via Prep HPLC to Give 9b and 9c in Pure Form.
[0194] To 230 mg of a mixture of 8b and 8c in a glass pressure tube
was added 16 ml methanol followed by 16 ml concentrated aqueous
ammonia, and the resulting mixture was stirred at 50.degree. C. for
16 hr. The reaction mixture was concentrated under vacuum and the
residue washed with ethyl acetate (3.times.10 ml) to give 210 mg of
a crude mixture of 9b and 9c. LC/MS in negative mode for 9b/9c
mixture confirmed m/z (M-1) 917 (calcd for
C.sub.32H.sub.51N.sub.10O.sub.10P.sub.2S.sub.2Si.sub.2.sup.-:
917.2.
[0195] Separation of the mixture of 9b/9c via prep HPLC. A 105 mg
portion of the crude mix of 9b and 9c in 4 ml of 30% CH3CN in 10 mM
triethylammonium acetate was applied to the prep HPLC column and
eluted using a gradient of acetonitrile and 10 mM triethylammonium
acetate (30->50% CH3CN over 20 minutes at 50 ml/min flow). HPLC
fractions containing pure 9b were separated from those containing
pure 9c. The pooled fractions were evaporated to remove CH3CN and
lyophilized to remove remaining water and volatile buffer to give
18 mg of 9b and 14 mg of 9c as the bis-triethylammonium salts.
[0196] f) Deprotection of TBS Groups of 9b with Triethylamine
Trihydrofluoride, Neutralization with TEAB, and Solid Phase
Extraction (SPE) with a C-18 Sep-Pak to Give Pure 10b as the
Bis-Triethylammonium Salt.
[0197] To 8 mg of 9b was added 0.4 ml of triethylamine
trihydrofluoride. The mixture was put on a shaker for 16 h at which
point an analytical HPLC of a 5 microliter sample neutralized with
100 microliter of 1 M triethylammonium bicarbonate (TEAB) indicated
consumption of starting material and appearance of a single new
product. The reaction mixture was then added dropwise with stirring
to a .about.10.times. volume of chilled 1 M triethylammonium
bicarbonate. The neutralized solution was then loaded on a Waters
C-18 Sep Pak, and after washing the column with 6 volumes of 10 mM
triethylammmonium acetate, the product was eluted with CH3CN: 10 mM
triethylammonium acetate (1:5). The CH3CN was removed via
rotoevaporation and the aqueous sample was lyophilized to dryness
to give 6 mg of 10b as the bis-triethylammonium salt. HRMS of 10b
in negative mode confirms m/z (M-H) 689.0526 (calculated for
C.sub.20H.sub.23N.sub.10O.sub.10P.sub.2S.sub.2.sup.-: 689.0521).
.sup.1H NMR (D.sub.2O) 35.degree. C. .delta.8.39 (s, 2H),
.delta.8.16 (s, 2H), .delta.6.16 (s, 2H), .delta.4.97-5.03 (m, 2H),
.delta.4.78 (m, 2H), .delta.4.50-4.55 (m, 4H), .delta.4.04-4.08 (m,
2H), .delta.3.20 (q, j=7 Hz), .delta.1.27 (t, J=7 Hz). .sup.31P NMR
(D.sub.2O) 25.degree. C. .delta.(ppm) 54.41.
[0198] g) Deprotection of TBS Groups of 9c with Triethylamine
Trihydrofluoride, Neutralization with TEAB, and Solid Phase
Extraction with a C-18 Sep-Pak to Give Pure 10c as the
Bis-Triethylammonium Salt.
[0199] To 6 mg of 9c was added 0.3 ml of triethylamine
trihydrofluoride. The mixture was put on a shaker for 16 h and a
work-up of a small aliquot as in (f) indicated consumption of
starting material and appearance of a single new product. The
reaction mixture was then added dropwise with stirring to a
.about.10.times. volume of chilled 1 M triethylammonium
bicarbonate. The neutralized solution was then loaded on a Waters
C-18 Sep Pak, and after washing the column with 6 volumes of 10 mM
triethylammmonium acetate, the product was eluted with CH3CN: 10 mM
triethylammonium acetate (1:5). The CH3CN was removed via
rotoevaporation and the aqueous sample was lyophilized to dryness
to give 4 mg of 10c as the bis-triethylammonium salt. HRMS of 10c
in negative mode confirms m/z (M-H) 689.0524 (calculated for
C.sub.20H.sub.23N.sub.10O.sub.10P.sub.2S.sub.2.sup.-: 689.0521).
.sup.1H NMR (D.sub.2O) 35.degree. C. .delta.(ppm) 8.50 (s, 2H),
.delta.8.37 (s, 2H), .delta.8.20 (s, 2H), .delta.8.10 (s, 2H),
.delta.6.17 (s, 2H), .delta.6.14 (s, 2H), .delta.5.06-5.07 (m, 2H),
.delta.4.96-5.02 (m, 2H), .delta.4.87-4.93 (m, 2H), .delta.4.75 (m,
2H), .delta.4.34-4.56 (m, 10H), .delta.3.98-4.13 (m, 2H),
.delta.3.20 (q, J=7 Hz), .delta.1.27 (t, J=7 Hz). .sup.31P NMR
(D.sub.2O) 25.degree. C. .delta.(ppm) 54.54, 54.84, 55.92
(minor).
Example 4. Synthesis of (11a), (11b) and (11c)
[0200] 11a, 11b and 11c were synthesized as described in Gaffney et
al. with the addition of prep HPLC purification of the final
product (exemplied below) instead of a recrystallization, in order
to achieve purities of .gtoreq.97% for biological testing.
Alternatively, the prep HPLC purification can be carried out after
the cyclization and deprotection steps as described for the
adenosine series in FIG. 6, Examples 2 and 3.
[0201] 11a
[0202] A 100 mg portion of 11a in 3 ml 10 mM triethylammonium
acetate was applied to the prep HPLC column and eluted using a
gradient of acetonitrile and 10 mM triethylammonium acetate in
water (0% to 10% CH3CN gradient over 22 minutes at 50 ml/min flow).
HPLC fractions containing pure 11a were pooled and the CH3CN was
removed via rotoevaporation and the remaining aqueous sample
lyophilized to dryness to give 40 mg of pure 11a as the
bis-triethylammonium salt. HRMS of 11a in negative mode as m/z
(M-H) 689.0893 (calculated for
C.sub.20H.sub.23N.sub.10O.sub.14P.sub.2.sup.-: 689.0876). .sup.1H
NMR (D.sub.2O) 45.degree. C. .delta.(ppm) 8.05 (s, 2H), 5.98 (s,
2H), 4.90 (m, 2H), 4.76 (m, 2H), 4.41 (m, 2H), 4.33 (m, 2H), 4.09
(m, 2H), 3.19 (q, J=7 Hz, 6H), 1.28 (t, J=7 Hz, 9H). 31P NMR
(D.sub.2O) 25.degree. C. .delta.(ppm) -1.24.
[0203] 11b
[0204] A 100 mg portion of the enriched 11b in 3 ml 6% CH3CN in 10
mM triethylammonium acetate was applied to the prep HPLC column and
eluted using a gradient of acetonitrile and 10 mM triethylammonium
acetate in water (6% to 18% CH3CN gradient over 22 minutes at 50
ml/min flow). HPLC fractions containing the pure 11b were pooled
and the CH3CN was removed via rotoevaporation and the remaining
aqueous sample lyophilized to dryness to give 40 mg (40% yields) of
pure 11b as the bis-triethylammonium salt. HRMS of 11b in negative
mode confirmed m/z (M-H) 721.0446 (calculated for
C.sub.20H.sub.23N.sub.10O.sub.12P.sub.2S.sub.2.sup.-:721.0419).
.sup.1H NMR (D.sub.2O) 45.degree. C. .delta. 8.05 (s, 2H), 5.98 (s,
2H), 5.03 (m, 2H), 4.77 (m, 4H), 4.10 (m, 2H), 4.08 (m, 2H), 3.19
(q, j=7 Hz, 6H), 1.28 (t, J=7 Hz, 9H). .sup.31P NMR (D.sub.2O)
25.degree. C. .delta. 54.87.
[0205] 11c
[0206] 60 mg of the enriched 11c in 3 ml 6% CH3CN in 10 mM
triethylammonium acetate was applied to the prep HPLC column and
eluted with a gradient of acetonitrile and 10 mM triethylammonium
acetate in water (6% to 18% CH3CN gradient over 22 minutes at 50
ml/min flow). HPLC fractions containing the pure 11c were pooled
and the CH3CN was removed via rotoevaporation and the remaining
aqueous sample lyophilized to dryness to give 30 mg (50% yield) of
pure 11c as the bis-triethylammonium salt. HRMS of 11c in negative
mode confirmed m/z (M-2H) 360.0171 (calculated for
C.sub.20H.sub.22N.sub.10O.sub.12P.sub.2S.sub.2.sup.-2: 360.0173).
.sup.1H NMR (D.sub.2O) 55.degree. C. .delta.(ppm) 8.13 (s, 2H),
8.03 (s, 2H), 5.97 (m, 2H), 5.06-5.12 (br, 4H), 4.98-5.00 (m, 2H),
4.81-4.83 (m, 2H), 4.04-4.08 (m, 4H), 3.20 (q, j=7 Hz), 1.27 (t,
J=7 Hz). 31P NMR (D.sub.2O) 25.degree. C. .delta.(ppm) 54.77,
56.00.
Example 5. Interferon Induction by CDNs
[0207] To determine the relative level of IFN-.beta. in antigen
presenting cells induced by each of the Rp, Rp dithio c-di-GMP
derivative molecules relative to the unmodified c-di-GMP molecules
as a signature of adjuvant potency, 1.times.10.sup.5 DC2.4 cells, a
mouse-derived H-2b-restricted mouse dendritic cell line, were
incubated with 5, 20, and 100 .mu.M of c-di-GMP, Rp, Rp and Rp, or
Sp dithio-diphosphate c-di-GMP, as well as c-di-AMP, Rp, Rp or Rp,
Sp dithio-diphosphate c-di-AMP molecules or HBSS for 30 minutes at
37.degree. C. with 5% CO2. After 30 minutes, cells were washed and
replaced with RPMI media containing 10% FBS. To measure the level
of induced IFN-.beta., cell culture fluids from each sample were
collected after 4 hours, and 10 .mu.L was added to 5.times.10.sup.4
L929-ISRE luciferase reporter cells cultured in RPMI media+10% FBS.
The relative level of IFN-.beta. production was determined by
measuring relative light units (RLU) after 4 hours of
incubation.
[0208] As shown in FIG. 7, the Rp, Rp dithio c-di-GMP and the Rp,
Rp dithio c-di-AMP diastereomers induced significantly higher
levels of IFN-.beta. than either the c-di-GMP or c-di-AMP
unmodified cyclic dinucleotide molecules. Further, the level of
IFN-.beta. induced by the Rp, Sp dithio c-di-GMP and the Rp, Sp
dithio c-di-AMP diastereomers was lower than the level induced by
both the Rp, Rp dithio c-di-GMP and the Rp, Rp dithio c-di-AMP
diastereomers as well as the native c-di-GMP and c-di-AMP
molecules. These results demonstrate that purified preparations of
Rp, Rp dithio c-di-GMP and the Rp, Rp dithio c-di-AMP diastereomers
more profoundly activate the innate immune response than the
unmodified c-di-GMP and c-di-AMP molecules as well as the Rp, Sp
dithio derivatives. The Rp, Sp thio derivatives of both c-di-GMP
and c-di-AMP poorly activated the innate immune response. It will
be apparent to the skilled artisan that preferred embodiments for
adjuvants are Rp, Rp dithio-diphosphate c-di-GMP or Rp, Rp
dithio-diphosphate c-di-AMP cyclic dinucleotides, due to their
properties of increased activation of the innate immune response,
as shown by magnitude of induced IFN-.beta. expression, as compared
to either Rp, Sp dithio-diphosphate c-di-GMP or Rp, Sp
dithio-diphosphate c-di-AMP or c-di-GMP or c-di-AMP molecules.
Example 6. Degradation of CDNs by Phospohodiesterases
[0209] One mechanism for the increased potency of the Rp, Rp
dithio-diphosphate c-di-GMP and c-di-AMP derivatives as compared to
unmodified native c-di-GMP and c-di-AMP may be the resistance of
the dithio-modified derivatives to degradation by host cell
phosphodiesterases. As a test for this mechanism, Rp, Rp dithio
c-di-GMP, unmodified c-di-GMP and also Rp, Rp dithio c-di-AMP and
c-di-AMP molecules were incubated with and without 1 mg of snake
venom phosphodiesterase (SVPD) overnight at 37.degree. C. Following
this incubation period, SVPD enzyme in the reactions was
inactivated and removed by incubation at 100.degree. C. for 10
minutes and the samples were then centrifuged at 14,000 rpm for 5
minutes. To test the relative capacity of the samples to activate
innate immunity, measured by the level of IFN-.beta. expression,
1.times.10.sup.5 DC2.4 cells were incubated with 100 .mu.M of Rp,
Rp dithio-diphosphate c-di-GMP and c-di-AMP derivatives and
unmodified native c-di-GMP and c-di-AMP processed from samples
incubated with these cyclic dinucleotide preparations for 30
minutes at 37.degree. C. with 5% CO2. After 30 minutes, the cells
were washed and replaced with RPMI media containing 10% FBS and
incubated for another 4 hrs. The culture fluids were then
harvested, and 10 .mu.L of these fluids were added to 5.times.104
L929-ISRE luciferase reporter cells grown in RPMI media containing
10% FBS. The relative level of IFN-.beta. expression was determined
by measuring relative light units (RLU) after 4 hours incubation in
the reporter cell line.
[0210] As shown in FIG. 8, the level of IFN-.beta. expression in
cells containing Rp, Rp dithio-diphosphate c-di-GMP ("RR-CDG") or
Rp, Rp dithio-diphosphate c-di-AMP ("RR-CDA") was equivalent,
regardless of whether the cyclic dinucleotides were incubated with
SVPD. In contrast, the level of IFN-.beta. expression was
significantly lower in cultures containing c-di-GMP ("CDG") or
c-di-AMP ("CDA") that had been previously incubated with SVPD, as
compared to cultures containing c-di-GMP or c-di-AMP that had not
been incubated with this enzyme. Furthermore, in cultures
containing cyclic dinucleotides not incubated with SVPD, the level
of IFN-.beta. expression was greater with Rp, Rp dithio-diphosphate
c-di-GMP or Rp, Rp dithio-diphosphate c-di-AMP as compared to
c-di-GMP or c-di-AMP. These data are further supportive of the
increased potency of Rp, Rp dithio-diphosphate c-di-GMP or Rp, Rp
dithio-diphosphate c-di-AMP as compared to c-di-GMP or
c-di-AMP.
Example 7. Immune Response Induction by CDNs
[0211] To test the enhanced in vivo immunogenicity of Rp, Rp dithio
c-di-GMP relative to unmodified c-di-GMP molecules, OVA-specific
CD4+ and CD8+ T cell responses were measured in PBMCs at 10 days
post vaccination in conjunction with CDN treatment. Vaccines were
prepared by combining 10 .mu.g of OVA protein (EndoFit OVA,
InVivogen) and Addavax (2% squalene final) with either 25 .mu.g or
5 .mu.g of cyclic dinucleotide, in a total volume of 100 .mu.L.
Groups of five female C57BL/6 mice (H-2b) were immunized once
subcutaneously (s.c) in the base of the tail with the vaccine
preparations, and the OVA-specific CD4+ and CD8+ T cell responses
in the peripheral blood mononuclear cell (PBMC) compartment were
determined by ELISpot analysis 10 days later. 1.times.10.sup.5
PBMCs and 1.times.10.sup.5 splenocyte feeder cells isolated from
aged-matched naive C57BL/6 mice were un-stimulated or stimulated
with 1 .mu.M of MHC class II peptide (OVA265-280 TEWTSSNVMEERKIKV)
or MHC class I (OVA257-264 SIINFEKL) peptide overnight and
IFN-.gamma. spot forming cells were measured, as described
previously.
[0212] As shown in FIG. 9, the CD4+ and CD8+ OVA-specific T cell
responses were of greater magnitude in mice immunized with vaccines
containing Rp, Rp dithio c-di-GMP as compared to unmodified
c-di-GMP, in formulations containing the same amount of cyclic
dinucleotide adjuvant. Furthermore, the magnitude of
antigen-specific CD8+ T cell responses were greater in mice
immunized with vaccine formulations containing 5 .mu.g of Rp, Rp
dithio c-di-GMP, as compared to mice immunized with vaccine
formulations containing either 5 .mu.g or 25 .mu.g of unmodified
c-di-GMP.
Example 8. T-Cell Response Induction by CDNs
[0213] To further assess the immunogenicity of Rp, Rp dithio
c-di-GMP relative to unmodified c-di-GMP molecules, SIV
gag-specific CD8+ and CD4+ T cell responses were measured. Five
C57BL/6 mice per group were immunized subcutaneously twice with
either 1 ug Rp, Rp dithio c-di-GMP or saline control formulated in
2% squalene-in-water with 10 ug SIV gag protein. Vaccinations were
separated by 20 days, and spleens were harvested six days after the
second vaccination. Immune responses were measured to SIV
gag-specific CD8 (AL11, SIV gag.sub.312-322, A) and CD4 (DD13, SIV
gag.sub.300-312, B) T cell epitopes by IFN.gamma. ELISpot assay.
Plates were scanned and spot forming cells (SFC) per well were
enumerated using an ImmunoSpot analyzer (CTL).
[0214] As shown in FIG. 10, animals immunized with RR c-di-GMP
induced significantly higher SIV gag-specific CD8 and CD4 T cell
responses compared to the animals that received the saline control.
These results demonstrate that the vaccine formulations with the RR
c-di-GMP derivative can induce SIV gag-specific CD4 and CD8 T cell
responses in vivo. The skilled artisan will recognized that vaccine
formulations containing Rp, Rp dithiophosphate c-di-GMP or Rp, Rp
dithiophosphate c-di-AMP are preferred, since such cylic
dinucleotides have increased potency as shown by higher magnitude
of vaccine-induced immune responses, and also higher magnitude of
vaccine-induced immune responses with comparatively lower dose
levels of adjuvant.
Example 9. Induction of Protective Immunity by CDNs
[0215] To establish the enhanced immunogenicity and accompanying
protective immunity induced by Rp, Rp dithio c-di-GMP relative to
unmodified c-di-GMP, OVA-specific CD8 T cell responses measured in
PBMC and protective immunity assessed against lethal bacterial
challenge. Vaccines were prepared by combining 10 .mu.g of OVA
protein (EndoFit OVA, InVivogen) and Addavax (2% squalene final)
with 25 .mu.g of cyclic dinucleotide, in a total volume of 100
.mu.L. Groups of five female C57BL/6 mice (H-2.sup.b) were
immunized twice subcutaneously (s.c) in the base of the tail with
the vaccine preparations. The interval between the prime and boost
immunizations was 36 days. The magnitude of both the memory and
expansion phases of the OVA257-specific CD8 T cell responses in
PBMC were quantified by intracellular cytokine staining (ICS)
analysis at both 27 days post-boost vaccination and at 3 days post
challenge with a 2.times. lethal dose (LD).sub.50 dose
(1.times.10.sup.5 colony forming units; CFU) of OVA-expressing
wild-type Listeria monocytogenes (WT Lm-OVA). For ICS analysis,
1.times.10.sup.5 PBMCs from test mice combined with
1.times.10.sup.5 splenocyte feeder cells isolated from aged-matched
naive C57BL/6 mice were un-stimulated or stimulated with 1 .mu.M of
MHC class I peptide (OVA257-264 SIINFEKL) for 5 hrs. in the
presence of Brefeldin A, and IFN-.gamma. production was measured by
flow cytometry on a BD FACSVerse.
[0216] As shown in FIG. 11A, mice immunized with vaccines
adjuvanted with Rp, Rp dithio-diphosphate c-di-GMP generated a
higher magnitude of OVA-specific CD8 T cell memory, as compared to
mice immunized with vaccines adjuvanted with unmodified c-di-GMP.
The OVA-specific memory CD8 T cells induced by immunization with
Rp, Rp dithio-diphosphate c-di-GMP adjuvanted vaccines expanded to
a higher magnitude following challenge with pathogen expressing the
cognate OVA antigen, as compared to the level of expansion of
OVA-specific memory CD8 T cells in mice immunized with vaccines
adjuvanted with unmodified c-di-GMP. The FACS plot shown in FIG.
11B demonstrates that the magnitude of OVA-specific CD8 T cell
memory approached 30% of the total CD8 T cell population in PBMC
from mice immunized with Rp, Rp dithio-diphosphate c-di-GMP
adjuvanted vaccines. The gold standard for effective immunization
is to test whether a vaccine candidate can confer protection
against subsequent challenge with a virulent pathogen. To test the
relative effectiveness of Rp, Rp dithio c-di-GMP and unmodified
c-di-GMP adjuvanted vaccines, mice were challenged with an
intravenous injection of a 2.times.LD.sub.50 dose (1.times.10.sup.5
CFU) of OVA-expressing wild-type Listeria monocytogenes (WT Lm-OVA)
at 27 days post boost immunization. Three days later, protective
immunity was determined by plating dilutions of homogenates of
spleens harvested from test mice at 3 days post WT Lm-OVA challenge
on brain-heart infusion agar media, and quantifying the number of
colonies following overnight incubation at 37.degree. C. FIG. 11C
shows that immunization of mice with Rp, Rp dithio-diphosphate
c-di-GMP adjuvanted vaccines afforded complete protection (below
the limit of detection, LOD) against virulent pathogen challenge.
It will be apparent to the skilled artisan that preferred
embodiments for adjuvants are Rp, Rp dithio-diphosphate c-di-GMP or
Rp, Rp dithio-diphosphate c-di-AMP cyclic dinucleotides, due to
their properties of conferring profound vaccine potency, as shown
by induction of high magnitude CD8 T cell memory pool which expands
upon challenge with the cognate antigen and provides complete
protection against virulent pathogen challenge.
Example 10. Induction of Effective Anti-Tumor Immunity by CDNs
[0217] The relative in vivo anti-tumor efficacy of the Rp, Rp
dithio c-di-AMP and unmodified c-di-AMP derivatives were evaluated
in a subcutaneous mouse model of prostate cancer. The derivative
molecules were formulated with 1.times.10.sup.6 irradiated whole
TRAMP-C.sub.2 murine prostate tumor cells expressing GM-CSF (GVAX).
Groups of 5 male C57BL/6 mice were implanted with 1.times.10.sup.5
TRAMP-C.sub.2 tumor cells subcutaneous in the footpad. On days 4
and 11 post tumor implantation, mice were administered vaccinations
subcutaneous in the flank of either GVAX alone, or GVAX formulated
with RR-CDA or CDA, and compared to HBSS control. Tumor growth was
monitored by calipers, and tumor volume was calculated.
[0218] As shown in FIG. 12, by day 52 post tumor implantation, the
mice vaccinated with GVAX+RR-CDA demonstrated significant tumor
growth inhibition as compared to HBSS control, with increased
anti-tumor efficacy as compared to GVAX alone or GVAX formulated
with the unmodified c-di-AMP derivative. These date demonstrate the
increased anti-tumor potency of the Rp, Rp dithio c-di-AMP
derivative molecule as compared to the unmodified c-di-AMP molecule
in a murine prostate cancer model.
Example 11. Prodrug Forms of CDNs
[0219] Prodrug strategies provide an attractive method for
facilitating partitioning into the bilayer of cells or delivery
liposomes. Acylation of the ribose 2'-OH of c-di-GMP, c-di-AMP and
dithio-analogs with C-12 to C-18 carboxylic acids could serve as a
valuable prodrug. Two examples are shown in FIG. 13 and described
in the example.
[0220] (a) Synthesis of Mono-2'-O-Myristoyl c-Di-GMP 12 from
11a.
[0221] To the bistriethylamine salt of 11a (8 mg, 9.0 micromoles)
was added 0.3 ml DMF, 30 microliters of pyridine and 15 mg of
myristic anhydride (34 micromoles). The reaction mixture was
stirred at room temp for 48 h and then heated at 60.degree. C. for
0.5 h. The mass of major product 12 was confirmed by LC/MS in
negative mode, with m/z (M-1) 889 (calcd for
C.sub.34H.sub.49N.sub.10O.sub.15P.sub.2--: 899.3). After
evaporation the residue was taken in up in 30% CH3CN in 10 mM TEAA,
filtered, and purified on a 20 mm prep C-18 HPLC column with
gradient elution (30 to 60% CH3CN in 10 mM TEAA over 20 min at a
flow of 20 ml/min). The fractions containing desired product were
combined, rotoevaporated and lyophilized to give 3 mg of
mono-2'-O-myristoyl c-di-GMP (M. HRMS of 12 in negative mode
confirms m/z (M-2) 449.1389 (calculated for
C.sub.34H.sub.48N.sub.10O.sub.15P.sub.2.sup.-2: 449.1393). .sup.1H
NMR (DMSO+1% D2O) 25.degree. C. .delta.(ppm) 7.98 (s, 2H), 5.98 (s,
1H), 5.73 (d, 1H), 5.66 (s, 1H), 4.74 (d, 2H), 4.54 (s, 1H), 4.23
(s, 1H), 3.81-3.99 (br, 4H), 2.55 (s, 2H), 1.44 (s, 2H), 0.85 (t,
3H). (NMR peaks at 10.61, 7.33 and 6.55 in neat DMSO were exchanged
on addition of 1% D.sub.2O). Methylenes of the myristoyl group were
obscured by DMSO and upfield triethylammonium acetate peaks. The
NMR is consistent with monoacylation at 2'-OH. .sup.31P NMR
(D.sub.2O) 25.degree. C. .delta.(ppm) -1.37, -2.06.
[0222] (b) Synthesis of Mono-2'-O-Myristoyl [Rp,Rp] Dithiophosphate
c-Di-GMP (13) from 11b.
[0223] To the bistriethylamine salt of 11b (12 mg, 13.0 micromoles)
was added 0.3 ml DMF, 30 microliters of pyridine, 15 mg of myristic
anhydride (34 micromoles) and catalytic DMAP. The reaction mixture
was stirred at room temp for 24 h and then heated at 60.degree. C.
for 2 h. The solvent was removed by rotoevaporation and the residue
taken up in 50% MeOH in 10 mM TEAA, filtered, and purified on a 20
mm prep C-18 HPLC column (50% MeOH in 10 mM TEAA isocratic for 5
min followed by gradient to 100% MeOH for 10 min and then 100% MeOH
for 10 min). The desired product eluted late in this methanolic
system. The fractions containing desired product were combined,
rotoevaporated, and then lyophilized to give 4 mg of
mono-2'-O-myristoyl [Rp,Rp] dithiophosphate c-di-GMP (13). HRMS of
13 in negative mode confirms m/z (M-2) 465.1148 (calculated for
C.sub.34H.sub.48N.sub.10O.sub.13P.sub.2S.sub.2.sup.-2: 465.1165).
.sup.1H NMR (DMSO+1% D.sub.2O) 25.degree. C. .delta.(ppm) 8.01 (s,
2H), 5.97 (d, 1H), 5.73 (d, 2H), 5.71 (m, 2H), 5.00 (m, 1H), 4.85
(m, 1H), 4.56 (m, 1H), 4.10-4.18 (m, 4H), 3.97 (m, 2H), 3.84-3.87
(m, 1H), 3.16 (s, 1H), 3.05 (d, 2H), 1.47 (br, 2H), 0.85 (t, 3H).
(NMR peaks at 10.60, 7.53, 6.90 and 6.63 in neat DMSO were
exchanged on addition of 1% D.sub.2O). Methylenes of the myristoyl
group were obscured by DMSO and upfield triethylammonium acetate
peaks. The NMR is consistent with monoacylation at 2'-OH. .sup.31P
NMR (CD3OD) 25.degree. C. .delta.(ppm) 56.66, 55.46.
[0224] A similar prodrug approach using acyloxyalkyl derivatization
of sulfur or oxygen on CDN thiophosphates and phosphates,
respectively, may also be used. The acyloxyalkyl structures in FIG.
14 are similar to Adefovir, an effective nucleoside analog pro-drug
that is used to treat HIV and HBV infection. Once inside the cell
intracellular esterases will cleave the acyl or acyloxyalky groups
present on 2'-OH or phosphate (thiophosphate) and regenerate the
underivatized cyclic dinucleotide.
Example 12. Pharmacological Activity of CDN Produgs
[0225] To determine the relative potency of the prodrug form of
c-di-GMP to activate the innate immune response, relative levels of
IFN-.beta. induced in a human monocyte cell line were assessed. For
these experiments, 4.times.105 THP1-Blue human monocytes were
transfected with an IRF-inducible secreted embryonic alkaline
phosphatase reporter gene (Invivogen), and incubated with 100 .mu.M
of c-di-GMP, mono-2'-O-myristoyl c-di-GMP or HBSS for 30 minutes at
37.degree. C. with 5% CO2. After 30 minutes, cells were washed and
plated in 96-well dish in RPMI media containing 10% FBS, and
incubated at 37.degree. C. with 5% CO2. Cell culture supernatants
from each sample were collected after 4 hours. 10 .mu.L of the cell
culture supernatants was added to QUANTI-Blue reagent (Invivogen)
and incubated for 15-30 minutes. Absorbance at 655 nm was measured
using a Model 680 spectrophotometer (BioRad).
[0226] As shown in FIG. 15, the mono-2'-O-myristoyl c-di-GMP
("mono-2'-O-myristoyl CDG") derivative induced significantly higher
levels of IFN-.beta. over the c-di-GMP unmodified cyclic
dinucleotide molecule, and over background (HBSS) levels in a human
monocyte cell line. Additionally, these data demonstrate in a human
monocyte cell line, the superior induction of the Rp, Rp dithio
c-di-GMP derivative molecules over the Rp, Sp dithio c-di-GMP and
c-di-GMP unmodified molecules. These results demonstrate that
purified preparations of mono-2'-O-myristoyl c-di-GMP derivatives
can activate the innate immune response in a human cell line.
Example 13. Induction of Immune Responses by CDN Prodrugs
[0227] To assess the ability of the mono-2'-O-myristoyl c-di-GMP
("mono-2'-O-myristoyl CDG") derivative to induce in vivo immune
responses, OVA-specific CD8 T cell responses were measured in
splenocytes at 7 days post second vaccination in conjunction with
CDN treatment. To test the ability of mono-2'-O-myristoyl c-di-GMP
relative to stimulate an OVA-specific immune responses, vaccines
were prepared by combining 10 .mu.g of OVA protein (EndoFit OVA,
Invivogen) and Addavax (2% squalene final) with either 0 (Control)
or 5 .mu.g of mono-2'-O-myristoyl c-di-GMP derivative
("mono-2'-O-myristoyl CDG"), in a total volume of 100 .mu.L. Groups
of five female C57BL/6 mice (H-2b) were immunized twice
subcutaneously (s.c) in the base of the tail with the vaccine
preparations, and the OVA-specific CD8+ T cell responses in the
spleens were determined by intracellular cytokine staining 7 days
later. 1.times.106 splenocytes were unstimulated or stimulated with
1 .mu.M of MHC class I (OVA257-264 SIINFEKL; SL8) peptide overnight
and IFN-.gamma. production was measured by flow cytometer on a BD
FACSVerse.
[0228] As shown in FIG. 16, vaccines that contained the
mono-2'-O-myristoyl c-di-GMP derivative induced greater immune
responses compared to Control vaccines. These results demonstrate
that a vaccine containing the mono-2'-O-myristoyl c-di-GMP
derivative can stimulate highly potent adaptive immune responses in
an animal model.
[0229] One skilled in the art readily appreciates that the present
invention is well adapted to carry out the objects and obtain the
ends and advantages mentioned, as well as those inherent therein.
The examples provided herein are representative of preferred
embodiments, are exemplary, and are not intended as limitations on
the scope of the invention.
[0230] It is to be understood that the invention is not limited in
its application to the details of construction and to the
arrangements of the components set forth in the following
description or illustrated in the drawings. The invention is
capable of embodiments in addition to those described and of being
practiced and carried out in various ways. Also, it is to be
understood that the phraseology and terminology employed herein, as
well as the abstract, are for the purpose of description and should
not be regarded as limiting.
[0231] As such, those skilled in the art will appreciate that the
conception upon which this disclosure is based may readily be
utilized as a basis for the designing of other structures, methods
and systems for carrying out the several purposes of the present
invention. It is important, therefore, that the claims be regarded
as including such equivalent constructions insofar as they do not
depart from the spirit and scope of the present invention.
[0232] While the invention has been described and exemplified in
sufficient detail for those skilled in this art to make and use it,
various alternatives, modifications, and improvements should be
apparent without departing from the spirit and scope of the
invention. The examples provided herein are representative of
preferred embodiments, are exemplary, and are not intended as
limitations on the scope of the invention. Modifications therein
and other uses will occur to those skilled in the art. These
modifications are encompassed within the spirit of the invention
and are defined by the scope of the claims.
[0233] It will be readily apparent to a person skilled in the art
that varying substitutions and modifications may be made to the
invention disclosed herein without departing from the scope and
spirit of the invention.
[0234] All patents and publications mentioned in the specification
are indicative of the levels of those of ordinary skill in the art
to which the invention pertains. All patents and publications are
herein incorporated by reference to the same extent as if each
individual publication was specifically and individually indicated
to be incorporated by reference.
[0235] The invention illustratively described herein suitably may
be practiced in the absence of any element or elements, limitation
or limitations which is not specifically disclosed herein. Thus,
for example, in each instance herein any of the terms "comprising",
"consisting essentially of" and "consisting of" may be replaced
with either of the other two terms. The terms and expressions which
have been employed are used as terms of description and not of
limitation, and there is no intention that in the use of such terms
and expressions of excluding any equivalents of the features shown
and described or portions thereof, but it is recognized that
various modifications are possible within the scope of the
invention claimed. Thus, it should be understood that although the
present invention has been specifically disclosed by preferred
embodiments and optional features, modification and variation of
the concepts herein disclosed may be resorted to by those skilled
in the art, and that such modifications and variations are
considered to be within the scope of this invention as defined by
the appended claims.
REFERENCES
[0236] 1 Reed, S. G., Bertholet, S., Coler, R. N. & Friede, M.
New horizons in adjuvants for vaccine development. Trends in
immunology 30, 23-32, doi:10.1016/j.it.2008.09.006 (2009). [0237] 2
Dubensky, T. W., Jr. & Reed, S. G. Adjuvants for cancer
vaccines. Seminars in immunology 22, 155-161,
doi:10.1016/j.smim.2010.04.007 (2010). [0238] 3 Kastenmuller, K. et
al. Protective T cell immunity in mice following protein-TLR7/8
agonist-conjugate immunization requires aggregation, type I IFN,
and multiple DC subsets. The Journal of clinical investigation 121,
1782-1796, doi:10.1172/JCI45416 (2011). [0239] 4 Coffman, R. L.,
Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate
immunity to work. Immunity 33, 492-503,
doi:10.1016/j.immuni.2010.10.002 (2010). [0240] 5 Burdette, D. L.
et al. STING is a direct innate immune sensor of cyclic di-GMP.
Nature 478, 515-518, doi:10.1038/nature10429 (2011). [0241] 6
Woodward, J. J., Iavarone, A. T. & Portnoy, D. A. c-di-AMP
secreted by intracellular Listeria monocytogenes activates a host
type I interferon response. Science 328, 1703-1705,
doi:10.1126/science.1189801 (2010). [0242] 7 Ishikawa, H. &
Barber, G. N. STING is an endoplasmic reticulum adaptor that
facilitates innate immune signalling. Nature 455, 674-678,
doi:10.1038/nature07317 (2008). [0243] 8 McWhirter, S. M. et al. A
host type I interferon response is induced by cytosolic sensing of
the bacterial second messenger cyclic-di-GMP. The Journal of
experimental medicine 206, 1899-1911, doi:10.1084/jem.20082874
(2009). [0244] 9 Bahjat, K. S. et al. (2005). [0245] 10 Bahjat, K.
S. et al. Cytosolic Entry Controls CD8+-T-Cell Potency during
Bacterial Infection. Infection and immunity 74, 6387-6397 (2006).
[0246] 11 Crimmins, G. T. et al. Listeria monocytogenes multidrug
resistance transporters activate a cytosolic surveillance pathway
of innate immunity. Proceedings of the National Academy of Sciences
of the United States of America (2008). [0247] 12 O'Riordan, M.,
Yi, C. H., Gonzales, R., Lee, K. D. & Portnoy, D. A. Innate
recognition of bacteria by a macrophage cytosolic surveillance
pathway. Proceedings of the National Academy of Sciences of the
United States of America 99, 13861-13866 (2002). [0248] 13
Schwartz, K. T. et al. Hyperinduction of host beta interferon by a
Listeria monocytogenes strain naturally overexpressing the
multidrug efflux pump MdrT. Infection and immunity 80, 1537-1545,
doi:10.1128/IAI.06286-11 (2012). [0249] 14 Davies, B. W., Bogard,
R. W., Young, T. S. & Mekalanos, J. J. Coordinated regulation
of accessory genetic elements produces cyclic di-nucleotides for V.
cholerae virulence. Cell 149, 358-370,
doi:10.1016/j.cell.2012.01.053 (2012). [0250] 15 Witte, C. E. et
al. Innate immune pathways triggered by Listeria monocytogenes and
their role in the induction of cell-mediated immunity. Advances in
immunology 113, 135-156, doi:10.1016/B978-0-12-394590-7.00002-6
(2012). [0251] 16 Desmet, C. J. & Ishii, K. J. Nucleic acid
sensing at the interface between innate and adaptive immunity in
vaccination. Nature reviews. Immunology 12, 479-491,
doi:10.1038/nri3247 (2012). [0252] 17 Rappuoli, R., Mandl, C. W.,
Black, S. & De Gregorio, E. Vaccines for the twenty-first
century society. Nature reviews. Immunology 11, 865-872,
doi:10.1038/nri3085 (2011). [0253] 18 Iwasaki, A. & Medzhitov,
R. Regulation of adaptive immunity by the innate immune system.
Science 327, 291-295, doi:10.1126/science.1183021 (2010). [0254] 19
Kawai, T. & Akira, S. The role of pattern-recognition receptors
in innate immunity: update on Toll-like receptors. Nature
immunology 11, 373-384, doi:10.1038/ni.1863 (2010). [0255] 20
Einstein, M. H. et al. Comparison of the immunogenicity and safety
of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer
vaccines in healthy women aged 18-45 years. Human vaccines 5,
705-719 (2009). [0256] 21 Ahmed, S. S., Plotkin, S. A., Black, S.
& Coffman, R. L. Assessing the safety of adjuvanted vaccines.
Science translational medicine 3, 93rv92,
doi:10.1126/scitranslmed.3002302 (2011). [0257] 22 Vance, R. E.,
Isberg, R. R. & Portnoy, D. A. Patterns of pathogenesis:
discrimination of pathogenic and nonpathogenic microbes by the
innate immune system. Cell host & microbe 6, 10-21,
doi:10.1016/j.chom.2009.06.007 (2009). [0258] 23 Barber, G. N.
STING-dependent signaling. Nature immunology 12, 929-930,
doi:10.1038/ni.2118 (2011). [0259] 24 Leber, J. H. et al. Distinct
TLR- and NLR-mediated transcriptional responses to an intracellular
pathogen. PLoS pathogens 4, e6 (2008). [0260] 25 Jin, L. et al.
MPYS is required for IFN response factor 3 activation and type I
IFN production in the response of cultured phagocytes to bacterial
second messengers cyclic-di-AMP and cyclic-di-GMP. J Immunol 187,
2595-2601, doi:10.4049/jimmunol.1100088 (2011). [0261] 26 Lauvau,
G. et al. Priming of memory but not effector CD8 T cells by a
killed bacterial vaccine. Science 294, 1735-1739 (2001). [0262] 27
Bahjat, K. S. et al. Suppression of cell-mediated immunity
following recognition of phagosome-confined bacteria. PLoS
pathogens 5, e1000568, doi:10.1371/journal.ppat.1000568 (2009).
[0263] 28 Tamayo, R., Pratt, J. T. & Camilli, A. Roles of
cyclic diguanylate in the regulation of bacterial pathogenesis.
Annual review of microbiology 61, 131-148,
doi:10.1146/annurev.micro.61.080706.093426 (2007). [0264] 29 Sauer,
J. D. et al. The N-ethyl-N-nitrosourea-induced Goldenticket mouse
mutant reveals an essential function of Sting in the in vivo
interferon response to Listeria monocytogenes and cyclic
dinucleotides. Infection and immunity 79, 688-694,
doi:10.1128/IAI.00999-10 (2011). [0265] 30 Barber, G. N.
Cytoplasmic DNA innate immune pathways. Immunological reviews 243,
99-108, doi:10.1111/j.1600-065X.2011.01051.x (2011). [0266] 31
Tanaka, Y. & Chen, Z. J. STING specifies IRF3 phosphorylation
by TBK1 in the cytosolic DNA signaling pathway. Science signaling
5, ra20, doi:10.1126/scisignal.2002521 (2012). [0267] 32 Ebensen,
T. et al. Bis-(3',5')-cyclic dimeric adenosine monophosphate:
strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine 29,
5210-5220, doi:10.1016/j.vaccine.2011.05.026 (2011). [0268] 33
Ebensen, T. et al. The bacterial second messenger cyclic diGMP
exhibits potent adjuvant properties. Vaccine 25, 1464-1469,
doi:10.1016/j.vaccine.2006.10.033 (2007). [0269] 34 Ebensen, T.,
Schulze, K., Riese, P., Morr, M. & Guzman, C. A. The bacterial
second messenger cdiGMP exhibits promising activity as a mucosal
adjuvant. Clinical and vaccine immunology: CVI 14, 952-958,
doi:10.1128/CVI.00119-07 (2007). [0270] 35 Libanova, R. et al. The
member of the cyclic di-nucleotide family bis-(3', 5')-cyclic
dimeric inosine monophosphate exerts potent activity as mucosal
adjuvant. Vaccine 28, 2249-2258, doi:10.1016/j.vaccine.2009.12.045
(2010). [0271] 36 Madhun, A. S. et al. Intranasal
c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces
multifunctional Th1 CD4+ cells and strong mucosal and systemic
antibody responses in mice. Vaccine 29, 4973-4982,
doi:10.1016/j.vaccine.2011.04.094 (2011). [0272] 37 Hu, D. L. et
al. c-di-GMP as a vaccine adjuvant enhances protection against
systemic methicillin-resistant Staphylococcus aureus (MRSA)
infection. Vaccine 27, 4867-4873, doi:10.1016/j.vaccine.2009.04.053
(2009). [0273] 38 Karaolis, D. K. et al. Cyclic di-GMP stimulates
protective innate immunity in bacterial pneumonia. Infection and
immunity 75, 4942-4950, doi:10.1128/IAI.01762-06 (2007). [0274] 39
Ogunniyi, A. D. et al. c-di-GMP is an effective immunomodulator and
vaccine adjuvant against pneumococcal infection. Vaccine 26,
4676-4685, doi:10.1016/j.vaccine.2008.06.099 (2008). [0275] 40
Karaolis, D. K. et al. Bacterial c-di-GMP is an immunostimulatory
molecule. J Immunol 178, 2171-2181 (2007). [0276] 41 Wille-Reece,
U. et al. Toll-like receptor agonists influence the magnitude and
quality of memory T cell responses after prime-boost immunization
in nonhuman primates. The Journal of experimental medicine 203,
1249-1258 (2006). [0277] 42 Adler-Moore, J. et al. Characterization
of the murine Th2 response to immunization with liposomal M2e
influenza vaccine. Vaccine 29, 4460-4468,
doi:10.1016/j.vaccine.2011.04.040 (2011). [0278] 43 Fujii, G.,
Ernst, W. & Adler-Moore, J. The VesiVax system: a method for
rapid vaccine development. Frontiers in bioscience: a journal and
virtual library 13, 1968-1980 (2008). [0279] 44 Gaffney, B. L.,
Veliath, E., Zhao, J. & Jones, R. A. One-flask syntheses of
c-di-GMP and the [Rp,Rp] and [Rp,Sp] thiophosphate analogues.
Organic letters 12, 3269-3271, doi:10.1021/ol101236b (2010). [0280]
45 Zhang, Z., Gaffney, B. L. & Jones, R. A. c-di-GMP displays a
monovalent metal ion-dependent polymorphism. Journal of the
American Chemical Society 126, 16700-16701, doi:10.1021/ja0449832
(2004). [0281] 46 Suzuki, N., Oyama, K.-i. & Tsukamoto, M.
Practical Synthesis of Cyclic Bis(3'-5')diadenylic Acid (c-di-AMP).
Chemistry Letters 40, 1113-1114, doi:10.1246/cl.2011.1113 (2011).
[0282] 47 Hyodo, M., Sato, Y. & Hayakawa, Y. Synthesis of
cyclic bis(3'-5')diguanylic acid (c-di-GMP) analogs. Tetrahedron
62, 3089-3094, doi:10.1016/j.tet.2006.01.025 (2006). [0283] 48 Yan,
H., Wang, X., KuoLee, R. & Chen, W. Synthesis and
immunostimulatory properties of the phosphorothioate analogues of
cdiGMP. Bioorganic & medicinal chemistry letters 18, 5631-5634,
doi:10.1016/j.bmc1.2008.08.088 (2008). [0284] 49 Ross, P. et al.
The cyclic diguanylic acid regulatory system of cellulose synthesis
in Acetobacter xylinum. Chemical synthesis and biological activity
of cyclic nucleotide dimer, trimer, and phosphothioate derivatives.
The Journal of biological chemistry 265, 18933-18943 (1990). [0285]
50 Grajkowski, A., Cieslak, J., Gapeev, A., Schindler, C. &
Beaucage, S. L. Convenient synthesis of a propargylated cyclic
(3'-5') diguanylic acid and its "click" conjugation to a
biotinylated azide. Bioconjugate chemistry 21, 2147-2152,
doi:10.1021/bc1003857 (2010). [0286] 51 Zhao, J., Veliath, E., Kim,
S., Gaffney, B. L. & Jones, R. A. Thiophosphate analogs of
c-di-GMP: impact on polymorphism. Nucleosides, nucleotides &
nucleic acids 28, 352-378, doi:10.1080/15257770903044523 (2009).
[0287] 52 Battistini, C., Fustinoni, S., Brasca, M. & Borghi,
D. Stereoselective synthesis of cyclic dinucleiotide
phosphorothioates. Tetrahedron, 1115-1132 (1993). [0288] 53
Hayakawa, Y. A facile synthesis of cyclic
bis(3'.fwdarw.5')diguanylic acid. Tetrahedron 59, 6465-6471,
doi:10.1016/s0040-4020(03)01045-7 (2003). [0289] 54 Coughlin, J. E.
et al. Orally bioavailable anti-HBV dinucleotide acyloxyalkyl
prodrugs. Bioorganic & medicinal chemistry letters 20,
1783-1786, doi:10.1016/j.bmc1.2010.01.010 (2010). [0290] 55 Ouyang,
S. et al. Structural Analysis of the STING Adaptor Protein Reveals
a Hydrophobic Dimer Interface and Mode of Cyclic di-GMP Binding.
Immunity, doi:10.1016/j.immuni.2012.03.019 (2012). [0291] 56
Baldwin, S. L. et al. The importance of adjuvant formulation in the
development of a tuberculosis vaccine. J Immunol 188, 2189-2197,
doi:10.4049/jimmunol.1102696 (2012). [0292] 57 Lee, A. W. et al. A
clinical grade cocktail of cytokines and PGE2 results in uniform
maturation of human monocyte-derived dendritic cells: implications
for immunotherapy. Vaccine 20 Suppl 4, A8-A22 (2002). [0293] 58
Lubong Sabado, R. et al. In vitro priming recapitulates in vivo
HIV-1 specific T cell responses, revealing rapid loss of virus
reactive CD4 T cells in acute HIV-1 infection. PloS one 4, e4256,
doi:10.1371/journal.pone.0004256 (2009). [0294] 59 Skoberne, M. et
al. KBMA Listeria monocytogenes is an effective vector for
DC-mediated induction of antitumor immunity. The Journal of
clinical investigation (2008). [0295] 60 Jin, L. et al.
Identification and characterization of a loss-of-function human
MPYS variant. Genes and immunity 12, 263-269,
doi:10.1038/gene.2010.75 (2011). [0296] 61 Schmidt, N. W. et al.
Memory CD8 T cell responses exceeding a large but definable
threshold provide long-term immunity to malaria. Proceedings of the
National Academy of Sciences of the United States of America 105,
14017-14022 (2008). [0297] 62 Pham, N. L. et al. Exploiting
cross-priming to generate protective CD8 T-cell immunity rapidly.
Proceedings of the National Academy of Sciences of the United
States of America 107, 12198-12203, doi:10.1073/pnas.1004661107
(2010). [0298] 63 Badovinac, V. P., Messingham, K. A., Jabbari, A.,
Haring, J. S. & Harty, J. T. Accelerated CD8+ T-cell memory and
prime-boost response after dendritic-cell vaccination. Nature
medicine 11, 748-756 (2005). [0299] 64 Harty, J. T. &
Badovinac, V. P. Shaping and reshaping CD8+ T-cell memory. Nature
reviews. Immunology 8, 107-119 (2008). [0300] 65 Coler, R. N. et
al. Development and characterization of synthetic glucopyranosyl
lipid adjuvant system as a vaccine adjuvant. PloS one 6, e16333,
doi:10.1371/journal.pone.0016333 (2011). [0301] 66 Singh, S.,
Briles, W. E., Lupiani, B. & Collisson, E. W. Avian influenza
viral nucleocapsid and hemagglutinin proteins induce chicken CD8+
memory T lymphocytes. Virology 399, 231-238,
doi:10.1016/j.virol.2009.12.029 (2010). [0302] 67 Singh, S. et al.
Non-replicating adenovirus vectors expressing avian influenza virus
hemagglutinin and nucleocapsid proteins induce chicken specific
effector, memory and effector memory CD8(+) T lymphocytes. Virology
405, 62-69, doi:10.1016/j.virol.2010.05.002 (2010). [0303] 68
Tewari, K. et al. Poly(I:C) is an effective adjuvant for antibody
and multi-functional CD4+ T cell responses to Plasmodium falciparum
circumsporozoite protein (CSP) and alphaDEC-CSP in non human
primates. Vaccine 28, 7256-7266, doi:10.1016/j.vaccine.2010.08.098
(2010). [0304] 69 Wille-Reece, U. et al. HIV Gag protein conjugated
to a Toll-like receptor 7/8 agonist improves the magnitude and
quality of Th1 and CD8+ T cell responses in nonhuman primates.
Proceedings of the National Academy of Sciences of the United
States of America 102, 15190-15194, doi:10.1073/pnas.0507484102
(2005). [0305] 70 Seder, R. A., Darrah, P. A. & Roederer, M.
T-cell quality in memory and protection: implications for vaccine
design. Nature reviews. Immunology 8, 247-258 (2008). [0306] 71
Wille-Reece, U., Wu, C. Y., Flynn, B. J., Kedl, R. M. & Seder,
R. A. Immunization with HIV-1 Gag protein conjugated to a TLR7/8
agonist results in the generation of HIV-1 Gag-specific Th1 and
CD8+ T cell responses. J Immunol 174, 7676-7683 (2005). [0307] 72
Jones et al., US20120178710.
[0308] Other embodiments are set forth within the following
claims.
* * * * *